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Summary
Human metabolism plays a key role in disease pathogenesis and drug action. Half a century
of biochemical literature leveraged by the advent of genomics allowed the emergence of
computational modeling techniques and the in silico analysis of complex biological systems.
In particular, Constraint-Based Reconstruction and Analysis (COBRA) methods address the
complexity of metabolism through building tissue-specific networks in their steady state. It is
known that biological systems respond to perturbations induced by pathogens, drugs ormalig-
nant processes by shifting their activity to safeguard key metabolic functions. Extending the
modeling framework to consider the dynamics of these complex systems will bring simula-
tions closer to observable human phenotypes. In this thesis, I combined physiologically-based
pharmacokinetic (PBPK) models with genome-scale metabolic models (GSMMs) to form
hybrid genome-scale dynamical models that provide a hypothesis-free framework to study
the perturbations induced by one or more perturbagen on human tissues. On a first stage,
these methodologies were applied to decipher the absorption of levodopa and amino acids by
the intestinal epithelium and allowed to derive a model-based diet for Parkinson’s Disease pa-
tients. In the next phase, we extended the study to 605 drugs in order to predict the occurrence
of gastrointestinal side effects through a machine learning classifier, using a combination of
gene expression andmetabolic reactions set as features. Finally, the approach upscaled to sev-
eral tissues, specifically to investigate the genesis of metabolic symptoms in type 1 diabetes
and to suggest key metabolic players underlying within and between-individual variability to
insulin action. Taken as whole, the integration of two modeling techniques constrained by
expert biological knowledge and heterogeneous data types will be a step forward in achieving
convergence in human biology.
1
2 SUMMARY
Chapter 1
Introduction: Integrative approaches for
drug development.
Manuscript in preparation.
1.1 Drug discovery and development: challenges and op-
portunities.
Drug development is the process of synthesizing a new chemical entity to treat a specific
condition or to control its symptoms. Since Galen to modern medicine, the advances in
the understanding of human biology and the development of new technologies fuelled great
drug discoveries and drove paradigms shifts in the conception of novel therapies [54, 114].
The process starts with identifying a target, such as membrane receptor proteins, then a
set of candidate small molecules are either designed or selected from compound libraries
[41, 248]. The best performingmolecule in animalmodels, the candidate, is further optimized
for improved pharmacokinetic properties. The candidate is then translated for first-in-human
trials where the compound is tested on a small set of healthy volunteers to investigate potential
human activity. In the second phase of clinical trials, patients are included in the trials to
further assess the safety and efficacy of the drug. In Phase III, the cohorts are enlarged to
include a greater number of volunteers in randomized controlled multicenter trials to assess
the added value of the drug in clinical practice. After marketing, the drug is monitored and
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the side effects are reported by clinical practitioners to national health agencies and to the
manufacturer [250] (Figure 1.1).
In 1997, the average cost of putting a molecule on the market was 500 million dollars
[181, 51]. In 2014, 2.6 billion dollars are required to successfully market a drug [157, 50].
Despite the increasing costs, the process is subject to high attrition rates [41]. In fact, one in
57 programs will succeed in providing a novel therapeutic alternative. In 2016, the Food and
drug administration (FDA) approved only 18 new drugs ( New molecular entities (NMEs)
and Biologics license application (BLAs)) in the worst rate since 2007 [158]. The causes of
failure were attributed at 56% to the efficacy of the drug and 28% to its safety. Moreover,
a recent study showed that two thirds of antineoplastic drugs approved by the European
medicine agency (EMA) between 2009-2013 failed to show an improvement over existing
therapies [49].
The high attrition rates are attributed to poor understanding of disease and drug mechanism.
The candidate molecule is often translated to clinical phases solely based on efficacy in rodent
models, or on high structural specificity towards the target, often overlooking the system as
a whole. A classical example surrounds high density lipoproteins (HDL) increasing drugs
(Torcetrapib, Dalcetrapib) that were thought to provide a protective effect in cardiovascular
disease based on empirical observations linking the increase of HDL to lower events of
heart attacks. The molecules failed to provide a protective effect because the decrease of
myocardial infarction was later linked to a lowering of low density lipoprotein (LDL) [240],
for which statins have been successfully developed. Furthermore, a recent study showed that
drug programs that have a high validation in biology such as human genetics and human
biology supporting the target e.g., genome-wide association studies (GWAS), had a success
rate in phase II of 62.5% as opposed to 5.9% to targets with low validation[111] [96]. The
overall clinical success rate of genetically validated small molecules was 63% in comparison
to 13% of success rate in traditional small molecules in Phase II [183].
In themidst of high attrition, high cost, drug developmentmodel, biology has turned to a data-
intensive field, mainly after the first sequencing of the human genome [129]. The leverage of
more than 60 years of biochemical literature, combined with whole-genome, high-throughput
sequencing enabled to reconstruct human biological systems in silico [57, 226]. Metabolism
being the support of biomarkers and the endpoint of the central dogma in biology, integrates
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Figure 1.1: The 2.6 billion dollar pill. The drug development process starts with the
screening of compound libraries, of which a set of leads is optimized in PK properties and
safety. The candidate is further optimized in preclinical models and translated into clinical
phases where the drug is tested on healthy volunteers and patients. After marketing, the drug
can be withdrawn if monitoring reveals an imbalanced risk-benefit. Percentages represent
the attrition rate in each phase [41]. In total, 1 in 57 drug programs succeeds.
the preceding genomic, transcriptomic and proteomic information [147, 146]. Modelling
metabolism through Constraint-based Reconstruction and Analysis (COBRA) [163] allows
to identify drug targets in a system-wide manner and to provide testable hypothesis thereby
increasing our understanding of disease and drug action. Coupled with targeted experiments,
COBRA modelling could provide a bird’s-eye view on the system and drive rational drug
design where in each of the steps of the drug development process, the model is further
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refined to answer a specific question at a given point in time.
1.2 Constraint-based modelling of large scale human bio-
logical networks
COBRA methods enable the reconstruction of human biological systems through surveying
the metabolic reactions in the literature, leveraging biological data in public repositories,
or performing genome-wide experiments. The set of reactions obtained are written in a
mathematical format as a stoichiometric matrix S(m,n), where the columns are represented by
n reactions and the rows are the m metabolites intervening in the biochemical reactions. If
the obtained set of reactions is: 
Reaction1 A+B→ C
Reaction2 D+E→ B
Reaction3 2 C+D↔ E
Reaction4 B+E→ C
Reaction5 A→ E
Reaction6 C→ A + E
the corresponding stoichiometric matrix S is:
S =
©­­­­­­­­­­«
R1 R2 R3 R4 R5 R6
A −1 0 0 0 −1 1
B −1 1 0 −1 0 0
C 1 0 −2 1 0 −1
D 0 −1 −1 0 0 0
E 0 −1 1 −1 1 1
ª®®®®®®®®®®¬
In the next phase, the system can be used to investigate the optimal conditions to perform
a specific metabolic function, such as carbohydrate metabolism in the liver, the transport of
metabolites by the intestinal epithelial cells, or a linear combination of metabolic reactions,
such as the basal maintenance metabolism in the muscle. The problem becomes then a linear
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program (LP), in which the sought metabolic capabilities are formulated as an objective
function, under a set of constraints on metabolic reactions to form the following problem:
max or min: cT1 v1 (1.1)
subject to:
Sv1 = b
vmin ≤ v1 ≤ vmax
where cTv is the objective function, c is the vector of coefficients of the metabolic reactions
in the objective function, v is the vector of metabolic fluxes going through the reactions and
the solution to problem 1.1, b is the change-of-concentration of metabolites in the considered
time step, which when set to 0, the system is considered in steady-state and the solution
becomes a subset of the null space of S and the problem is referred to as Flux Balance
Analysis (FBA) [167]. Additionally, a set of bounds are subjected on the metabolic rates of
the reactions such that the allowed interval of a given reaction would be between vmin and
vmax . For example all reactions but reaction 3 are irreversible, which translates to a vmin ≥ 0,
while reversible reaction 3 would have vmin < 0 and vmax > 0. Solving problem 1.1 would
return the optimal theoretical objective Z1 for the system under the given constraints e.g., the
maximal growth of the cancer cells in a chemically defined medium, and the solution v of
metabolic reactions rates achieving the objective. The flux vector v would inform about the
pathways involved in disease progression or drug action. Practically, problem 1.1 is often
under-determined (m < n), the set of solutions achieving the optimal objective is then the
Alternate Optimal Solution (AOS) space. Delimiting the AOS space becomes of paramount
importance in human biological models as the solutions would be reported as intervals of
metabolic rates rather than single values, thereby increasing the robustness of results. Flux
Variability Analysis (FVA) [142] allows the characterization of the AOS through performing
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two linear programs for each ith reaction with a total of 2n linear programs as the following:
max and min: cTi vi
subject to:
Svi = b
cT1 vi = Z1
vmin ≤ vi ≤ vmax
,where cTi has one in the i
th entry and zero otherwise. The optimal objective cTi v ofminimizing
reaction i gives its lower bound given the optimal objective of problem 1.1, while maximizing
cTi v gives the upper possible bound. Additionally, as metabolic models increased in size to
include thousands of reactions thereby covering several human metabolic pathways, the
mining of information and extraction of knowledge from models becomes a challenging task.
In order to select the most important metabolic reactions contributing to the emergence of
a given phenotype, the sparsity induced by minimizing the 1-norm of v in parsimonious
flux balance analysis (pFBA) [132], enables a minimal set of reactions to carry flux and sets
the remaining reactions to zero. Sparsity is achieved through adding a second objective in
problem 1.1, to minimize for the sum of flux i.e., 1-norm of v:
min:
n∑
i=1
|v3,i |
subject to:
Sv3 = b
cT1 v3 = Z1
vmin ≤ v3 ≤ vmax
Minimizing for the 1-norm allows to obtain a reduced AOS space, which is particularly
useful in the analysis of large models. Additionally, the decrease of the AOS space could be
achieved through considering prior information about the state of the system. Wefirst consider
program 1.1, where S corresponds to the metabolic network of e.g., the liver hepatocyte with
the objective set as metabolism of a given xenobiotic. After optimizing program 1.1, we
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would like to investigate the effect of genetic mutation that would block reaction vi, on the
metabolism of the xenobiotic. We consider then the following program:
max: cTv4
subject to:
Sv4 = b
v4,i = 0
vmin ≤ v4,[1,n]\{i} ≤ vmax
Similarly, we obtain an optimal objective and a set of optimal solutions. Although as liver
metabolism might not be completely disrupted as an effect of mutation, and in order to
make the results comparable, an additional objective would minimize the euclidean distance
between v4 and v1. The secondary program referred to as Minimization Of Metabolic
Adjustments (MOMA) [205] is formulated as follows:
min: | |v1 − v4 | |2
subject to:
Sv4 = b
v4,i = 0
vmin ≤ v4,[1,n]\{i} ≤ vmax
The obtained flux distribution would be then minimally distant and interpretable in the same
context. The above discussed methods allow to study a given system in a given point of time,
to provide a snapshot of metabolism. In cases where the dynamics of the system are sought,
dynamic genome-scale frameworks provide an alternative to the steady-state assumption.
1.2.1 Dynamic flux balance analysis frameworks
The afore-mentioned methods allow to study the metabolic flux distribution of human
metabolic network (FBA), assess the allowable space of AOS (FVA), potentially reducing the
AOS to the most important metabolic features (pFBA) or through contextualizing the net-
work to a prior information about the unperturbed state of the system (MOMA). While these
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approaches provide a snapshot of metabolism under a given set of environmental, biochemi-
cal, and genetic conditions subjected as constraints, the inclusion of the temporal dimension
requires specific modelling frameworks. The study of dynamical human biological systems
would inform about the dynamics of response to extrinsic perturbations in the environment
and idiosyncratic properties such as modulation of gene expression. Dynamic flux balance
analysis (dFBA) has been described in the early development of COBRA methods [236], in
bioengineering applications where the growth over time of Escherichia coli was predicted in
different media. The method was formally described later and it was applied to predict the
diauxic growth of Escherichia coli in acetate and glucose [141], the mechanisms involving
each substrate, and the subsequent shift in growth rates. There were two main approaches
to simulate metabolic models dynamically, the first would solve for the entire time horizon
through a terminal objective function corresponding to the final metabolite concentration,
referred to as Dynamic Optimization Approach (DOA). The second is the Static Optimization
Approach (SOA), where the time horizon is divided in p time steps and and the metabolic
model is solved in each time step. As SOA seemed to agree with experimental data [141],
the approach has been the main implementation of dFBA. It consists of solving the metabolic
model for a time step, deriving growth and uptake rates, then updatingmedium concentrations
with the consumed and secreted metabolites, to finally compute the growth in the next time
step using new availability constraints in the medium. Taking a simple model of Escherichia
coli grown on glucose, the problem would be in any given time step t:
max: cTv5 (1.2)
subject to:
Sv5 = b
vmin ≤ v5 ≤ vmax
let Z5 be the optimal biomass objective of problem 1.2. Then the new concentration z of a
metabolite in the medium is:
z(t + dt) = z(t) + Szv5B.dt (1.3)
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,where dt is the length of the time step, Sz is the row corresponding to metabolite z in the
S matrix, and B is the biomass at this time step. Updating the availability constraints would
be setting the new concentration of z as the new upper bound of uptake of z. The metabolite
concentrations time-course are actually identical to the numerical solution through Euler’s
forward method of:
dz
dt
= SzvB (1.4)
dFBA has been applied to ecosystem microbiology [259], where the dynamical interaction
between two bacteria were simulated using a multi-species framework named DyMMM
for dynamic multi-species metabolic modelling. Later, dFBA has been used to couple a
steady-state metabolic model to an ordinary differential equations (ODE) based model of
external substrate dynamics. In this case, a structural set of deterministic ODEs covers a
set of processes in the organism independently from the metabolic model. Coupling both
model in a hybrid framework gave improved prediction of growth dynamics [43] and set the
basis for the first whole-cell integrated dynamical model [108]. The challenges faced by the
bioengineering modelling community was the modelling of break points were the bacteria
instantaneously shifts its metabolism when the preferred carbon source is depleted, which
may cause integration failure at fixed time steps. Reducing the time stepmay circumvent some
of the infeasibilities, yet the simulation time might increase dramatically. Direct Approaches
(DA) that embed the COBRAmodel as a right hand side of ODEs allowed to use the common
ODE numerical solvers to adapt the time step as a function of the derivative and use higher
order numerical schemes to improve stability and convergence [85, 259]. Solutions to FBA
programs being non-unique and rather forming anAOS space, the dFBA programsmight have
different solutions depending on the LP solver, with metabolite kinetics forming production
envelopes rather than a unique time-course path. The issue was addressed through adding
a set of secondary objectives to select a unique solution through the dFBA lab framework
[74, 95].
The success of dFBA was mainly validated in bacterial systems applied in bioengineering
applications, and was later applied to human metabolism [168]. Dynamically modelling drug
kinetics requires high-quality global metabolic reconstructions of human physiology.
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1.2.2 Global reconstruction of human metabolism
More than 60 years of human biochemical research produced a considerable amount of dis-
coveries related to the function of proteins and metabolic reactions. Sequencing the human
genome further developed our knowledge about gene function and essentiality. Moreover,
proteins of unknown functions could be predicted using comparative genomics on the se-
quences and the structures, which allowed to fill the gaps in metabolic pathways. The global
reconstruction of human metabolism encompassed the knowledgebase of human metabolic
reactions and their encoding genes and proteins, enabling the study of a number of metabolic
diseases such as Inborn Errors of Metabolism (IEM) [193], diabetes [224], and the metabolic
syndrome [148] in silico. The first knowledgebase of human metabolism (Recon) [57] was
built through surveying the biochemical literature and assembling 3,311 metabolic reactions
encoded by 1,496 genes, into a comprehensive and stoichiometrically coherent set. The
second version [226, 218] expanded the coverage of reactions to 7,440 reactions, 2,626
metabolites, 1,789 genes, and 99 subsystems and added a number of objective functions
relevant to the human physiology through a community-driven, precise protocol of high
quality reconstruction generation [223]. Another global assembly of human metabolism was
the Human Metabolic Reaction (HMR) [146, 147] reconstruction which included more than
7,000 reactions, 4,000 genes, and 3,000 metabolites.
Tailoring the global reconstruction through applying relevant bounds and constraints allowed
to derive context-specific models such as tissue and cell type specific models [204, 255], and
a wide variety of disease models ranging from Alzeihmer’s disease [215] to cancer [66] and
diabetes [224].
Recently, the first model of human organ-resolved metabolism [225] named Harvey after
William Harvey (1578-1657), allowed to tailor the global reconstruction Recon into 20 dif-
ferent organs, six sex organs, and six blood cells, using human proteomic and metabolomic
data and the manual curation of the organ-specific biochemical pathways, totalling more than
80,000 reactions, 50,000 metabolites, and 100 metabolic subsystems. The model connected
the organs through blood circulation and accurately captured inter-organ cycles. Addition-
ally, constraints pertaining to human physiology such as anthropomorphic parameters, human
energy use, cardiac output, renal filtration rate, and gut microbiome metabolism, enables the
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study of a number of human disorders and the stratification of patients.
The global reconstruction of human metabolism provides a framework to study disease
through incorporating thermodynamics, gene expression, and proteomics into context-specific
models. Likewise, the study of drug effects on the human body requires the integration of
COBRA models with pharmacokinetic models that describe the absorption, distribution,
metabolism, and excretion of the drug.
1.3 Pharmacokinetic modeling
1.3.1 Pharmacokinetic pharmacodynamic modelling (PKPD)
The assessment of the absorption, distribution and elimination parameters of new chem-
ical entities has been a central question in the clinical phases of drug development. Non-
compartmental analysis (NCA) allows to compute themain pharmacokinetic parameters (area
under the curve (AUC), maximum concentration Cmax , and Tmax which is the time where
Cmax is realized ) assuming a first-order linear model. Although in cases of non-linear drug
disposition and when the analysis is sought to go beyond describing the general parameters to
rather predict the outcome of the next clinical phases, compartmental modelling becomes the
gold standard. ODE-based models of pharmacokinetics (PK) usually describe one, two or
three compartments, whose parameters are identified through fitting the model on empirical
data using linear and non-linear regression. In case of low molecular weight and hydrophilic
compounds, the drug is absorbed in the first compartment and immediately eliminated by a
linear process (Figure 1.2-A). The compartment in this case represents the central compart-
ment or blood. The absorption can be modelled as IV, where the total amount of the drug
is immediately available in the first compartment or Per os, where the absorption process is
linear with respect to the dose following a rate of absorption ka. The elimination can be also
modelled as a linear process with rate kel . Single compartment model equations are:
dC
dt
=
ka ∗ D
V
− kel ∗ C (1.5)
,where C is the concentration of the drug in compartment 1, D is the drug dose, V is the
apparent volume of distribution of the drug in the compartment, and ka, kel are rates (time−1)
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of absorption and elimination, respectively. In cases where the drug is lipophilic, it would
probably bind to tissues after the absorption and exhibit a second elimination phase due to
late release form deep compartments (Figure 1.2-B). The situation can be modelled as a two
compartment model, where the first one idealizes the blood compartment and the second one
would be the tissues where the drug binds and is slowly released thereafter. The equations of
such model are:
dC1
dt
=
ka ∗ D
V1
− (kel + k12) ∗ C1 + k21C2
dC2
dt
= k12C1 − k21 ∗ C2
(1.6)
,where C1, C2 are the drug concentrations is compartment 1 and compartment 2 respectively
such as C1 = A1V1 , C2 =
A2
V2
, A1 and A2 are the amounts of drug, V1 and V2 are the drug
apparent volume of distribution in compartment 1 and 2, respectively. ka and kel are
as introduced previously, k12 and k21 are the rates of inter-compartmental diffusion from
compartment 1 to compartment 2 and back, respectively. Furthermore, the elimination can
be modelled as a saturable process, where liver enzymes or kidney transporters could exhibit
dose-independent excretion rates. Saturation is modelled as Michaelis-Menten process,
where the 2-compartment model is written as follows:
dC1
dt
=
ka ∗ D
V1
− k12 ∗ C1 − vmax ∗ C1KM + C1 + k21C2
dC2
dt
= k12C1 − k21 ∗ C2
(1.7)
,where KM is the enzyme constant and vmax is the maximal rate of the enzyme. PK models
expanded beyond the classical representation to better describe the pharmacology of each
compound, through adding various compartments and using different types of equations
to describe physiological processes. Before the first-in-human trials, the parameters of
the equations are often unknown, or at best roughly estimated through NCA. Therefore,
after fitting the PK model on drug time-course concentrations in healthy volunteers, the
compound parameters are estimated through non-linear regression, providing thereby a better
understanding of the properties of the compounds. Oftentimes, several models are fit on the
data and consequently compared on how well they explain the data through statistical metrics
such as the Akaike Information Criterion (AIC) and the Bayesian Information Criterion
(BIC). Model selection compares not only models of a different set of ODEs i.e., structural
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Figure 1.2: Different types of PKPD models. A- Monocompartmental PK model, B- Bicom-
partmental PK model, C- Direct effect PD model, D- PD model with effect compartment, E-
Indirect effect model, F- Physiologically based PD model.
models, but also models with sensibly the same ODEs with slight variations. For example, in
population pharmacokinetics (POP-PK), the parameters of the classical PK models can have
two components, the mean population part and the individual part. Using Non-linear mixed
effect (NLME) modelling, POP-PK then allows to explain between and within-individual
variability to drug response. Model selection is mainly about selecting the minimal models
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that explain the data best. In that sense, model reduction has to be performed through
eliminating correlated parameters and the inclusion of covariates such as age, sex, and weight
in drug parameters. For example, the volume of distribution increases with weight, thus it
can be written as following:
V = θ + η ∗ w (1.8)
,where θ the population mean, η is the individual part and w is the weight. The solution of the
ODEs with the estimated parameters allows to extrapolate the PK profiles in a larger set of
volunteers or patients, in order to guide later phases of clinical trials thereby enabling optimal
design of experiments. Beyond the description of pharamcokinetics, modelling provides a
support to include pharmacodynamics or in other terms: what the drug does to the body.
PKPD models link pharamcokinetic models to surrogate end-points e.g., the decrease of
Hb1ac with anti-diabetic drugs. The pharmacodynamic effect can be modelled in various
ways, depending on the delay between the administration and effect and known biology in
the site of action. In cases of fast absorption and rapid distribution, the effect is observed
immediately after the administration. The pharmacodynamics (PD) can be described through
a direct compartment, where the drug concentrations are directly linked to the observed
phenotype [232] (Figure 1.2-C). The direct compartment is described as follows:
Edrug =
C1
EC50 + C1
E = Ebase ∗ (1 − Edrug)
(1.9)
,where E is the measured biomarker or the surrogate end point, Ebase corresponds to the
basal effect prior to the administration of the compound, Edrug is the effect induced by the
drug, EC50 is the concentration of the drug that induces half of the maximal effect and C1
is the plasma concentration of the drug, often represented by the central pharmacokinetic
compartment. In real world cases, the drug concentrations are measured as well in target
organs in animal models which enables the modelling of the site of action. In many cases, the
drug reaches the site of action after a certain delay as a result of slow perfusion, a signalling
transduction cascade or the metabolism of prodrugs. The effect compartment has been sug-
gested [208] as an intermediate step between the pharmacokinetic compartment and the direct
compartment. The drug concentrations from the central compartment would be subjected
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to a delay in the effect compartment before transducing to the direct compartment (Figure
1.2-D). If the hysteresis between the administration and the effect can be observed in the raw
data, then the following effect compartment can be proposed to model the phenomenon:
dCe f f
dt
= ke0 ∗ (C1 − Ce f f )
Edrug =
C1
EC50 + C1
E = Ebase ∗ (1 − Edrug)
(1.10)
,where theCe f f is the concentration of the drug in the effect compartment and ke0 is the delay
parameter usually estimated from the curve fitting process as it represents the intermediary
absorption and metabolism steps before reaching the site of action. The effect compartment
addresses the delays caused by pharmacokinetic constraints. Likewise, in cases of delay
in the pharmacodynamic processes, the indirect effect was suggested [207] to model the
hysteresis where the effect is neither directly linked to the central compartment nor the effect
compartment (Figure 1.2-E). The indirect effect compartment is modelled as follows:
dE
dt
= kin − koutE (1.11)
As an example, a target protein synthesized by a zero-order rate kin and degraded by a
first-order rate kout whose synthesis is stimulated by a drug, can be modelled as following:
dE
dt
= kin(1 + Emax
Ce f f
Ce f f + EC50
) − koutE (1.12)
Symmetrically, different versions of the indirect compartment can model the inhibition and
stimulation of the synthesis and degradation of the target. Generally, pharmacodynamic
models exist in a wide variety of instances to describe various drug mechanisms. The
pharamcokinetics of biologics for instance directly depend on their binding to the target. In
this case, the pharamcodynamics drive the pharamcokinetics through target-mediated drug
disposition (TMDD) models [55].
Finally, PKPD models allow to give insights into drug effects in relation to their pharmaoki-
netic properties. Coupled models of pharamcokientics and pharamcodynamics allow to fit
simultaneously the collected data of drug concentrations and their effect such as the target
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and biomarker concentration or a given clinical or physiological end point. The parameters of
PKPD models are often a statistical representation that best reflect the goodness-of-fit of the
model on the data. When the physiology of the system is better characterized, physiologically-
based models replace the statistical parameters with mechanistic ones, thereby representing
in greater detail the actual biology of the target system.
1.3.2 Physiologically-based pharmacokinetic modelling (PBPK)
PKPD models are statistical depictions of the pharmacological processes that are employed
to predict drug disposition beyond the trial individuals and to guide future experiments.
As such, PKPD models are rather phenomenological and lack appropriate representation
of the biological system and the mechanism of drug action. In contrast, PBPK models
were developed in order to go beyond the statistical representation as they integrate the
known physiology of the studied system [105]. The physiological models are based on the
description of human organs as compartments modelled by their weights, volume, and blood
perfusion rate. Mainly used in toxicology in the beginning [9], PBPK models were able
to address the distribution of compounds in the different organs and assess the extent of
the exposure to a given molecule [171]. In modelling of pharmacological agents, the PD
compartments of classical PKPD model can be modified to account for known perfusion
parameters in the tissue of interest giving rise to semi-physiological models [245] (Figure
1.2-F). The full integration of PBPK model in drug disposition uses detailed compartments
of organs, where the drug absorption is modelled as following:
dCT
dt
=
ratein − rateout
VT
ratein = QTCA
rateout = QT
CT
Kp/B : P
(1.13)
,whereCT is the drug concentration in the tissue,QT is the blood perfusion of the tissue, VT is
the volume of the tissue,CA is the arterial concentration of the drug, Kp is the tissue to plasma
partition coefficient, and B : P is the blood to plasma ratio that indicates the free fraction of
the drug in the plasma. The human body with its different organs modelled as compartments
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is represented through a generic whole-body (WB) model [170] (Figure B.1-C), that can be
further expanded for the requirements of distribution of a specific drug. The basic description
of each organ is based on the modelling of the in-flow of the compound through the blood
perfusion, its metabolism in the organ, and the out-flow through the circulation (Equation
1.13). Additionally, several organ models [178, 177, 176] were suggested to predict the
organ-specific distribution and the concentrations of drugs in the tissue, taking into account
the composition in phospholipids, neutral lipids, water, and the interstitial fraction combined
with compound-specific parameters such as molecular weight, pKa, and permeability. The
inclusion of these models in WB-PBPK allowed to accurately estimate the tissue to blood
partition coefficient and the kinetics of the free fraction of drugs in the plasma using solely in
vitro data [186, 185, 175]. Furthermore, detailed description of the physiology of a particular
system can be embedded in the WB-PBPK model such as the gastrointestinal tract that can
be further compartmentalized into lumen and epithelieum as well as the different anatomical
parts of the organ [10, 38].
PBPK-PD models [122] additionally include in the organ compartments the pharmacody-
namics of the drug, where the drug interacts with organ specific pathways and processes.
The power of PBPK models resides in the estimation of the human pharmacokinetics based
mainly on in vitro data. The in vitro-in vivo extrapolation (IVIVE) [254] is of paramount
importance in the translation process from preclinical to clinical phases to ensure the safety
of human trials [135, 221] and the dosing scheme for optimal efficacy. The emergence of
PBPKmodeling in pharmacology has been leveraged by the integration of PBPKmodels and
simulation algorithms in software such as Simcyp (Simcyp, Sheffield, UK) , GastroPlus [3],
MATLAB Simbiology toolbox (The MathWorks, Natick, MA, USA), and PKSIM-MOBI
[60]. The latter is an open-source platform that enables modelling of pharmacological pro-
cesses from the molecular level up to the population level.
Yet, in order to model organ-specific biology using ODEs, the lack of human parameters
and unknown kinetics of the biological processes hinders the development of fully dynamic
models. Constraint-based modelling of organ physiology using transcriptomic, proteomic,
and metabolic data, can be coupled to PBPK models using dFBA frameworks to either serve
as a pharmacodynamic endpoint, or to model the pharmacokinetics.
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1.4 Combining COBRA and PBPK
Because of the challenges pertaining to the development of dynamic genome-scale models
[72], hybrid models of biological systems that encompass continuous (ODE) and discrete
(FBA) behaviour, have been described in bacteria [43, 108], and paved the way towards
kinetic genome-scale models. Combining two formalisms has the advantage of increasing
the coverage of reactions, metabolites and phenotypic prediction, in addition to the temporal
dimension (Table1.1). Moreover, additional constraints can arise from the combined model,
thereby reducing the space of possible phenotypes to biologically relevant ones. Recently, the
approach have been applied to human physiology through the integration of human hepatocyte
metabolic model with an ODE-based PBPK model of allopurinol [119] to investigate the
effect of enzymopathies on ammonia detoxification in the liver and the reduction of uric acid
production following allopurinol treatment. Hybrid PBPK-COBRA models [37, 145] were
also applied in the study of phenytoin and estradiol drug-drug interaction [210]. Combined
PBPK and COBRA models are anecdotic, but we expect their number and applications to
extend in the community with the development of methods and tutorials. There are two ways
of constructing hybrid, bi-formalism models.
Table 1.1: Comparison of PBPK models with metabolic models.
Model PBPK COBRA
Coverage a few metabolites genome-scale
Dynamics dynamical steady state
Prediction quantitative semi-quantitative
Parameters many few
Concept Top-down (curve-fitting) Bottom-up (network reconstruction)
1.4.1 COBRA as pharmacodynamics - horizontal coupling
The foundations of systems pharmacology were built on the promise of integration of systems
biology models as pharamcodynamic endpoints in PKPDmodels [98, 47]. Pharamcodynam-
ics defined as ‘what the drug does to the body‘ would link drug concentrations to the surrogate
end point and would be represented in PKPD models through phenomenological equations.
Coupling COBRA models as pharmacodynamics in PBPK-PD models implies that the PK
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of the drug is deterministic for the entire simulation time. The coupling is considered hi-
erarchical as concentrations from the PK compartment will shift the states of the COBRA
model through time e.g., the detoxification of ammonia using a genome-scale network of the
hepatocyte [119]. Also referred to as indirect coupling [119], the method requires the iden-
tification of contact points between the PBPK-PD model and the COBRA model. Assuming
that reaction R1 is modeled in both the PBPK and COBRA model, the method consists of
solving the ODEs for each time step and subjecting the derivative terms as constraints in the
metabolic model. In the PBPK model, the concentrations of metabolite M are determined
by a production term vd,R1 and consumption terms vd,R2 and vd,R3 such as the following:
dM
dt
= Mvd,R1 − Mvd,R2 − Mvd,R3 (1.14)
,where d stands for dynamic. The COBRA model is dynamically constrained for each time
step and Mvd,R1 is set as a bound in the counterpart of vd,R1 which is vm,R1, where m stands
for metabolic.
max or min: cTvm
subject to:
Svm = b
vm,R1 ≤,=, ≥ Mvd,R1
vm,min ≤ vm ≤ vm,max
In most cases, the rates of absorption of the drug and its metabolites would be the most
straightforward flux to couple. The PBPK-PD endpoint could be a signalling cascade involv-
ing metabolic enzymes, whose concentrations could set the upper bounds in COBRAmodels.
While the coupling will preserve the pharmacokinetic profile of the drug, the COBRAmodel
would have several states induced by dynamically changing the bounds of reactions in FBA
programs, thereby tracking the activation of metabolic pathways over time, as an effect of the
drug (Figure 1.3-A).
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Figure 1.3: Coupling PBPK and COBRA models. A– Horizontal hierarchical coupling
consists of solving the PBPK model first in discrete time steps and subjecting reaction rates
as constraints in the COBRA model to track the metabolic shift in the network as an effect
of drug constraints. Depending on the research question, reaction constraints can be set as
lower or upper bounds. B- Vertical coupling assumes a cross-talk between both models.
As such the PK profile of the drug is not determined by the ODEs alone. In the first step,
after solving the PBPK model, the derivatives are applied as constraints in the COBRA
model. Additional constraints are set to represent a specific condition that is not captured by
the ODE, such as enzymatic deficiency. The COBRA model is solved to obtain a solution
satisfying the constraints. Finally, derivative terms in PBPK corresponding to reactions in
the COBRA model solution are set accordingly and the PBPK model is integrated for the
next time step. The PK of the drug obtained from the PBPK model is drawn in blue and its
new PK constrained by the PBPK-COBRA model is represented in green.
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1.4.2 COBRA as pharmacokinetics - vertical coupling
Practically, hierarchical coupling would require more than one constraint to induce a shift in
the steady state of the COBRA model. Since PBPK models describe usually the drug and its
metabolites, additional constraints arising fromgene expression experiments ormetabolomics
could be added to further inform the model [247].
When drug pharmacokinetics are modulated by the COBRA model, as in the case of a
decrease in the drug metabolising enzyme (DME) activity in the liver, enzymopathies, or in
cases where the interaction with the target influences the PK as in TMDD, the coupling would
be direct. To illustrate the method, let us consider the previous PBPK model and a COBRA
model sharing reaction R1. Solving the ODEs in the first time step allows to compute the
termMvd,R1 corresponding to the flux of R1. In the COBRAmodel, Mvd,R1 is set as an upper
bound in the counterpart of vd,R1 which is vm,R1. Additional constraints could be added, such
as blocking vm,R6 to model an enzymopathy.
max or min: cTvm (1.15)
subject to:
Svm = 0
vm,R1 ≤ Mvd,R1
vm,R6 = b
vm,min ≤ vm ≤ vm,max
Solving problem 1.15 allows to obtain vm,R1 which sets a new value for vd,R1 under the
specified enzymopathy constraints and the ODEs 1.14 are integrated for the next time step.
The concentration time-course of the drug in the hybrid model is different from the PK
profile predicted by the set of ODEs alone (Figure 1.3-B). The method was described in
the prediction of ammonia detoxification in patients presenting urea cycle disorder [119],
where the PBPK model described the PK processes of ammonia combined with a COBRA
model of the hepatocyte whose ornithine carbmylase flux was gradually decreased to describe
the progression of the disorder, allowing the prediction of the PK of ammonia in patients.
Another coupled model predicted alcohol concentration in volunteers who presented different
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alcohol dehydrogenase enzyme activity [230]. In type 1 diabetes (T1D), a PBPK model of
glucose-insulin-glucagon interplay was coupled to a multi-cellular model of a myocyte,
hepatocyte and adipocyte, where the impairment of T1D-related genes influenced the time-
course of glucose [242]. We applied this approach to predict the gastrointestinal absorption of
levodopa under dietary constraints wherein the presence of amino acids would induce either
luminal competition or basolateral trans-stimulation, which gave rise to complex PK profiles
depending on the diet composition and the time of intake [81]. As the models include several
organs and describe several metabolic processes, the issue of the non-uniqueness of solution
and the non-smoothness of PK profile have been addresses through reducing the AOS space
with a secondary objective (pFBA) [229].
Taken together, COBRAmodels can extend the pharmacodynamics of PBPKmodels through
a genome-scale coverage of metabolites and reactions. They alternatively can be used to
predict the kinetics of the drug under new constraints arising from cellular processes such as
enzymopathies. The inclusion of PKPD modelling, constraint-based modelling, and hybrid
models under the umbrella of systems pharmacology [233] has the potential to leverage the
drug development process through increasing our understanding of disease pathophysiology
and drug mechanism.
1.5 A new drug development paradigm
The target discovery and drug development process has been through several paradigm shifts.
In the second half of the twentieth century, target discovery in the preclinical stage was driven
by empirical observation on animal models, where a set of compounds were screened on
disease animal models such as cancer. Rodents carrying patient-derived tumour xenograft
were tested for a number of compounds and the dose was selected through titration methods.
If the xenograft shrinks in size, then the compound had higher chances of translation into the
clinical phases with little known about its mechanism and the reasons of success or failure.
Later, the advent of crystallography and the availability of cytoplasmic and transmembrane
protein structures that formed themajority of drug targets, allowed the development of the key-
lock paradigm [154]. Small molecules that fit in specific binding pockets of target proteins
to induce a stimulatory or inhibitory effect, were designed through docking experiments.
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Computer-aided drug design and molecular dynamics are a powerful tool towards rational
and optimal drug design. Nonetheless, this target-centric approach failed in considering
the biological system as a whole and the selective inhibition of important signalling hubs
induced long lasting side effects. Notably, Cyclooxygenase 2 (COX-2) inhibitor Rofecoxib
indicated as an-inflammatory agent induced high risk of heart failure and provoked up to
30,000 deaths post-marketing between 1999 and 2004 [106]. At the same time, biology and
pharmacology became data-intensive disciplines following the development of sequencing
techniques [129] and the availability of data in public databases. The post-genomic drug
discovery and development process has to build on known biology and fundamental science
through integrating the different layers of information into convergent, hypothesis-freemodels
of the target system [235]. In line with recent calls to build model-based drug-development
process by regulators [164] and by academics [162, 233], we propose a novel drug discovery
and development paradigm that builds context-specific dynamicalmetabolicmodels of human
disease through transforming publicly available data into queriable knowledgebases. In the
following, I will detail the vision entailed by a novel, data-intensive, model-based drug
development process (Figure1.5) and provide examples applicable in preclinical and clinical
phases using the work I carried during the course of my PhD.
1.5.1 Preclinical phase
Disease signatures as targets
The main outcome of sequencing technologies in human disease was the discovery of single
nucleotide polymorphisms (SNPs) related to disease using thousands of genome wide se-
quences of healthy individuals and patients. Yet, GWAS studies showed that i) most of these
SNPs were in non-coding regions of the genome wherein a small number of diseases could be
linked to the change of sequence or structure of an enzyme, and ii) they were able to provide
disease signatures. Specifically, disease signatures correspond to the gene expression profile
in a given condition. Similarly, drug-induced gene expression experiments provided the gene
expression related to a perturbation induced by a small molecule. Notably, the connectivity
map [128, 216] has over 1.7 million in vitro drug and drug-like induced gene expression pro-
files in different cell types, at different doses and different time points. Conceptually, if the
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drug-induced gene expression profile reverses the gene expression induced by a disease, then
it can be a potential candidate for further development. For example, the reverse transcription
concept has been used to treat dyslipedimia in mouse models [243] and repurpose drugs in
nephropathy [258] and in small cell lung cancer [99]. Particularly, it presents a potential
avenue for repurposing the existing drugs on the market for new indications [58]. The clin-
ical phase would then start directly in phase two, accelerating considerably the process and
reducing the costs. Using molecules existing in the market allows to use the post-marketing
safety data to reduce the amount of clinical experiments performed. Moreover, building
context-specific metabolic models of drug and disease through combining gene expression
with biochemical networks allows to get insight into the phenotype of interest and predict
metabolic biomarker thereby providing a rationale for the optimal design of experiments.
Target-free drug repurposing and reclassification
The current drug classification system is based on the indication and the chemical class of
the compound. The indication of the drug is oftentimes suggested prior to the beginning of
the drug development program. If the drug proves to be active towards the clinical indication
then it will be classified in the family of compounds that have similar activities such as the
antibiotics class and the antidepressants class. Although in reality, small molecules have
more than one activity. The current classification is biased towards the indication tested and
intended for in the preclinical phase. The repurposing of Sildenafil and Minoxidil in erectile
dysfunction and hair loss respectively, showed that a given drug could be moved from one
class to the other as in case of Minoxidil from a hypotensive agents to a dermatological agent.
The classification of drugs has to take into account their molecular, genetic and biochemical
profile. Such classification will enable to use compounds in the same class exchangeably in
similar indications, thereby harnessing drug repositioning efforts. We applied this concept
to reclassify drugs with respect to their gastrointestinal effects. The drug-induced gene
expression profiles from the connectivity map [216] were used to tailor generic small intestine
epithelial cell models to represent the drug action on the gut wall. Then, we clustered drugs
with similar metabolic profiles into sets that had a similar genome-wide fingerprint (Chapter
2). Notably, the clusters did not match the usual drug classes as currently reported by
medicine agencies.
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Prediction of gastrointestinal side effects
Metabolic modeling combined with machine learning was applied in the prediction of drug
iatrogenic effects. Using drug induced gene expression data [216] and reported drug target
[115], context-specific models informed about disrupted metabolic pathways [260], and
accurately predicted the occurence of adverse reactions [206].
Since the oral absorption of drugs is themost common route of administration, gastrointestinal
side effects are the most frequent adverse reactions. They can induce a lower compliance
to the treatment and sometimes cause the treatment to stop. The accurate prediction of
gastrointestinal side effects in the preclinical phase, based solely on in vitro data can provide
invaluable information about the safety of the compound and guide the decision to proceed
with clinical phases. Using the connectivity map drug gene expression profiles [216], we
built drug-constrained metabolic models of the gastrointestinal epithelium of FDA approved
drugs (Chapter 2). We developed a machine learning classifier that linked drug genetic and
metabolic profiles to the induced side effects as reported in the SIDER database [33] and
their mechanism of action as reported by the FDA National drug code directory (NDCD). We
showed that the accuracy of prediction improved in comparison to approaches that use gene
expression alone. We concluded in this work, that context-specific models of metabolism, in
addition to gene expression, taken as features in a machine learning classifier could accurately
predict adverse reactions.
The integration of multi-layer biology of genetic and metabolic signatures is a powerful
tool to assess the clinical symptoms induced by xenbiotics in the preclinical phase. Moving
towards the clinical phases, the translation of preclinical discovery to human has been equally
in addressed in the context of PBPKmodels [222] and metabolic modeling [22]. A consensus
rat and human model [22] allowed to highlight species metabolic differences and to predict
biomarkers to 76 drugs enabling thereby the translation of preclinical findings to clinical
phases.
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Figure 1.4: Evolution of absorption models in pharmacokinetic modeling. A- Monocom-
partmental PKmodel, B- Compartmentalized absorption and transit (CAT) model taking into
account anatomical sections of the gastrointestinal tract. C- Advanced compartmentalized
absorption and transit (ACAT) absorption, dissolution, and transit model. D- Small intestine
epithelial cell (sIEC)-ACAT systems pharmacology model.
1.5.2 Clinical phase
Improving the bioavailability of Levodopa
Metabolic modeling was applied in the prediction of the effects of the most commonly used
marketed compounds [194]. In early clinical phases, the compound is tested for potential
interactions with other drugs and diet in order to optimize its efficacy and derive recommen-
dations. As the lack of efficacy is one of the major reasons for the failure of drug development
programs, we developed a gastrointestinal model to study the efficacy of a drug-diet inter-
action, namely levodopa and amino acids [81]. Levodopa is a supplementation therapy in
Parkinson’s disease, which is caused by the decrease of the amount of dopamine produced
in the brain as an effect of the loss of dopaminergic neurons. The supplementation of the
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precursor of dopamine, levodopa, allows to restore the normal levels of dopamine in the
brain. Levodopa has a similar chemical structure to amino acids, thereby it competes for
absorption in the blood brain barrier and the gut wall. It is recommended for patients to
avoid amino acid-rich diet to maintain the efficacy of the drug and decrease the ’on-off’
phenomenon where a patient exhibits akinetic phases followed by dyskinesia. Although, the
absorption of levodopa in the blood brain barrier is well documented, its transport in the gut
wall was assumed to happen in a similar fashion. Recently, novel transporters of levodopa
in the gut wall were identified [32], which provided novel insights about the concomitant
absorption of levodopa and dietary amino acids. As steady state metabolic models cannot
address time-dependant phenomena, we developed a multi-scale dynamical model (Figure
1.4-D) of the absorption of levodopa along the gastrointestinal tract and we embedded a
genome-scale model of the small intestine epithelial cell in the gut compartments to account
for the molecular interaction between the drug and diet. We showed the mechanism beyond
successful empirical dietary recommendations and provided a novel model-based diet for
Parkinson’s disease patients. We classified amino acids by their synergistic ability towards
levodopa absorption. A recent clinical trial [159] showed that the absorption of levodopa was
improved when soybeans were administered concomitantly, which confirmed several aspects
of our hypothesis.
This example particularly showed the importance of the modeling-experiment loop in drug
development [118, 121], where the simulations integrate new findings and guide future
experiments, that in return, validate the predictions and calibrate the model.
Assessing between- and within-patient response to insulin
In later clinical phases, where the trials are expanded to a great number of participants to
include several anthropomorphic groups of healthy individuals and patients, the variability
of response is a major outcome of population studies which can lead to the stratification of
patients through adapting the dose or deriving counter-indication for non-response groups.
At this stage, clinical and molecular information about the drug is available and enables
the modeling of drug pharmaockinetics in disease models [46, 120]. Furthermore, it can
guide the large-scale experiments through modelling synthetic populations of patients. We
considered type 1 diabetes as an example for this concept. Type 1 diabetes is caused by
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Figure 1.5: A new drug development paradigm. Using known biology and publicly available
databases, integrative disease models are built to describe the multi-layer biology of the
disease. Instead of optimizing the compound for its binding affinity to a specific target, the
compound is optimized for its ability to reverse the disease network state. Drug signature
networks are built in a similar fashion to disease networks and compounds that reverse
the systemic fingerprint of the disease are selected for further development in a target-free
manner. If the small molecule exists in the market then it is moved to phase II clinical trials
and repurposed for the current indication. Otherwise, the compound efficacy and safety
are assessed through querying side effect databases and performing animal experiments to
support the decision to move to the clinical phases. In clinical phases, an iterative approach
combining empirical observation on patients and healthy individuals and the modelling of
synthetic populations to guide further experiment.
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the decrease of insulin-producing cells in the pancreas, thereby causing a deregulation of
the glucose-insulin-glucagon system. The onset of the disease takes place at early stages of
life and requires constant supplementation of insulin to restore glucose levels. The variabil-
ity of response between and within the same individual requires a constant monitoring and
adaptation of the dose in addition to high socio-economical burden coming from frequent
doctor visit. Type 1 diabetes being a systemic disease, we integrated a whole-body metabolic
model with a dynamical model of glucose-insulin-glucagon system [202], gene expression
data measured in T1D patients as well as the concentration time-course of key metabolites
induced by insulin to build an integrated model of type 1 diabetes. We used the model to sim-
ulate a population of T1D patients and derived factors underlying inter and intra-individual
variability (Chapter 5). Additionally, we compared the metabolic signature of T1D to existing
drug signatures and hypothesized a set of molecules as adjuvants in insulin therapy.
Taken together, as models of biological systems are increasing in scope and size [73], the
integration of genome-scale hybrid dynamical models in all steps of the target discovery,
preclinical trials, first-in-human trials to the assessment of drug-drug and drug-food interac-
tions can leverage the drug development processes. The emergence of system-based design
of therapies can optimize the outcomes and ensure higher success rates.
1.6 Scope and aim of the thesis
The project described in this thesis was built on four main objectives. First, to predict the
gastrointestinal side effects of drugs based solely on in vitro data and to classify drugs with
respect to their metabolic and transcriptomic signature. Second, to predict the efficacy of
levodopa under different dietary schemes using a dynamical genome-scale model of the gas-
trointestinal tract. Third, to design efficient computational methods in metabolic modelling to
allow the simulation of large-scale metabolic models. Last, to upscale the combined models
of genome-scale metabolism (COBRA) and drug disposition (PBPK) from the gastrointesti-
nal tract to whole-body level.
Efficacy and safety being the twomajor reasons for the failure of drug development programs,
I addressed the safety of compounds in the first part using drug-induced gene expression to
derive context-specific models of the gut wall. I used the features of the metabolic models
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to predict gastrointestinal side effects and to classify drugs with respect with their metabolic
and gene expression signature rather than by their indication (Chapter 2). In the second part,
I addressed drug efficacy with respect to a drug-food interaction specifically to optimize the
gastrointestinal bioavailability of levodopa through optimizing diet using a hybrid PBPK-
COBRA model (Chapter 3). The third part surrounds the design of fast software for the
simulation of large-scale metabolic models (Chapter 4), which allows the upscaling of the
combined models of metabolism and drug disposition to whole-body level. The whole-body
model allowed to assess the between and within-patient variability to insulin action (Chapter
5). A brief description of the chapters and the individual contributions is provided in the
following section.
Chapter 2: Predicting gastrointestinal drug effects using contextualized
metabolic models.
Chapter 2 describes the prediction of gastrointestinal side effects using a statistical classifier
based on in vitro drug-induced gene expression and in silico predicted gut wall metabolism.
Then, we used genetic and metabolic features to go beyond the indication-based classification
of drugs to assess compound similarities. The gut wall metabolic model was later used to
assess the efficacy of the gastrointestinal absorption of levodopa (Chapter 3]).
Contributions
Marouen BenGuebila (M.B.G.) and Ines Thiele (I.T.) wrote themanuscript, M.B.G. designed
the study and carried the analysis. I.T. supervised the project.
Chapter 3: Model-based dietary optimization of late-stage, levodopa-
treated, Parkinson’s disease patients.
Chapter 3 addresses the bioavailability of levodopa when co-administered with different types
of nutritional schemes. The small intestine COBRA model was combined with a dynamical
model of levodopa dynamics in the intestine (ACATmodel). The combined model allowed to
provide a mechanism-based diet to improve the efficacy of levodopa, which was in agreement
with a recent clinical trial [159] . The results were published in NPJ systems biology and
applications in June 2016 [81]. The chapter is a reprint of the published paper. The hybrid
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modeling approach was then upscaled to a whole-body level (Chapter 5) through designing
efficient parallel tools for metabolic modeling (Chapter 4).
Contributions
M.B.G. and I.T. wrote the manuscript and designed the study. M.B.G. carried the analysis
and drew the figures. I.T. supervised the project.
Chapter 4: Efficient parallel strategies for solving large-scale metabolic
models.
Chapter 4 is a description of the efficient implementation of FVA and the creation of sam-
pling warmup points through combining message passing interface (MPI) and open multi-
processing (OpenMP) parallel libraries which allowed to perform dynamical load balancing.
The consequent gain in speed and memory allows to address large-scale metabolic models
such as the model described in Chapter 5.
Contributions
M.B.G. wrote the manuscript. M.B.G. and I.T. designed the study. M.B.G. carried the
analysis and drew the figures. I.T. supervised the project.
Chapter 5: Pan-organ model integration of regulatory and metabolic
processes in type 1 diabetes.
The hybrid modeling approach upscaled from the gastrointestinal system to whole-body
metabolism. The glucose insulin model (GIM) of glucose dynamics [202] was coupled to
Harvey, the organ-resolved human metabolic model to assess the between and within patient
variability to insulin response and suggest co-drugs for diabetes control.
Contributions
M.B.G. and I.T. wrote the manuscript and designed the study. M.B.G. carried the analysis
and drew the figures. I.T. supervised the project.
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Chapter 6: Concluding remarks.
Chapter 6 is a reflection of my vision for the emergence of hybrid modeling in biomedical
applications and the challenges that are facing the community with that respect.
Contributions
M.B.G. wrote the chapter.
Chapter 2
Predicting gastrointestinal drug effects
using contextualized metabolic models.
Manuscript in preparation.
Abstract
Gastrointestinal side effects are the most common class of adverse reactions with orally
absorbed drugs. They decrease the patient compliance to the treatment and reduce its
efficacy. The prediction of the effects of a new chemical entity on the gut wall based on in
vitro data solely can improve the safety of marketed drugs and first-in-human trials. We used
the drug-induced gene expression data from the connectivity map to build a drug-specific
small intestine epithelial cell (sIEC) metabolic model. The combined measured in vitro gene
expression and the in silico predicted metabolic rates in the gut wall were used as features
for a multi-label support vector machine (SVM) to predict the occurrence of side effects. We
showed that combining local gut wall specific metabolism with gene expression performs
better than gene expression alone, which indicates the role of small intestine metabolism in
the development of adverse reactions. Furthermore, we reclassified FDA-labelled drugs with
respect to their genetic and metabolic profiles to show hidden similarities between seemingly
different drugs. The linkage of xenobiotics to their transcriptomic andmetabolic profile could
take pharmacology far beyond the usual indication-based classification.
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2.1 Introduction
Side effects are unintended effects of administered xenobiotics that lead to the decrease of
the efficacy of the treatment, a lower compliance of the patients, and eventually the cessation
of the treatment with the development of adverse physiological consequences. Up to 25% of
drug development programs failed because of a lack of safety in first-in-human trials [88].
Therefore, the prediction of side effects of drugs in the preclinical phase using solely in vitro
data holds the promise of decreasing the high attrition rates in drug development. Moreover,
oral administration of drugs being the most common route of disposition, the gastrointestinal
side effects are the most common class by occurrence [18, 144], particularly in geriatry [100].
Therefore, identifying compounds that can cause serious gastrointestinal adverse reactions
from the ones that have benign effects could help optimizing the drug in the preclinical phase
before the first-in-human trials.
The prediction of iatrogenic effects have been addressed mainly through a target-based ap-
proach, wherein the inhibition of a specific target could not only induce the desired effect
but also suppresses all physiological process implicating the target protein [33]. Recently,
with the availability of genome-wide transcriptome profile of more than 20,000 compounds
in the connectivity map [216], new approaches have considered linking the off-target effects
to adverse reactions. Specifically, the interaction of the compound with non-target genes was
hypothesized to drive the emergence of side effects. Recent efforts combined drug-induced
gene expression with its chemical structure and Gene Ontology (GO) processes as features
to accurately predict side effects [246]. Notably, it has been shown that metabolic genes are
among the most predictive features for the classification [246]. Additionally, context-specific
drug metabolic models built on generic reconstruction of human metabolism [260] allowed
to identify metabolic dysregulation underlying the emergence of side effects.
In this study, we considered a context-specific metabolic model of gut wall where the drug-
induced gene expression constrained the space of metabolic phenotypes. The uniform sam-
pling of the solution space [25] allowed to derive differential scores between the drug specific
model and the unperturbed model. Furthermore, we combined the metabolic reactions with
drug-induced gene expression to build and cross-validate amulti-label support vectormachine
to predict the occurrence of side effects. Finally, the transcriptomic and metabolic profiles
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of drugs allowed to cluster compounds by their signatures enabling a new classification that
goes beyond the usual drug indication, thereby offering new insights into drug repurposing.
The combination of local gut wall metabolism [195] with drug transcriptomic profile allowed
to contextualize gene expression data thereby increasing the predictive capability of side
effect classifiers. Extending the classification to a more comprehensive set of side effect
and tissue specific models could provide useful information at the preclinical phase of drug
development thus reducing costs and attrition rates.
2.2 Methods
2.2.1 Data generation
We used the SIDER [33, 123] side effect database to extract intestinal side effect described
as preferred terms (PT) in the MedDRA dictionary. The matching compounds were then
queried in the L1000 LINCS dataset of compound gene expression[216, 128] through the
iLINCS API [109]. The level 4 data reporting the differential expression z-scores of the 978
landmark genes was subsequently subjected to the small intestine epithelial cell metabolic
model (sIEC) [195] which consists of 1282 metabolic reaction. On average 50 genes per
drug model were mapped onto the sIEC. The exchange reactions for the sIEC model were set
for standard European diet as described previously [195] over 24h of interval. Consequently,
we prioritized gene expression measured after 24h on intestinal cell lines, namely HT115,
MDST8, SW-948, NCI-H716, HT-29, SW620, HCT 116, and LoVo. Only genes that were
differentially expressed with a p-value lower than 0.05, were kept for further analyses. For
each drug, an sIEC tailored metabolic model was generated in the form of a linear program
(LP) (Section 2.2.2). Model infeasbilities arising from competing constraints, particularly
with the exchange reactions were minimally relaxed both in cardinal and amplitude (Section
2.2.2), rendering them feasible. Under the drug constraints, we computed the possible flux
values for each of the 1282 reactions through the uniform sampling of the linear program’s
solution space, using Artificially Centered Hit-and-Run (ACHR) implemented in the COBRA
Toolbox [93]. The sampling was unbiased as it did not assume any objective function. We
generated 100,000 points for each model using 1000 iteration step per point, starting from
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a 10,000 warmup points. Sampling of metabolic models allowed to determine a set of
phenotypes of the modelled organism, particularly, it determines the distribution of reaction
rates under a set of constraints [25]. For eachmetabolic reaction of a specific drug-constrained
sIEC, the sampled flux distribution was compared to the drug-free sIEC model and z-scores
were derived for each reaction. Using the generated data, we created a matrix consisting of
gene expression and metabolic flux in columns representing the features, and drugs in rows
representing the observations. The matrix had 605 drugs and 2260 features consisting of
978 landmark genes and 1282 metabolic reactions, with standardized predictors as z-scores
that were directly used for learning and cross-validation. We computed the minimal and
maximal flux capacity for each reaction using Flux Variability Analysis (FVA) and used them
as features in the classification as suggested previously [206]. In this case the feature matrix
had 1282*2 columns. We also considered the gene expression matrix alone with 978 genes
corresponding to the columns.
2.2.2 Subjecting gene expression as constraints on metabolic models
A manually curated metabolic model of the small intestine epithelial cell (sIEC) was pre-
viously constructed to study the effect of inborn errors of metabolism (IEMs) on human
physiology [195]. The metabolic model is formulated as a linear program as follows:
max: cTv (2.1)
subject to:
Sv = 0
vmin ≤ v ≤ vmax
,where cT .v is the objective function, v is the flux vector of metabolic reactions, c is the
vector of objective coefficients, S(m,n) is the stoichiometric matrix linking m metabolites
and n reactions, vmin is the reaction lower bound vector, and vmax is the reaction upper
bound vector. The system assumes steady state such that S.v = 0, which is referred to as Flux
Balance Analysis (FBA)[167] . Flux variability analysis (FVA) [142] determines the minimal
and maximal value feasible by each reaction, through maximizing and minimizing for each
reaction as an objective function, consistent with the applied constraints. Differential gene
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expression zi of gene i encoding reaction j modifies the allowable range of each reaction
obtained by FVA such as the following:
vmin, j = minFVA, j + zi ∗ std(v j)
vmax, j = maxFVA, j + zi ∗ std(v j)
,where vmin and vmax are the new lower and upper bounds of the sIEC drug model, and
minFVA and maxFVA are the lower and upper bounds of the drug-free sIEC determined by
FVA, std(v j) is the standard deviation in reaction j assuming a normal distribution of the
fluxes between minFVA and maxFVA. Similar to E-Flux [36, 28], this formulation of reaction
constraints allows to keep the original structure of the model and changes the reaction bounds
according to gene expression, because transcript levels cannot be used as conclusive evidence
about the enzymatic activity of proteins [140, 116, 68] and metabolic fluxes but are rather
used to constrain the capacity and the space of possible flux values of the corresponding
reaction. Because FVA bounds determine the solution space, scaling FVA bounds by gene
expression constrains the sampling in a new space. Other recent formulations considered
protein concentration to constrain flux capacity [196].
Infeasible sIEC-drug model may occur because of conflicting constraints. If problem 2.1 is
infeasible, we minimally relaxed the constraints in both the amplitude of relaxation and the
cardinal of relaxed reactions, through solving the following problem:
min: | |p| |1, | |q | |1
subject to:
Sv = 0
vmin − p ≤ v ≤ vmax + q
,where p is the relaxation vector of the lower bound and q is the relaxation vector of the
upper bound. Minimizing the 1-norm of p and q ensures both sparsity (minimal cardinal of
reactions to be relaxed), with minimal total sum of relaxation amplitude.
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2.2.3 Building the multi-class support vector machine
The support vector machine multi-label learning was converted to 43 binary SVM single-
label problems, using binary relevance in a one-versus-all scheme, where each classifier
corresponded to an intestinal side effect as reported by SIDER preferred terms. The side
effects occurring for only one drug were discarded and the total set was reduced to 36 side
effects. The dataset used in classification were standardized in the SVM call.
The support vector machine classifier [44] was compared to a set of classifiers namely,
Random forest [29], Logistic regression [153], and Naïve Bayes [69] with their defaults
parameters (Figure A.1). The performance was assessed using the following metrics [16]:
accuracy, area under the ROC curve (AUROC), area under the precision-recall curve (AUPR),
weighted accuracy, and weighted recall. The weighted recall and weighted accuracy were
computed using the average of the accuracy and recall of each label, weighted by the label
size.
Feature selection algorithm
Given the high number of features, we proceeded to the selection of the most predictive genes
and metabolic reactions through various algorithms using the feature selection toolbox [187]
implemented in MATLAB (2017a release, Natick, MA, USA). The genes and metabolic
reactions were then ranked by importance and used as input for the SVM multi-label model.
We tested 11 method of feature selection and compared them with regards to the performance
of the SVM classifier as assessed by the area under the ROC curve (Figure A.2). The
algorithms tested with their default parameters were ReliefF [113], mutinffs [137], FSV
[27], Laplacian [90], MCFS [31], L0 [84], Fisher score [79], udfs [252], llcfs, cfs [83].
ReliefF showed the highest predictive capability for the selected features and was kept for
further analysis. Briefly, the algorithm ranks the features by importance based on a k-nearest
neighbour graph. Consequently, the k parameter has to be optimized.
k parameter of ReliefF
The k parameter of ReliefFwas varied through a range of values and the results were compared
with respect to the area under the ROC curve. Usually a low value of k would not allow for
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strong separation of predictive features, while a k equal to the number of drugs would lead
to the failure of the algorithm. A k equal to 80 allowed to obtain the highest predictability of
the model (Figure A.3).
Number of features
The number of the most predictive features was assessed through testing different values. The
ReliefF algorithm takes as input the feature matrix and the corresponding side effect labels of
the training set and computes the ranking and weights of the features. Selecting 20 features
allowed to obtain the highest area under the ROC curve (Figure A.4).
Cross-validation method
In order to avoid over-fitting and to enhance the accuracy of the classifier, various cross-
validation methods were tested. K-folds cross-validation consists of splitting the dataset into
k parts and performing learning on k-1 folds and the last fold would be used for testing. The
leave-one-out cross-validation trains the classifier on n-1 points and validates the prediction
on the nth data point. The 3, 5, and 10 fold cross-validation as well as leave-one-out were
compared for loss and predictability (??). As cross-validation methods seemed comparable
in prediction outcome (??), we selected 3-fold cross-validation for further analysis because
it requires less computation time. The process is summarized in the following steps:
1. Divide the dataset into test (20%) and training (80%) set
2. Train a single-label classifier for each label with 3-fold cross-validation on the training
set
3. Repeat step two twice with a different partition of the training and validation set
4. Predict the label of the test set using the trained models
5. Repeat step one to four, 100 times taking each time a different partition of the test and
training set.
Finally, the posterior probabilities and the prediction loss on the test set were averaged for
each side effect label.
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Misclassification cost
Class imbalance is frequently encountered in biological datasets [212, 86]. In our case, the
occurrence of intestinal side effects varies widely from frequent unspecific disorders to rare
side effects occurring with a few drugs. The misclassification cost matrix C was set to the
inverse of the label frequencies such that:
C = ©­«
0 1nt−Sf
1
Sf
0
ª®¬
, where the rows correspond to the observed labels, the columns correspond to the predicted
labels in each binary classifier, nt is the size of the training set, and S f the side effect frequency.
The effect of class balance (Figure A.6) improved the classification performance.
Observation weight
Intestinal side effects occur with different empirical frequencies per drug. For every label, the
weight of every drug was set to its frequency as reported in the SIDER database. Information
about 485 side effect frequency were available over 1053 total number of side effects induced
in the 36 labels. The missing information was set to the default of 1 and no further data
imputation was done. Adding observation weights induced a slight decrease in the mean of
the area under the ROC curve for intestinal side effects (Figure A.7) and was not subsequently
kept as a parameter in the model, likely because of the effect of the missing 54% of side effect
frequency.
SVM kernel
The kernel functions of support vector machines that were tested include a linear, Gaussian
and 3rd order polynomial function. The Gaussian kernel function had the highest mean of
the area under the ROC curve per label (Figure A.8) and was consequently set as a label-
wide function. We also looked for the optimal kernel functions per label using MATLAB
hyperparameter optimisation routine.
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Optimal hyperparameters
The optimal hyperparameters obtained for the SVM in the previous analyses and summa-
rized in table A.1 ensured high predictability and accuracy. Additionally, the automatic
tuning of hyperparameters available in MATLAB was tested for hyperparameters listed in
table A.2. The automatic tuning routine finds the optimal set of parameters that minimize
the cross-validation loss, where each binary classifier can have a different set of optimal
parameters. Manually tuning global hyperparameters had a better area under the ROC curve
than individually optimized hyperparameters (Figure A.9) because the set of automatically
tuned parameters in the 2017a release of MATLAB does not include all of the parameters,
particularly the number of features and the feature selection method.
2.2.4 Drug community identification, validation, and interpretation
Graph clustering
A significance test on the principal components was performed using a 100 independent
permutation of the columns of the feature matrix. 15 principal components had a p-value <
0.001 and were retained for subsequent analysis. Then we constructed a graph based on the
k-nearest-neighbour (KNN) [6] of each drug with k equal to 20, using the Jaccard index as a
distance metric.
J(dA, dB) = |dA ∩ dB ||dA ∪ dB |
, where dA and dB are two given drugs in the networks, |dA ∩ dB | is the number of common
neighbours and |dA ∪ dB | is the union of drug neighbours.
Community detection
Drug clusters in the network were identified using the Jaccard-Louvain algorithm [23] as
previously reported [209] and the second level of community clustering gave eight clusters
and was selected for further analysis.
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Cluster visualisation
For further validation and visual inspection, the clusters were visualized using the Barnes-Hut
Stochastic Neighbourhood Embedding (Bh-SNE) [234], with Euclidean distance, a perplexity
of 30 and exaggeration of 4 on the 15 first principal components of the combined feature
matrix. The seed used for the plot was 97.
Cluster validation
We performed network perturbations to assess the stability of the identified clusters. The
value of k in the KNN algorithm was randomly selected in a uniform distribution between
2 and 50. We then selected independently 85% of the drugs and built the Jaccard-based
adjacency matrix, of which we removed 5% of the edges and added 5% of new random edges.
Finally random noise values were added to the edges and the Jaccard-Louvain[23] algorithm
identified communities in the perturbed network. The process was repeated 200 times. To
validate the selected clusters [209], stability and purity were selected as external measures
and were computed for each cluster [241]. Stability is measure of diversity in the clusters of
each perturbation trial. Briefly, if the points assigned to a given cluster in a given trial have
a high diversity of points from the original clustering assignment, the stability would be low.
Stability was computed as the following:

Stability = 1 − instability
Instability = 1n
∑n
i=1
Ei
EToti
Ei =
∑
i pilog(pi)
EToti =
∑m
j=1 p jE j
, where Ei is the entropy of a given cluster in trial i, EToti is the total entropy in trial i, pi is
the fraction of a given cluster size over all data points in trial i, m is the number of clusters
and n is number of trials. Purity is similar to stability and consists of the enumeration of data
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points in a given cluster i that were labelled as cluster j. Purity is computed as follows:

Purity = 1 −∑mj=1 |clj ||nDrugs |Pj
Pj = 1|clj |Maxi(|clij |)
, where m is the number of clusters, |cl j | is the size of cluster j, Pj is the purity of cluster
j, Maxi(|clij |) is the size of the largest cluster i contained in cluster j of the unperturbed
clustering.
Gene set enrichment
In each cluster, the top differentially expressed genes were identified and submitted for
pathway enrichment in KEGG [107] through Enrichr API [125, 35]. Then the 10 most
significantly enriched terms (p < 0.05) were assigned to each cluster.
2.3 Results
The prediction of iatrogenic gastrointestinal drug effects based on in vitro data could im-
prove the assessment of safety of new chemical entities. We combined drug-induced gene
expression data with metabolic models of the gut wall to develop an SVM classifier. We
employed the classifier to predict the occurrence of common gastrointestinal side effects and
the biological processes involved in their development. Furthermore, we classified the drugs
using their transcriptomic and metabolic signatures to provide insights into drug action and
mechanism. Finally, including more tissues through context-specific metabolic models could
extend the approach to additional labels of side effects.
2.3.1 Generating the combined drug gene expression and metabolism
matrix
In order to model drug effects on the gastrointestinal system, a manually-curated constraint-
based model of the small intestinal epithelial cell (sIEC) [195] was contextualized for each
drug. The upper and lower bounds of every metabolic reaction were adjusted by the relative
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Figure 2.1: Overview of the pipeline of data generation and analysis in this study. Drug
induced gene expression were collected through the connectivity map API. The drug side
effects occurrence was obtained from the SIDER database, and the drug mechanism and
physiological effect was collected from the FDA National Drug Code Directory (NDCD).
The drug-induced gene expression were subjected as constraints on a small intestine epithelial
cell (sIEC)metabolic model to derive a context-specificmodel for each drug. After minimally
resolving infeasible models, the uniform sampling of the solution space of the sIEC allowed to
derive z-scores of metabolic fluxes in the treated and drug-free model. Combining the drug-
induced gene expressionwith predicted differentialmetabolic fluxes in a singlematrix allowed
to train and cross-validate a multi-label support vector machine. Finally, the clustering of
drugs based on their transcriptomic and metabolic profiles allowed to find hidden similarities
beyond the indication based-classification.
expression of the gene encoding the enzyme catalysing the reaction. The obtained context-
specific drug-sIEC model was generated for every drug using the differential gene expression
data obtained from the connectivity map [216]. In models where the subjected constraints
rendered the linear program infeasible, a set of reactions of minimal cardinality was relaxed
by a minimal amplitude to obtain a feasible model. In order to assess the impact of drug
constraints on metabolic models, the minimal and maximal metabolic flux per reaction was
computed by FVA for each drug-constrained sIEC as suggested previously [206]. Although,
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informing the classifier of the distribution of possible flux values per reaction rather than its
bound could be of higher predictive capability. We sampled the drug-constrained solution
space of each sIEC model and derived differential scores between the flux distribution per
reaction of the drug-free sIEC and the drug-constrained sIEC. Following these steps, we
obtained four features matrices: the differential gene expression of each drug obtained from
the connectivity map, the FVA metabolism matrix obtained by the upper and lower bound of
each reaction, the samplingmetabolismmatrix consisting of the differential score of flux value
distribution per reaction, and the combined gene expression and sampled metabolism matrix
which is a combination of the first and third matrices. The class matrix relating each drug to
its side effects was obtained through parsing the SIDER database [124]. Further information
about drug mechanisms, physiological effect, marketing date, and pharmacological class
were obtained from the FDA NDCD database (Figure 2.1).
2.3.2 Combining measured gene expression and simulated gut wall
metabolism predicts intestinal iatrogenic effects
Drug induced gene expression provided strong features for side effect prediction, especially
with side effect classes that have links to metabolism [246]. We used this finding to fur-
ther improve the prediction of intestinal side effects through subjecting gene expression as
constraints in the metabolic model of small intestine epithelial cell (sIEC), thereby contex-
tualizing gut wall metabolism to derive the intestinal metabolic fingerprint of every drug.
As previously observed [246], gene expression alone was the support of most predictive
features (Figure 2.2-A). Metabolic reaction fluxes alone were less predictive as it takes into
account the genes with metabolic activity in the sIEC (Figure 2.2-A). Particularly, sampling
the metabolic model allowed to improve the classification as it informs about the distribution
of metabolic fluxes per reaction rather than the minimal and maximal bound of metabolic
reactions alone as reported by FVA (Figure 2.2-A). Combining gene expression and predicted
metabolism gave the highest predictive rates in the multi-label SVM classifier as average of
individual labels (Figure 2.2-A), and in comparison to other classifiers (Figure A.1).
Unspecific or likely non metabolic side effects such as gastrointestinal obstruction were
among the least predictable with an area under the ROC curve of 0.67 using combined gene
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expression and sampled reaction fluxes. Side effects involving gut wall metabolism were
highly predictable using combined features (Figure 2.3, Table A.3) such as intestinal carci-
noma (0.96), ulcer (0.97), and toxicity (0.92). The merged intestinal side effect classifier
using the individual binary classifiers could better predict (0.94) intestinal side effects based
on combined gene expression and metabolism in comparison to gene expression (0.935) or
metabolism alone using FVA (0.92) and sampling (0.931) as shown by the micro-averaged
ROC curve (Figure 2.2-B). The most predictive metabolic reactions were enriched in the
subsystems of sIEC and the most predictive genetic features were enriched in gene ontology
biological processes database (both at p<0.001). The 10 most represented subsystems mainly
involved transport in various locations (extracellular, exchange, mitochondrial, endoplasmic
reticulum) as well as catabolic and synthetic functionalities (Figure 2.2-C). The gene ontol-
ogy biological processes enriched groups involved mainly the regulation of transcription and
apoptotic process (Figure 2.2-D).
2.3.3 Drug classification using transcriptional and intestinal metabolic
activity
The construction of the drug feature matrix consisting of gene and metabolic reaction vectors
per drug allowed the use of clustering techniques to classify drugs in the gene and metabolism
space. Using the community detection algorithm Jaccard-Louvain [23], we identified eight
drug clusters based on their genetic and metabolic signature (Figure 2.4-A). Each cluster
had a stability and purity greater than 0.75 (Figure A.10-D). In particular, transcriptional
and intestinal metabolic activity were aligned with the identified clusters (Figure 2.4-B).
Interestingly, the identified clusters did not map on the FDA NDCD’s Established Pharmaco-
logical Class (EPC) (Figure A.10-A) suggesting that classical indication-based classification
could overlook genetic and molecular aspects of small molecules’ pharmacodynamics. Most
small molecules had a low genetic and metabolic fingerprint as reported previously [125]
and targeted mainly the various transport subsystems (Figure A.10-C) of the enterocyte,
which is the main function of the gut wall. Cluster one and eight involved a high number
of genes and metabolic reactions mainly due to cytotoxic drugs which was also reflected on
the FDA NDCD’s Physiological Effect (PE) (Figure 2.4-C) by the presence of terms linked
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Figure 2.2: Evaluation metrics for the multi-label support vector machine intestinal side
effects classifier. A-Comparison of individual side effect classifier predictive capability as
measured by the out-of-sample area under the ROC curve using genetic, metabolic, and
combined genetic and metabolic features. B-ROC curve of the micro-averaged multi-label
SVM classifier using genes, metabolism and combined genes and metabolism as features.
C-Top 10 enriched metabolic subsystems and D-gene ontology biological process terms
ranked by the number of metabolic and genetic representatives. G stands for genes, Ms for
metabolism sampling, Mf for metabolism FVA, andGMs for genes andmetabolism sampling.
to inflammation and immunity. Additionally, cluster eight and one were linked to malignant
side effects (Figure A.10-A).
Cluster seven had a high number of active fluxes in the small intestine epithelial cell. Inter-
estingly, a number of terms linked to the central nervous systems were found, which hints to
potential gut-brain shared molecular processes, probably linked to the similar composition
of the blood brain barrier and the gut wall transporters [17]. In addition to cluster seven,
cluster two had a low transcriptomic and a high metabolic profile. The EPCs linked to these
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clusters were mostly compounds whose action is mediated through metabolic, e.g., xanthine
oxidase, or signalling, e.g., PPARαmolecule binding (Figure 2.4-D). Ubiquitous targets, e.g.,
cyclooxygenase and histamine receptors would consequentially induce pronouncedmetabolic
effects.
On the high transcription and high metabolism profile represented by cluster one and eight
(Figure 2.4-E), the presence of molecules acting on the central nervous systems by their FDA
NDCD’s Mechanism of Action (MoA) confirms links between the gut and brain metabolism.
Additionally, since cluster one and eight encompassed anticancer drugs as previously ob-
served, this finding further supports ongoing repurposing trials of antidepressants in can-
cer therapy [99]. Moreover, neurokinin-1 antagonists, a class of drugs prescribed for the
suppression of cytotoxic drug-induced emesis, and 5-lipoxygenase inhibitors, indicated for
inflammatory bowel disease, had a high genetic and metabolic profile indicating potential
links between gut symptomatology and genome-wide transcriptional and metabolic modula-
tion. We further enriched the top differentially enriched genes in each cluster in the KEGG
[35, 107] database (Figure 2.4-E) and selected the terms pertaining to gastrointestinal physi-
ology. Epithelial cell signalling in H. pylori infection was linked to cluster seven which had
low transcriptomic and high metabolic profile suggesting metabolism-modulated signalling
through kinases following the infection. E.coli infection term belonged to the same cluster
which suggests that both pathogens might involve the same kinase but also that similar treat-
ment might overcome both infections. Phenotypes involving rather signalling mechanisms
than metabolism e.g., Vibrio cholerae infection belonged to cluster six that had low intestinal
metabolic fingerprint.
Taken together, the multi-layer biology of drug effects allowed to accurately predict iatro-
genic gastrointestinal effects using an SVM classifier. The clustering of drugs based on
their metabolic and genetic signature has the potential to unravel potential similarities in the
mechanism of action of compounds in relation to their physiological effects.
2.4 Discussion
The prediction of side effects using only in vitro data of small molecules is a requisite of
safe first-in-human trials and low attrition rates in the clinical phases. The connectivity map
2.4. DISCUSSION 51
Figure 2.3: (Continued on the following page.)
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Figure 2.3: Out-of-sample ROC curve for intestinal obstruction, gastrointestinal toxicity,
carcinoma, ulcer, polyp, candidasis, hemorrhage, and inflammation. The features used for
comparison were the sampled flux values in metabolic models, the minimal and maximal
flux values per reaction as reported by FVA, gene expression reported in the connectivity
map, and the combined gene expression and sampled reaction flux value. The comparison
was performed using the area under the ROC curve. G stands for genes, Ms for metabolism
sampling, Mf for metabolism FVA, and GMs for genes combined with metabolism sampling.
of drug signatures [216] provided a large set of gene expression profiles corresponding to
small molecules perturbagens. Therefore, we modelled the metabolism of gut wall under
drug-induced perturbation to predict iatrogenic effects using an SVM classifier. Sampling
of the metabolic model provided better classification results than FVA bounds as features.
Moreover, combining gene expression with modelling captured both metabolic and non-
metabolic effects in relation to side effect development. Finally, classifying compounds
with respect to their metabolic and transcriptomic fingerprint suggested drug repurposing
strategies that could provide new therapeutic alternatives.
2.4.1 Model generation and parameter selection
The connectivity map [216] provided a large-scale resource of small molecule transcriptomic
signature and enabled the genome-wide assessment of drug off-target effects, thereby ex-
panding pharmacology beyond the study of the drug primary target alone. The integration of
drug-induced gene expression with generic metabolic models of human metabolism allowed
to identify key disrupted metabolic functions [260] resulting from adverse reactions. Sim-
ilarly, the integration of known target effects of drugs as identified from DrugBank [251],
and using flux bounds obtained by FVA as features to predict side effects [206] allowed to
accurately predict several classes of side effects. Although, this approach remains limited
to drugs with inhibitory effects on metabolic targets, and a fortiori of known targets. In our
approach, the integration of drug-induced gene expression with metabolic networks allowed
to circumvent the inhibitory target limitation [194] and allowed most importantly to model
the drug off-target effects which were suggested to be the main driver of side effects. We
showed that informing the classifier with the distribution of metabolic fluxes per reaction
using sampling rather than providing the bounds of the reaction using flux variability analysis
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Figure 2.4: (Continued on the following page.)
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Figure 2.4: Drug community identification based on measured transcriptional and simulated
gut wall metabolic profile. A-Visualisation of the eight validated drug clusters through
Barnes-Hut Stochastic Neighbourhood Embedding (Bh-SNE) plot. B-Transcriptional and
gut metabolic activity of the identified clusters showed different levels of drug specificity
per cluster. C-Bipartite graph of drug clusters and FDA NDCD’s physiological effect (PE).
D-Bipartite graph of drug clusters and FDA NDCD’s established physiological class (EPC).
E-Graph linking drug clusters to FDA NDCD’s mechanism of action (MoA) and KEGG
enriched pathways of the gene pertaining to each cluster. The diagram was done using
Rawgraphs [151].
increased the predictive power of the classifier (Figure 2.2-A,B). Additionally, restricting
the prediction to a set of organ-specific side effects using a manually curated tissue-specific
metabolic model captured local metabolism in relation to the emergence of organ-specific
adverse reactions.
Improving the prediction of occurrence of side effects relies greatly on the quality and com-
pleteness of the dataset used. It is highly likely that weighting the variables by the side
effects frequency per drug can improve the predictions and leverage the prediction of rare
side effects. Nevertheless, only 46% of side effects had frequency information associated
whose inclusion did not improve the prediction accuracy (Figure A.7). The missing infor-
mation could be potentially filled by either manual expert curation or crossing databases.
Moreover, the physiological effect and mechanism of action in the FDA NDCD were missing
for a number of drugs as well. Additionally, the chronopharmacology of drug action is also
of paramount importance in detecting the emergence of side effects. The connectivity map
provides a number of experiments at several time interval that we did not exploit in our
analysis as not all drug-induced gene expression were measured for different time points.
Such data can take the predictions from looking at snapshots of transcription and metabolism
to dynamical models linking the emergence of side effects to time-dependant processes.
2.4.2 Sampling the metabolic model of the gut wall achieved the highest
prediction accuracy
Conceptually, drug-induced gene expression could play a major role in the genesis of adverse
reactions. Particularly, it was shown to be predictive towards side effects classification,
especially when combined with other drug features such as chemical structure and cell
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morphology after treatment [246]. The combination of gastrointestinal local metabolism
constrained by metabolic gene expression and the differential expression of non-metabolic
genes allowed to achieve the most accurate prediction of gastrointestinal side effects (Figure
2.2-A,B). The combination of multiple layers of biology consisting of transcriptomic and
predicted metabolic features was key in capturing drug-induced perturbations related to side
effects. Furthermore, the approach can be scaled to several tissues to include all the label of
side effects using semi-automatic and manually curated models of human metabolism [204].
Remarkably, sampling metabolic models alone achieved a good accuracy taking into account
that only the metabolic subset of genes from the connectivity map was modelled. Therefore,
we suggest that a reduced set of in vitro experiments to measure the differential expression
of metabolic genes would give an invaluable insight into the emergence of adverse reactions
of a new chemical entity in the preclinical phase which can guide the rational design of first-
in-human trials. Furthermore, the emergence of whole-cell models [108, 219] that integrate
metabolism alongside several physiological functions would allow the mapping of non-
metabolic genes onto computational models of the cell to capture the cell-wide disruption
of physiological processes that lead to the emergence of side effects. With the generated
combined gene and gut wall metabolism matrix in hand, we classified the small molecules
with respect to their signatures to highlight their common features.
2.4.3 Drug reclassification beyond the chemical class
Drugs are often classified with respect to their pharmacological indication and their chemical
family. The many examples of marketed drug repurposed for new indications [133] shows
that a small molecule can have rather many effects. Drug repurposing have gained great in-
terest in the recent years, as it allows to greatly decrease the drug development process using
compounds whose safety is well documented. In order to find common properties of drugs,
we identified clusters of compounds that share similar genetic and metabolic signatures in the
gut wall. Interestingly, compounds that involved a high number of metabolic reactions with a
high amplitude of variation included CNS drugs like serotonin antagonists indicated for psy-
chotic episodes that were later suggested to treat chemotherapy-induced emesis. Moreover,
those compounds belonged to the same cluster with neurokinin inhibitors that are primarily
56 CHAPTER 2. INTESTINAL SIDE EFFECT PREDICTION
indicated for the prevention of emesis as well. Serotonin antagonists are also indicated to treat
the inflammatory bowel syndrome, which further showed the similarity between the blood
brain barrier and the gut wall metabolism and gene expression. Furthermore, anticancer
drugs and the drugs that treat their side effects, the anti-emesis drugs, clustered together
in the high transcriptomic, high metabolic activity cluster, further supporting the idea that
reversing the molecular fingerprint of a compound can reverse its effects. Particularly, re-
versing the fingerprint of the compound locally, in the gut wall, would be a potential strategy
to reverse gastrointestinal side effects of drugs through the administration of co-drugs, while
preserving its main activity in the target tissue.
Furthermore, the clusters of drugs that we identified in our analysis did not match FDA
marketing date (Figure A.10-B). Despite the emergence of the key-lock paradigm [154] in
drug development using molecular dynamics and docking experiments in early 1990s that
decreased the number of drugs interacting with a high number of targets, colloquially called
’dirty drugs’, there are still opportunities for further enhancement in the design of precise
therapies.
We developed and employed a multi-label support vector machine on genetic and metabolic
fingerprint of marketed small molecule compounds to accurately predict the occurrence of
gastrointestinal side effects. The drug features allowed to classify drugs based on their
metabolic and genetic profile, which is a promising avenue for drug repurposing to revert side
effects and unravel new indications. The development of large scale, publicly available, com-
pound resources combined with complex mathematical models of cellular biology provides
a new way of providing patients with safer and more effective therapies.
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Abstract
Levodopa has been the gold standard for Parkinson’s disease treatment for more than 40
years. Its bioavailability is hindered by dietary amino acids, leading to fluctuations in the
motor response particularly in late-stage (stage 3 and 4 on Hoehn and Yahr scale) patients.
The routine dietary intervention consists of low-protein (< 0.8 g/kg) diets or the redistri-
bution of daily protein allowance to the last meal. Computational modeling was used to
examine the fluctuation of gastrointestinal levodopa absorption under consideration of the
diet by (i) identifying the group of patients that could benefit from dietary interventions,
(ii) comparing existing diet recommendations for their impact on levodopa bioavailability,
and (iii) suggesting a mechanism-based dietary intervention. We developed a multiscale
computational model consisting of an ODE-based ACATmodel and metabolic genome-scale
sIEC model. We used this model to investigate complex spatiotemporal relationship be-
tween dietary amino acids and levodopa absorption. Our model predicted an improvement in
bioavailability, as reflected by blood concentrations of levodopa with protein redistribution
diet by 34% compared with a low-protein diet and by 11% compared with the ante cibum
(a.c.) administration. A systematic analysis of the effect of different amino acids in the diet
suggested that a serine-rich diet could improve the bioavailability by 22% compared with
the a.c. administration. Optimizing dietary recommendations in quantity, composition, and
intake time holds the promise to improve levodopa efficiency and patient’s quality of life
based on mechanistic models of gut physiology.
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3.1 Introduction
The gut wall is the first physiological barrier that encounters nutrients and xenobiotics
absorbed orally [130], where food–drug interactions take place. These interactions are
complex, as in the case of levodopa absorption and a protein-rich diet. Levodopa is the
gold standard treatment in Parkinson’s disease [30] and has a similar chemical structure as
cyclic amino acids[59]. Supplementing Parkinson’s disease patients with levodopa restores
the dopamine levels in the brain and prevents motor symptoms [62]. It shares the same
transporters with amino acids in the gut, brain, and kidneys,leading to competition that
decreases its entry to target sites[161]. Therefore, dietary recommendations are given to
Parkinson’s disease patients [97] as levodopa bioavailability is influenced by diet[39]. Low-
protein diet (LPD) limits protein intake to aminimal amount for everymeal (< 0.8 g/kg of body
weight). Another option is protein redistribution diet (PRD),where patients are recommended
to take the daily protein allowance in the last meal. PRD has a better efficacy with lower off
phenomena (e.g., akinesia) leading to improved life quality, especially at the latest stages of
Parkinson’s disease (3 and 4 on Hoehn and Yahr (HY) scale)[34]. The molecular mechanism
of this improvement remains poorly understood. The recent identification of luminal and
basolateral levodopa transporters in the human sIEC was a major step for a better evaluation
of dietary recommendations. It has been shown that, in addition to luminal competition, the
presence of amino acids in the basolateral side of enterocytes trans-stimulates the absorption
of levodopa leading to a higher bioavailability of the drug [32]. Computational modeling
could be used to further elucidate the role of diet and levodopa absorption and to provide
a basis for rational design of dietary recommendations. Such modeling should ideally
(i) describe the levodopa kinetics in the gastrointestinal tract, as well as the other organs
and (ii) consider sIEC-mediated uptake of levodopa and dietary amino acids.For the first
aspect, PBPK modeling is an ideal computational approach because it describes with a set
of ordinary differential equations cellular, tissue, and whole-body distribution of drugs. In
particular, whole-body generic PBPK models have been described in the literature and used
to investigate the effects of xenobiotics and mechanistically predict tissue concentrations of
drugs [105]. Moreover, organ and process-specific PBPK models have been developed, such
as the ACAT model, for which in vitro parameters were used to estimate gastrointestinal
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absorption of drugs in human along seven small intestinal segments [3]. An advantage of the
PBPK modeling is that it captures the dynamics of the modeled system. However, it requires
the availability or fitting of many parameters, which may not be always easy to be obtained
and thereby limits the size and resolution of the described system. In contrast, the COBRA
approach assumes the modeled biological system to be at a steady state, thereby allowing
the description of large systems, such as cells and organs, at the molecular level, while
not requiring complete knowledge about the model parameters[163]. COBRA models are
assembled based on genome annotations and biochemical data [223] and subjected to physio-
chemical, genetic, thermodynamic, and biological constraints[19]. Recently, a genome-scale
model of the enterocyte-specific metabolism (‘sIEC model’) has been published, describing
known metabolic transformations and transport activities in sIECs[195]. This model has
been constructed on the basis of global human metabolic reconstruction [57] which has been
also recently extended for more refined metabolic content[226][192], as well as for a drug
module[194]. In this study, we (i) develop a combined multiscale PBPK–COBRAmodel and
(ii) use it to investigate the complex spatiotemporal relationship between amino acids and
levodopa kinetics and its impact on Parkinson’s disease patients.
3.2 Methods
To generate the multiscale gastrointestinal model, we (i) expanded the whole-body generic
PBPKmodel[170] by the ACATmodel[3], (ii) added levodopa transport reactions to the sIEC
model [32], and (iii) coupled both models with respect to a specific time step.
3.2.1 Whole-body PBPK modeling and system identification
The ACAT model[3] and the whole-body generic PBPK [105] (Figure 3.1,Figure fig:s1levo-
A) model were implemented and combined in Matlab (2014b release, MathWorks, Natick,
MA, USA). Details on the models and their integration can be found in the supplementary
section dynamical modeling of levodopa (Text B.2). The whole-body generic PBPK model
with ACAT component consisted of 42 ordinary differential equations and 243 parameters. In
the following, we will refer to this ACAT-expanded whole-body generic model as WB-ACAT
model. The kinetic parameters of levodopa (Table B.1 and B.2) were identified through
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fitting of the WB-ACAT model on averaged data from 24 fasting healthy volunteers’ plasma
concentrations after oral (Per os) administration of 200 mg of a standard formulation of lev-
odopa and 50 mg of peripheral metabolism inhibitor (benserazide) [110] ((Text B.2); Figure
fig:s1levo-B). The goodness of fit was assessed through visual inspection (Figure fig:s2levo),
the Kolmogorov–Smirnov test [150] with a resulting P = 0.9994, and the Pearson’s correla-
tion coefficient with r = 0.99 (P < 0.0001). The delay in the GER parameter induced by food
was inferred by sequentially fitting data from a two-occasion study[39]: plasma levodopa
concentrations in the fasted state and plasma levodopa concentrations after aproteic meal.
For the first occasion (fasted), all model parameters were estimated except GER, which was
set, as reported in the literature, for the fasting state (Table 3.1). For the second occasion
(fed), all kinetic parameters were fixed and only GER was estimated. The sequential fitting
approach was undertaken, as it allowed quantification of varying parameter between fed and
fasted states. The time-dependent parameter sensitivity analysis with respect to levodopa
concentrations in plasma was computed as the result of the following non-normalized time-
dependent derivative:
sensitivity =
∂y
∂x
(3.1)
where x represents the vector of all WB-ACAT model parameters and y represents the
plasma concentrations of levodopa. Then, the absolute time integral for every parameter was
computed for every parameter using trapz function in Matlab.
3.2.2 sIEC model
To take into account the gutwallmetabolism and transport, the sIEC stoichiometricmodelwas
used. The sIEC model contains a thorough collection of metabolic and transport pathways
of amino acids, which provided non-intuitive metabolite utilization strategies in different
conditions [195]. To account for levodopa uptake and secretion by the transporters (En-
trezGene ID: 11067-6591, 117247, 23428-6520), 36 levodopa reactions were added to the
model, representing the specific stoichiometric coefficients for the transported co-metabolites
accounting for competition and trans-stimulation (Text B.2) in the reported order of affinity
[239] as measured experimentally [32]. The resulting sIEC_levodopa model, to which we
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will refer in the remainder as sIEC model, consisted of 433 metabolites, 1318 reactions, and
616 genes.
3.2.3 Coupling algorithm
The coupling between seven sIEC models and the WB-ACAT model (Figures 1 and 4) was
achieved by performing dynamic flux balance analysis[236], which computes uptake rates
of each of the seven sIEC models using as constraints the outcome of the simulation of the
WB-ACAT model, which were subsequently set as derivatives dXdt in the WB-ACAT model.
We implemented this coupling with the static optimization approach (SOA) [141], which
discretizes the simulation time into a defined number of steps and simulates sequentially the
PBPK and COBRAmodel for every step [141] (Figure 3.4). The total simulation time of 18 h
was divided into steps of 0.1 h, which represents a good compromise between the integration
tolerance of the dynamical model, the simulation time, and the steady state assumption of
the sIEC model with respect to the fast kinetics of levodopa in the blood following Per os
administration [43]. SOA assumes steady state of the metabolic network in intervals of 0.1
h, the sIEC model will reach a different steady state depending on the changing constraints
of levodopa between the different time intervals.
3.3 Results
3.3.1 Modeling intestinal absorption of levodopa using a combined
PBPK–COBRA model
To model the temporal, spatial, and metabolic effects of levodopa transport along the gas-
trointestinal tract, we developed a combined PBPK and COBRA model (Figure 3.1). This
model combines the advantages of PBPK modeling through a comprehensive whole-body
model with refined gastrointestinal absorption (WB-ACAT) model and of COBRAmodelling
through a mechanistically accurate and detailed small intestinal cell models (sIEC models),
representing the metabolic functions of seven small intestinal segments (duodenum, two
jejunum segments, and four ileum segments). The WB-ACAT model takes into account
the dissolution and transit of a standard formulation of levodopa with respect to the pH and
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Figure 3.1: Themultiscale PBPK–COBRAmodel used in this study. We combined a spatially
and temporally refined PBPK model (deemed WB-ACAT) of the gastrointestinal tract with
seven copies of a mechanistically accurate and detailed metabolic model of small intesti-
nal epithelial cells (sIEC). COBRA, constraint-based reconstruction and analysis; PBPK,
physiologically based pharmacokinetic; WB-ACAT, whole-body advanced compartmental
absorption and transit.
volume of each compartment, through the identified parameters of fasted and fed states. To
ensure a biologically relevant set of parameters, the model was fit onto human data and con-
strained with values reported in the literature (Figure fig:s1levo-B). In addition, the global
search option with the constrained optimization algorithm (Text B.2) allowed obtaining a
global minimum. The subsequent absorption, metabolism, and secretion of levodopa by
enterocytes were captured by the sIEC models (Figure 3.2-A) which were not added for the
stomach and the colon as no absorption is assumed to take place in these two compartments.
Both models were coupled using dynamic flux balance analysis (seeMethods and Figure 3.1).
The WB-ACAT-sIEC model was then used to identify patients in need of dietary recommen-
dations and to provide mechanism-based optimized diet for Parkinson’s disease patients. The
internal metabolites of the sIEC were assumed to be in steady state, while levodopa had a
concentration rate-of-change equal to the fluxes of the dynamical model through imbalanced
exchange reactions.
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Figure 3.2: Levodopa and amino acids affinities for enterocyte transporters. (a) One trans-
porter (antiporter) in the luminal side and two transporters (one antiporter and one uniporter)
in the basolateral side are involved in the absorption and secretion of levodopa. (b) Amino
acids are ordered by affinity for the transporter. Dibasic and neutral amino acids compete for
the luminal uniporter. Aromatic amino acids uniporter is involved in the basolateral secretion
of levodopa. The basolateral antiporter exchanges levodopa for amino acids. In both a and b,
four fifths of levodopa is secreted through the basolateral uniporter and one fifth through the
antiporter. Amino acids in the colored circle go with the corresponding colored route.
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3.3.2 Dietary intervention is needed for HY 3 and HY 4 patients
Using themultiscale PBPK–COBRAmodel, we addressed the questionwhether there is a par-
ticular subset of Parkinson’s disease patients that would benefit the most by the recommended
adjustment of dietary proteins[39] [34]. In particular, we investigated the pharmacokinetic
profile of levodopa in a fasted state (Figures B.3 and B.1-C, Text B.2) and in a fed state with a
concomitant administration of aproteic and proteic meal (Figure 3.3-A). An ante cibum (a.c.)
administration of 100 mg of levodopa every six hours was simulated (Figure 3.3-A). Each
disease state on HY scale has a therapeutic window, in which the efficiency of the treatment is
optimal as reflected by the control of symptoms [39]. A dose below the therapeutic window
leads to persistence of the symptoms while a higher dose could trigger adverse effects, such
as dyskinesia. Since the threshold concentrations of the therapeutic window have been de-
termined with a 100 mg dose[39], the model was simulated at the specified doses, assuming
that the parameters are dose independent. In fact, nonlinear behaviour has been observed at
very high, non-clinical doses[131]. The resulting levodopa pharmacokinetic profile in the
a.c. administration state showed a higher area under the curve (AUC) in the first HY stage
(colored areas in Figure 3.3-A). The decrease in AUC is inversely proportional to the disease
stage. The simulation of the fed state with aproteic meal involved changing of physiological
parameters (Table 3.1). The pharmacokinetic profile showed a decrease in the maximum
concentration (Cmax) and a delay in the corresponding time (Tmax). With the concomitant
administration of proteic and aproteic meals, the plasma concentration of levodopa stayed
below the threshold of the therapeutic window of HY 3 and HY 4 patients and did not cover
optimally the therapeutic window for HY 2. Based on this information, we concluded that
dietary intervention would be most beneficial for Parkinson’s disease patients in HY 3 and
HY 4.
3.3.3 PRD improves the bioavailability of levodopa over LPD
In later stages of Parkinson’s disease, the reported superiority of PRD over LPDmay be due to
an increase in bioavailability of levodopa. To test this hypothesis, the pharmacokinetic profile
of levodopa under both LPD and PRD was simulated. In the LPD setting, 0.8 g amino acids
per kg body weight were administered in silico together with 200 mg of levodopa three times
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Figure 3.3: Predicted pharmacokinetics of levodopa under different dietary conditions. (a)
a.c., proteic, and aproteic meals influence on the pharmacokinetic profile of levodopa. The
efficacy threshold values for the different disease progression stages were plotted in dashed
lines on Hoehn and Yahr scale (HY1 to HY 4). The more advanced the stage, the higher
the levodopa concentration threshold. The AUC corresponding to HY1 in the fasted state
is the blue area, HY 2 is the red area, and HY 3 is the green area (b) The pharmacokinetic
profile of levodopa under LPD diet. (c) The pharmacokinetic profile of levodopa under PRD
diet, LPD diet and a.c. administration. (d) The pharmacokinetic profile of levodopa with
the model proposed serine-rich diet, which can increase the bioavailability of levodopa. (e)
Relative variation of the AUC of levodopa under different dietary conditions in comparison
to the fasted state. a.c., ante cibum; AUC, area under the curve; LPD, Low-protein diet; PRD,
protein redistribution diet.
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a day (t.i.d.) every 6 h. LPD assumes that levodopa dose is taken before the meal; hence,
none of the physiological parameters (Table 3.1) were effective in the simulation. Since
LPD and PRD are recommended in late-stage Parkinson’s disease patients, with pronounced
impairment of gastric emptying that can go up to 7 h [87], it is assumed that the last meal
with < 0.8 g/kg of body weight of proteins is still present in the small intestine. To account
for the different affinities of amino acids for the luminal transporter and the subsequent
competition with levodopa, cystine and ornithine were first simulated as these amino acids
have the highest and lowest affinity (Figure 3.2-B, Table 3.1), respectively. The AUC above
the efficacy threshold decreased by 11.24% for ornithine and by 22.91% for cysteine in
comparison to the a.c. administration (Figure 3.3-B). PRD is based on the redistribution
of the daily protein allowance to the last meal, for the latest stages of Parkinson’s disease
[34]. It has been demonstrated that gastric emptying rate (GER) decreases severely in the
latest stage of Parkinson’s disease. Moreover, the kinetics of amino acids in the plasma,
after protein ingestion, are higher than the baseline after 8 h [26]. We consequently assumed
that a high fraction of amino acids is present in the systemic circulation and in the portal
vein, particularly, when the next levodopa dose is taken the following day. In particular, the
transstimulation effect on levodopa secretion by amino acids was captured with the sIEC
basolateral transporters (Figure 3.4). The simulation showed that a higher flux through the
basolateral antiporter induced a higher bioavailability of levodopa, which is reflected by the
increase of AUC above the efficacy threshold throughout the day (11.23%) in comparison to
the fasted state (Figure 3.3-C). Taken together, these results support the observed superiority
of PRD over LPD to increase the systemic bioavailability of levodopa, which is reflected in
our simulations by the cumulative increase in the AUC (34%).
3.3.4 Impaired gastrointestinal processes reduced levodopa efficacy
The slower gastric motility, induced by food and several conditions, decreases the bioavail-
ability of orally absorbed drugs [39], including levodopa. We identified the parameter for
GER for the fasted and the fed state based on a two-occasion study [39] (see Methods for
details, Table 3.1). We used the fitted GER to simulate the kinetics of levodopa in Parkinson’s
disease patients with the concomitant administration of food (Figure 3.3-A). The parameter
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Figure 3.4: Multiscale modeling of theWB-ACAT-sIECmodel for the absorption of levodopa
by the small intestine. The key steps of the sequential coupling algorithm are illustrated. Step
1 (PBPKmodeling): the physiological parameters of levodopa distribution were identified by
fitting data from healthy individuals45 onto the WB-ACATmodel. Step 2 (PBPKmodeling):
the WB-ACAT model, together with the obtained parameters, was simulated for one-time
step. Steps 3 (PBPK modeling): the flux values were retrieved, depending on the competi-
tion or trans-stimulation mode, for absorption and secretion reactions/metabolites that are in
common between the WB-ACAT and the sIEC models. Step 4 (COBRA modeling): as the
WB-ACAT model captured seven distinct sIEC segments, the flux values for each segment
were set as upper bound on the one sIEC model corresponding to this segment. Step 5
(COBRA modeling): for each sIEC model, FBA was performed with the levodopa luminal
uptake reaction or basolateral secretion as objective function, depending on the mode. Step 6
(COBRA modeling): the obtained FBA flux values for each sIEC model were set as param-
eters for the derivatives in the corresponding sIEC segments of the WB-ACAT model. The
new rates initialized the next time step in the PBPK modeling (Step 3). Numbers with single
and double subscript correspond to competition and trans-stimulation, respectively. COBRA,
constraint-based reconstruction and analysis; PBPK, physiologically based pharmacokinetic;
sIEC, small-intestine epithelial cell; WB-ACAT, whole-body advanced compartmental ab-
sorption and transit.
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sensitivity analysis with respect to levodopa plasma concentrations showed that the top 5
ranking parameters among the 243 whole-body parameters were gastrointestinal parameters
(Figure fig:s4levo, Table B.4). These findings highlight the importance of oral absorption
in the dynamics of levodopa and consequently the emergence of fluctuations in the motor
response.
3.3.5 Ranking of amino acids effects toward levodopa bioavailability re-
vealed serine-rich diet as a potential augmenting diet for levodopa
in silico
Figure 3.5: Ranking of amino acids with respect to the levodopa fraction that reaches the
brain. Amino acids with lowest ranking were those which competed with levodopa in the
intestine. A second set of amino acids did not interact with levodopa and, consequently, the
levodopa pharmacokinetics was identical to those of the fasted state. A third set improved
the levodopa absorption and also did not compete with amino acid uptake by the brain.
The objective function in the simulations was the levodopa transport reaction across the
blood–brain barrier using an extended sIECmodel, to which a kidney and brain compartment
with the corresponding levodopa transport reactions were added. sIEC, small-intestine
epithelial cell.
The competition and trans-stimulation between levodopa and amino acids take place
mainly in the gut, brain, and kidneys[239]. To capture also these interactions in our WB-
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ACAT-sIEC model, we extended the sIEC model by a kidney and brain compartment (Table
B.5) and included the corresponding levodopa transport reactions (sIEC*, Text B.2). To
simulate this interaction between the three organs in the levodopa bioavailability, we set
the levodopa influx rate to the intestinal lumen to the arbitrary value of 15 mmol/g of dry
weight/h (Table B.6), of which 66% could reach the systemic circulation in the fasting
state and 30% of the absorbed fraction was eliminated by the kidneys, in accordance with
experimental data[39]. We then simulated the simultaneous administration of levodopa with
the different amino acids by selecting as objective function the brain transport reaction for
levodopa. This simulation allowed us to systematically determine, which amino acid would
lead to a higher flux of levodopa transported to the brain and thus, could result in a better
clinical outcome. We found that threonine, serine, and asparagine resulted in the highest
brain bioavailability of levodopa (Figure 3.5). To our knowledge, these amino acids have not
been reported to compete with levodopa in the small intestine and in the brain. Moreover,
the amino acids were predicted to compete with levodopa for elimination in the kidneys
and trans-stimulate levodopa secretion from the intestinal lumen. It has been shown that
serine improves dopamine production [70]. Consequently, we ranked serine as the amino
acid with the highest contribution to levodopa bioavailability. Using the WB-ACAT-sIEC
Table 3.1: Fed versus fasted state physiological parameters.
Parameters Fasted/ante cibum Fed
GER 3.96 per h 0.33 per h
Stomach volume 50 ml 1000 ml
Colon volume 1000 ml 7000 ml
Small intestine transit rate 2.1 per h 0.57 per h
Gastric pH 2 5
Abbreviation: GER, gastric-emptying rate. The physiological parameters in fasted and fed
state were taken from the literature.49 The gastric-emptying rate was estimated by sequential
fit on levodopa plasma concentrations in fasted and fed states onto the WB-ACAT model.
model, we predicted that the addition of serine in the systemic circulation could improve
the bioavailability of levodopa as shown by the increase of the AUC above the efficacy
threshold (22.02%) (Figure 3.3-D,E). The subsequent increase of amino acids concentration
in the plasma improved the bioavailability of the next dose through a higher absorption in
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the basolateral side of the seven compartments of the small intestine. Taken together, we
propose that a serine-rich meal after a levodopa dose could improve the brain bioavailability
of levodopa.
3.4 Discussion
Motivated by the observation that protein-containing meals can alter the levodopa bioavail-
ability and thus the motor symptoms of Parkinson’s disease patients, we developed a mul-
tiscale PBPK–COBRA model of the gastrointestinal tract. We then investigated different
dietary strategies. Our key results include: (i) late-stage, levodopa-treated Parkinson’s dis-
ease patients would benefit the most by dietary intervention; (ii) PRD but not LPD improved
the bioavailability of levodopa; (iii) gastrointestinal transit and loss of levodopa explained
most of the variability in levodopa bioavailability; and (iv) serine-rich diet could increase the
brain levodopa bioavailability. Taken together, we demonstrate that computational modeling
could add further mechanistic insight into the diet-levodopa interactions and may be used to
propose Parkinson’s disease patient-specific dietary intervention strategies.
3.4.1 The combined model: construction, assumptions and validation
In this study, we developed a spatially, temporally, and mechanistically detailed model of the
human gastrointestinal tract (Figure 3.1) by combining two powerful modeling techniques:
PBPK and COBRA. In comparison to the other efforts[119], we demonstrate here that this
hybrid modeling technique can be further expanded by including more refined PBPK models
(i.e., the ACAT model), as well as by integrating more than one stoichiometric metabolic
models (i.e., seven sIEC models) (Figure 3.1). Importantly, the simulation settings were
consistent with literature reports, such as levodopa being absorbed equally in all the parts
across small intestinal[131], while amino acids were only absorbed in the proximal jejunum
(jejunum 1 and 2 in the model)[1]. The kinetic profile of levodopa with concomitant admin-
istration of proteic diet in late-stage patients (Figure 3.3-A) matched the profile of levodopa
of one case patient with gastrointestinal resection[160], which suggests that inhibitory amino
acids completely block the access of levodopa to the intestinal transporters in the sites of
absorption. These findings show that the proposed hybrid modeling approach (Figure 3.1)
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provides a powerful tool to assess diet–drug interactions, which requires interrogation at the
physiological, as well as biochemical level [233].
3.4.2 Late-stage, levodopa-treated Parkinon’s disease patients would
benefit the most by dietary intervention
In the last stages of Parkinson’s disease, levodopa-treated patients experience fluctuations in
the motor response[40]. The on-off phenomena are correlated to inadequate concentrations
of levodopa reaching the brain. Since the impairment of the gastrointestinal motility in
Parkinson’s disease [64] increases with disease progression, the erratic absorption of lev-
odopa, especially with diet, is one of the factors causing motor fluctuations. As our model
showed (Figure 3.3-A), the decrease in levodopa absorption was lower with respect to the
therapeutic threshold in early-stage patients with low impairment of gastric emptying, while
it substantially decreased the bioavailability of levodopa in later stages of Parkinson’s disease.
These results are in agreement with reported clinical trials[40], and routine, where HY 3 and
HY 4 patients are recommended to follow a dietary plan, such as PRD and LPD.
3.4.3 Gastrointestinal transit and loss of levodopa explained most of the
variability in levodopa bioavailability
Constipation is a clinical symptom associated with Parkinson’s disease, particularly at the
later stages[64]. Overall, the GER is inversely proportional to the disease stage[53]. In
addition, levodopa is degraded in the stomach and intestine lumen as a consequence of gut
microbiota[214], luminal enzymes [161], and chemical degradation[3]. The higher residence
time of levodopa in the gastrointestinal tract, caused by the slower GER, leads to a higher
degraded fraction. The predicted decrease in the maximal concentration (Cmax) was the
result of the combination of a slow GER and the luminal degradation (Figure 3.3-A). The
parameter sensitivity analysis showed that gastric and intestinal processes were the most
influential factors for levodopa bioavailability (Table B.4, Figure fig:s4levo). The GER has
been shown to be the main parameter that induces a delay in levodopa absorption[53]. Our
observation is further consistent with the reported decrease in levodopa efficiency with pH34
andHelicobacter pylori infection [89] [173]. The levodopa loss in the stomach alsomotivated
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approaches that bypassed the gastrointestinal tract [67] and the intestine[161], as well as
provides a rationale for investigational prokinetics for Parkinson’s disease patients[198]. The
absorptive profile of levodopa has been reported to show multiple peaks in plasma and an
erratic absorption. Such erratic kinetics were not observed in the simulations (Figure 3.3-
A), which suggests that GER is a time-dependent parameter, as suggested previously[244].
Our results suggest that the plasmatic concentrations of levodopa were higher 2 h after the
administration than the a.c. administration. This observation could be explained by the
absorption of levodopa in the ileum, where the competition with amino acids has not been
reported[1]. This finding indicates a role of ileal levodopa absorption in the formation of
delayed plasmatic peaks.
3.4.4 PRD but not LPD improved the bioavailability of levodopa
It has been shown that PRDhad a better clinical outcome than LPD[34]. In silico, the PRDhad
also a better performance due to the improved bioavailability of levodopa (Figure 3.3-B,C). A
combination of factors has been suggested to result in the superiority of protein redistribution
diet[34]. In LPD, we showed that competing amino acids decreased the levodopa peak
(Figure 3.3-A,B). It is likely that the decrease is more pronounced with impaired GER. A
slower GER potentializes the loss of levodopa by competition through exposing the dietary
proteins to intestinal peptidases for longer periods of time, thus releasing amino acids. It
has been shown that in healthy volunteers after protein intake, a minor part of the diet is
transformed into free amino acids in the small intestine, while the major part forms di- and
tri-peptides and is absorbed by PEPT1[2]. A clinical trial conducted on healthy volunteers
showed no difference in the pharmacokinetics of levodopa when absorbed alone or with a
solution of proteins, which questioned the influence of the gastrointestinal processes on the
absorption of levodopa [184]. With most proteins being transformed into non-competing
peptides, levodopa is not subjected to competition for luminal transporters. Thus, the delay
in GER exacerbates the competitive potential of dietary amino acids, which leads to higher
loss of levodopa in the small intestine.
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3.4.5 Serine-rich diet could increase the brain levodopa bioavailability
Basolateral amino acids, mimicking the post prandial state, have been shown to trans-stimulate
the secretion of levodopa[32]. The latter finding provides opportunities for augmenting di-
etary intervention. Serine supplementation increased in silico the bioavailability of levodopa
for Parkinson’s disease patients with moderately impaired GER (Figure 3.3-D). Furthermore,
the exchange of levodopa with amino acids could be a clearance route for amino acids, thus,
preventing further competition in the brain (Figure fig:s5levo). Serine also modulates the ac-
tivation of N-methyl-D-aspartate class of glutamate receptors (NMDARs), which were hown
to be involved in dopamine synthesis and release[70]. Thus, serine-rich diet could improve
the absorption of levodopa and the production of dopamine[78]. Recently, a clinical study on
late-stage Parkinson’s disease patients has demonstrated a higher bioavailability of levodopa
and an improvement of ‘on’ times with soybean [159]. Given that soybean is mainly com-
posed of 2331 mg/100 g of glutamate, 1411 mg/100 g of aspartate, 982 mg/100 g of arginine,
and 687 mg/100 g of serine, it appears that inhibitory effects of arginine are counteracted by
the predicted beneficial effects of serine and glutamate, while aspartate was predicted to be
neutral (Figure 3.5). This finding suggests that a cumulative, dose-dependent effect of amino
acids on the ranking scale that we have developed (Figure 3.5), in a given diet, is a good
assessment of its effects on the pharmacokinetics of levodopa. A higher bioavailability of
levodopa allows (i) a better clinical outcome, (ii) a decrease in the daily dose with (iii) the
subsequent decrease in adverse reactions. Taken together, we demonstrate in this study that
the combination of genome scale and dynamical models can be used to assess the diet–drug
interactions and can provide a valuable tool to design nutritional intervention strategies.
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Abstract
GSMMs of living organisms are used in a wide variety of applications pertaining to health and
bioengineering. They are formulated as LP problems that are oftentimes under-determined.
FVA characterizes the alternate optimal solution (AOS) space enabling thereby the assess-
ment of the solution’s robustness. fastFVA (FFVA), the C implementation ofMATLAB FVA,
allowed to gain substantial speed up, although the parallelism was managed through MAT-
LAB. We present veryfastFVA (VFFVA), a pure C implementation of FVA, that relies on a
hybrid MPI/OpenMP management of parallelism. The flexibility of VFFVA allowed to gain
consequent speedup factors and to decrease memory usage 14 fold in comparison to FFVA.
Finally, VFFVA allows to process a higher number of GSMMs in faster times accelerating
thereby biomedical modeling and simulation.
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4.1 Introduction
Modeling and simulation of biological systems gained tremendous interest thanks to the
increasing predictive ability of the modeled systems in healthcare and in the biotechnology
industry [75, 168]. Microbial and human systems are most amenable to modeling given the
wealth of data in the literature along with the development of computational methods.
Particularly, COBRA methods enable the reconstruction of the metabolism of biological
systems in silico as linear programs [163]. Subsequently, an objective function of the system
is formulated and optimized for e.g., biomass yield, metabolite production. Although the
objective is uniquely determined, the set of corresponding solutions forms the space of
alternate optimal solutions (AOS) that describe the possible conditions in which the optimal
objective is achievable. The AOS space is quantified using flux variability analysis (FVA)
[142], which provides a range of minimum and maximum values for each variable of the
system. Biologically, these values overlap with the fitness of a given system to achieve
optimality and allow to validate the metabolic phenotype through matching the empirical
ranges with the FVA bounds. fastFVA (FFVA) [80], a recent implementation of FVA gained
tremendously in speed over the fluxvariability COBRA toolbox MATLAB function
[20]. Two main improvements were the driving factor of the gained efficiency: first, the
C implementation of FVA which allowed a higher flexibility using the CPLEX C API in
comparison to MATLAB. The second was the use of the same LP object, which avoided
solving the problem from scratch in every iteration, thereby saving presolve time. FFVA is
compiled as MATLAB Executable (MEX) file, that can be called from MATLAB directly.
Yet, given the exponentially growing size of the metabolic models, FFVA is ran in parallel
in most cases. Parallelism simply relies on allocating the cores through MATLAB parpool
function and running the iterations through parfor loop. The load is statically balanced over
the workers such as they process an equal amount of iterations. Nevertheless, the solution
time varies greatly between LPs which does not guarantee an equal processing time among
the workers in static load balancing. Oftentimes, the workers that were assigned a set of
fast-solving LPs, process their chunk of iterations and stay idle, waiting to synchronize with
the remaining workers, which can result in less efficient run times. We present veryfastFVA
(VFFVA), a pure C implementation of FVA, that has a lower level management of parallelism
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over FFVA. The program is provided as a standalone, that does not rely on MATLAB
thereby offering an open source alternative for constraint-based biological analysis. The
major contribution lies in the management of parallelism through a hybrid OpenMP/MPI, for
shared memory and non-shared memory systems respectively, which offers great flexibility
and speedup over the existing implementations. While keeping the up-mentioned advantages
of FFVA, load balancing in VFFVA was scheduled dynamically [217] in a way to guarantee
equal run times between the workers. The input does not rely on MATLAB anymore as the
LP problem is read in the industry standard .mps file, that can be also obtained from the
classical .mat files through a provided converter. The improvements in the implementation
allowed to speed up the analysis by a factor of three and reduced memory requirements 14
fold in comparison to FFVA and the Julia-based distributedFBA implementation [94], in a
similar parallel setting.
Taken together, as metabolic models are steadily growing in number and complexity, their
analysis requires the design of efficient tools. VFFVA allows to make the most of modern
machines specifications in order to run a greater amount of simulation in less time thereby
enabling biological discovery.
4.2 Material and methods
4.2.1 Flux variability analysis
The LP problem representing the metabolic model has n reactions that are bounded by lower
bound lb(n,1) and upper bound ub(n,1) vectors. The matrix S(m,n) represents the stoichiometric
coefficients of each of the m metabolites involved in the n reactions. The system is usually
constrained by S.v = 0 to represent the steady-state, also referred to as Flux Balance Analysis
(FBA) [167]. An initial LP optimizes for the objective function of the system to obtain a
unique optimum e.g., biomass maximization, like the following:
maximize Zbiomass = cTbiomassv
subject to
S.v = 0
lb < v < ub
(4.1)
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The system being under-determined (m < n), there can be an infinity of solution vectors v(n,1)
that satisfy the unique optimal objective (cTv), with c(n,1) as the objective coefficient vector.
In order to delineate the AOS space, the objective function is set to its optimal value, and the
n dimensions of the problem are iterated over. Consequently, each of the reactions is set as
a new objective function and is maximized and minimized for. The total number of LPs is
then equal to 2n. The problem is described as the following:
iterate over i ∈ [1, n]
set ci = 1
max/min Zi = cTv
subject to
S.v = 0
cTbiomassv = Zbiomass
lb < v < ub
(4.2)
The obtained minimum and maximum objective value for each dimension defines the range
of optimal solutions.
4.2.2 Management of parallelism
Problem 4.2 is entirely parallelizable through allocating the 2n LPs among the available work-
ers. The strategy used so far in the existing implementations was to divide 2n equally among
the workers. Although, the solution time can vary widely between LPs and ill-conditioned
LPs have a higher convergence time. Dividing equally the LPs among the workers does not
ensure an equal load on each worker.
In shared memory systems, Open Multi-Processing (OpenMP) library allows to balance the
load among the threads dynamically such that every instruction runs for an equal amount of
time. Since it is challenging to estimate a priori the run time of an LP, the load has to be
adjusted dynamically, depending on the chunks of the problem processed by every thread. In
the beginning of the process, the scheduler will divide the original problem in chunks and
will assign the workers a chunk of iterations to process. Each worker that completes the
assigend chunk will receive a new one, until all the LPs are processed.
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In systems that do not share memory, Message Passing Interface (MPI) was used to create
instances of Problem 4.2. Every process then calls the shared memory execution through
OpenMP.
In the end, the final program is comprised of a hybrid MPI/OpenMP implementation of paral-
lelism which allows a great flexibility of usage, particularly in High Performance Computing
(HPC) setting.
4.2.3 Another application: generation of warmup points
The uniform sampling of metabolic models is a common unbiased tool to characterize
the solution space and determine the flux distribution per reaction [25, 155]. Sampling
starts from pre-computed solutions called warmup points, from which the sampling chains
start exploring the solution space. The generation of p ≥ 2n warmup points is done in a
similar fashion to FVA. The first 2n points are actually solutions of the FVA problem, while
the points ≥ 2n are solutions corresponding to a randomly generated coefficient vector c.
Another difference with FVA, lies in the storage of the solutions v rather than the optimal
objective cTv. We compared the generation of 30,000 warmup points using the COBRA
toolbox function createWarmupMATLAB and a dynamically load-balanced C implementation
createWarmupVF.
4.2.4 Model description
A selection of models [80] was tested on FFVA and VFFVA. The models (Table 4.1) are
characterized by the dimensions of the stoichiometric matrix Sm,n. Each of them represent the
metabolism of human and bacterial systems. Models pertaining to the same biological system
with different S matrix size, have different levels of granularity and biological complexity.
4.2.5 Hardware and software
VFFVA and createWarmupVFwere run on aDell HPCmachinewith 72 Intel Xeon E5 2.3GHz
cores and 768 GigaBytes of memory. The current implementation was tested with Open MPI
v1.10.3, OpenMP 3.1, GCC 4.7.3 and IBM ILOG CPLEX academic version (12.6.3). FFVA
and createWarmupMATLAB were tested with MATLAB 2014b and distributedFBA was run
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Table 4.1: Model size and description.
Model Organism Size
Ecoli_core Escherischia coli (72,95)
P_putida Pseudomonas putida (911,1060)
EcoliK12 Escherischia coli (1668,2382)
Recon2 Homo sapiens (4036,7324)
E_Matrix Escherischia coli (11991,13694)
Ec_Matrix Escherischia coli (13047,13726)
Harvey Homo sapiens (157056,80016)
on Julia v0.5. ILOG CPLEX was called with the following parameters:
PARALLELMODE=1
THREADS=1
AUXROOTTHREADS=2
Additionally, large scale coupled models with scaling infeasibilites might require
SCAIND=-1
The call to VFFVA is done from bash as follows:
mpirun -np <nproc> --bind-to none -x OMP_NUM_THREADS=<nthr> ./veryfastFVA
<model.mps> <scaling>
,with nproc is the number of non-shared memory processes, nthr is the number of shared
memory threads, scaling is CPLEX scaling parameter where 0 leaves it to the default (equi-
libration) and -1 sets it to unscaling. createWarmupVF was called in a similar fashion:
mpirun -np <nproc> --bind-to none -x OMP_NUM_THREADS=<nthr>
./createWarmupPts <model.mps> <scaling>
For large models, OpenMP threads were bound to physical cores through setting the environ-
ment variable
OMP_PROC_BIND=TRUE
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while for small models, setting the variable to FALSE yielded faster run times. The schedule
is set through the environment variable
OMP_SCHEDULE=<schedule,chunk>
where schedule can be static, dynamic or guided, and chunk is the minimal number of
iterations processed per worker at a time.
4.2.6 Other possible implementations
The presented software can be implemented in Fortran since the library OpenMP is sup-
ported as well. Additionally, Python’s mutliprocessing library allows to dynamically load
balance tasks between non-shared memory processes, but the parallelism inside one process
is often limited to one thread by the Global Interpreter Lock (GIL). This limitation could
be circumvented through using OpenMP and Cython [21]. The advantage of VFFVA lies in
the implementation of two levels of parallelism following a hierarchical model where MPI
processes are at a top-level and OpenMP threads at a lower level. The MPI processes manage
the coarse-grain parallelism and OpenMP threads manage the finer-grained tasks that share
memory and avoid copying the original problem, which increases performance and saves
consequent memory. This architecture adapts very well with modern distributed hardware in
HPC setting.
4.3 Results
The OpenMP/MPI hybrid implementation of VFFVA allowed to gain important speedup
factors over the static load balancing in the MATLAB implementation. In this section, we
benchmarked the run times of VFFVA in comparison to FFVA at different settings then we
compared different strategies of load balancing and their impact on the run time per worker.
While in FFVA the authors benchmarked serial runs [80], in the present work, the emphasis
was placed upon parallel run times.
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4.3.1 Parallel construct in a hybrid OpenMP/MPI setting
The MATLAB implementation of parallelism through the parallel computing toolbox pro-
vides great ease-of-use, wherein two commands only are required to allocate and launch
parallel jobs. Also, it saves the user the burden of finding out if the jobs are run on memory
sharing systems or not. VFFVA provides the user with a similar level of flexibility as it
supports both types of systems. In addition, it allows to access advanced features of OpenMP
and MPI such as dynamic load balancing. The algorithm starts first by assigning chunks of
iterations to every CPU (Figure 4.1), in which a user defined number of threads simultane-
ously processes the iterations. At the end, the CPUs synchronize and pass the result vector
to the master CPU to reduce them to the final vector.
The main contributions of VFFVA are the complete use of C, which impacted mainly the
computing time of small models (n < 3000) and the dynamic load balancing that was the
main speedup factor for larger models.
CPUs
Threads
1 2
1 1 22 3 3
Metabolic 
reactions (n)
Dynamical
load balancing
Shared 
memory
Message passing
of optimization results
Non shared 
memory
Model input
(.mps)
Figure 4.1: Hybrid OpenMP/MPI implementation of FVA ensures two levels of parallelism.
The distribution of tasks is implemented following a hierarchical model where MPI manages
coarse-graine parallelism in non-shared memory systems and OpenMP processes within
each MPI process manage fine-grain parallelism taking advantage of the shared memory to
improve performance.
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4.3.2 Impact on computing small models
We run VFFVA and FFVA five times on small models i.e., Ecoli_core, EcoliK12, P_putida.
VFFVA had at least 20 fold speedup (Table 4.2). The main contributing factor was the use
of C over MATLAB in all steps of the analysis. In particular, the loading time of MATLAB
java machine and the assignment of workers through parpool was much greater than the
analysis time itself.
The result highlighted the power of C in gaining computing speed, through managing the
different low-level aspects of memory allocation and variable declaration.
In the analysis of large models, where MATLAB loading time becomes less significant,
dynamic load balancing becomes the main driving factor of the gained speedup.
Table 4.2: Comparison of run times of FFVA and VFFVA in small models in seconds.
Model
FFVA
mean(std)
loading and
analysis
time
VFFVA
mean(std)
loading and
analysis
time
FFVA
mean(std)
analysis
only
2 cores
Ecoli_core 19.5(0.5) 0.2(0.01) 0.37(0.1)
P_putida 19.2(0.7) 0.6(0.02) 0.81(0.09)
EcoliK12 20.4(0.6) 2.2(0.06) 2.41(0.09)
4 cores
Ecoli_core 19.6(0.6) 0.2(0.005) 0.32(0.01)
P_putida 19.4(1) 0.5(0.02) 0.61(0.01)
EcoliK12 20(0.8) 1.3(0.04) 1.64(0.08)
8 cores
Ecoli_core 19.4(0.5) 0.2(0.03) 0.35(0.05)
P_putida 19.6(0.7) 0.4(0.04) 0.53(0.009)
EcoliK12 20(0.49) 0.9(0.01) 1.22(0.08)
16 cores
Ecoli_core 20.2(0.4) 0.2(0.008) 0.41(0.05)
P_putida 19.5(0.4) 0.4(0.04) 0.51(0.03)
EcoliK12 22(0.7) 0.7(0.01) 0.87(0.03)
32 cores
Ecoli_core 22.2(0.4) 0.3(0.008) 0.6(0.12)
P_putida 21.5(0.6) 0.4(0.01) 0.53(0.004)
EcoliK12 21.5(0.6) 0.6(0.03) 0.78(0.04)
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4.3.3 Impact on computing large models
The speedup gained on computing large models (Recon2 and E_Matrix) reached three folds
with VFFVA (Figure 4.2) at 32 threads with Recon 2 (35.17s vs 10.3s) and E_Matrix (44s
vs 14.7s). In fact, with dynamic load balancing, VFFVA allowed to update the assigned
chunks of iterations to every worker dynamically, which guarantees an equal distribution of
the load. In this case, the workers that get fast-solving LPs, will get a larger number of
iterations assigned, while those that get ill-conditioned LPs and require more time to solve
them, will get fewer LPs in total, in such way that all workers synchronize at the same time
to reduce the results. Particularly, the speedup achieved with VFFVA increased with the size
of the models and the number of threads (Figure 4.2-E_Matrix). Finally, we further explored
the different load balancing startegies (static, guided and dynamic) with two of the largest
models (Ec_Matrix and Harvey).
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Figure 4.2: Run times of Recon2 and E_Matrix model using FFVA and VFFVA on 2,4,8,16,
and 32 threads. The guided schedule was used in the benchmarking.
4.3.4 Load management
Load management describes the different approaches to assign iterations to the work-
ers. It can be static, where an even number of iterations is assigned to each worker.
Guided schedule refers to dividing the iterations in chunks of size n/workers initially
and remainingiterations/workers afterwards. The difference with static lies in the dynamic
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assignment of chunks, in a way that fast workers can process more iteration blocks. Finally,
dynamic schedule is very similar to guided except that chunk size is given by the user, which
allows a greater flexibility. In the following section, we will compare the load balancing
strategies of Ec_Matrix and Harvey models.
Figure 4.3: Run times of Ec_Matrix model. A-Run times of Ec_Matrix model at 2,4,8,16,
and 32 threads using FFVA and VFFVA. B-Run time per worker in the static, guided, and
dynamic schedule using 16 threads. C-The number of iterations processed per worker in the
static, guided, and dynamic schedule using 16 threads.
Static schedule
Using static schedule, VFFVA assigned an equal number of iterations to every worker. With
16 threads, the number of iterations per worker equalled 1715 and 1716 (Figure 4.3-C).
Expectedly, the run time varied widely between workers (Figure 4.3-B) and resulted in a final
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time of 393s.
Guided schedule
With guided schedule (Figure 4.3-A), the highest speedup (2.9) was achieved with 16 threads
(Figure 4.3-B). The run time per worker was quite comparable and the iterations processed
varied between 719 and 2581. The final run time was 281s.
Dynamic schedule
Using a dynamic load balancing with a chunk size of 50 resulted in similar results to the
guided schedule. The final run time equalled 197s, while FFVA took 581s. An optimal
chunk size has to be small enough to ensure a frequent update on the workers load, and big
enough to take advantage of the solution basis reuse in every worker. At a chunk size of 1
i.e. each worker is assigned 1 iteration at a time, the final solution time equalled 272s. The
reason being that if the worker is updated quite often with new pieces of iterations, then it
looses the stored solution basis of the previous problem and has to solve from scratch.
Similarly, Harvey model [225] (Figure 4.4-A) had a 2-fold speedup with 16 threads using
a chunk size of 50 (806 mn) compared to FFVA (1611 mn). The run times with guided
schedule (905 mn), dynamic schedule with chunk size 100 (850 mn) and chunk size 500
(851 mn) were less efficient due to the slower update rate leading to a variable analysis time
per worker (Figure 4.4-B,C,D). VFFVA on 8 threads (1323 mn with chunk size 50) proved
comparable to FFVA (1214 mn) and distributedFBA (1182 mn) on 16 threads, thereby saving
computational resources and time.
4.3.5 Impact on memory usage
In MATLAB, the execution of j parallel jobs implies launching j instances of MATLAB.
On average, one instance needs 2 Gb. In parallel setting, the memory requirements are
at minimum 2 j Gb, which can limit the execution of highly parallel jobs. In the Julia-
based distributedFBA, the overall memory requirement exceeded 15 Gb at 32 cores. VFFVA
requires only the memory necessary to load j instances of the input model, which corresponds
to the MPI processes as the OpenMP threads save additional memory through sharing one
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Figure 4.4: Run times per worker of Harvey model. A- Total run time of the different load
balancing schedules at 8, 16, and 32 threads. B-Run time per worker as a function of the
number of iterations processed using the guided schedule and the dynamic schedule with
chunk size of 50, 100, and 500 with 8 threads, C-16 threads, and D-32 threads.
instance of the model. The differences between the FFVA and VFFVA get more pronounced
as the number of threads increases (Figure 4.5) i.e., 13.5 fold at 8 threads, 14.2 fold at 16
threads, and 14.7 fold at 32 threads.
Finally, VFFVA outran FFVA and distributedFBA both on execution time and memory
requirements (Table 4.3). The advantage becomes important with larger models and higher
number of threads, which makes VFFVA particularly suited for analysing the exponentially-
growing-in-size metabolic models in HPC setting.
Table 4.3: Comparative summary of the methods’ features.
Feature VFFVA distributedFBA FFVA FVA
Speed ++++ +++ ++ +
Memory +++ ++ + +
Load balancing dynamic static static static
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Figure 4.5: Physical memory usage at 8, 16, and 32 threads using FFVA, VFFVA, and
distributedFBA.
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4.3.6 Creation of warmup points for sampling
We compared the generation of 30,000 warmup points using the COBRA toolbox function
createWarmupMATLAB and a dynamically load-balanced C implementation createWarmupVF
on a set of models (Table 4.4). Since the COBRA toolbox implementation does not support
parallelism, we run it on a single core and divided the run time by the number of cores to
obtain an optimistic approximation of the parallel run times. The speedup achieved varied
between four up to a factor of 100 in the different models (Table 4.4). Similarly to FFVA
[80], the main factor for the speedup was the C implementation that allowed the reuse of the
LP object in every iteration and save presolve time. Equally, the dynamic load balancing
between workers ensured a fast convergence time.
Taken together, the dynamic load balancing strategy allows the efficient parallel solving of
metabolic models through accelerating the computation of FVA and the fast preprocessing
of sampling points thereby enabling the modeller to tackle large-scale metabolic models.
Table 4.4: Generation of sampling warmup points using dynamic load balancing.
Model createWarmupMATLAB createWarmupVF
Cores 1 1 2 4 8 16 32
Ecoli_core 149 2.8 1.8 0.8 0.7 0.5 0.5
P_putida 385 12.5 13 8 4 2 2
EcoliK12 801 49 43 23 10.4 9.5 9.1
Recon2 11346 288 186 30 32 24 21
E_Matrix NA* 602 508 130 52 43 43
Ec_Matrix NA* 5275 4986 924 224 118 117
* The generation of warmup points of E_Matrix and Ec_Matrix models did not converge after
20000 s. The creation of warmup points can vary widely between runs as it involves the
generation of a random c vector in the linear program. The runs were repeated three times
and the average was reported.
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Pan-organ model integration of
regulatory and metabolic processes in
type 1 diabetes.
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Abstract
Type 1 diabetes is a systemic disease triggered by a local autoimmune inflammatory reaction in
the insulin-producing cells. The disruption of the glucose-insulin-glucagon system induces
organ-wide, long-term effects on glycolytic and non-glycolytic processes. Mathematical
modeling of the whole-body regulatory bihormonal system helped identifying intervention
points to ensure a better control of type 1 diabetes mellitus. We present a whole-body model,
developed using an integrative modeling framework termed CRONICS, linking regulation
and metabolism in an organ-resolved manner. The developed framework allowed to cor-
rectly predict disrupted metabolic processes in type 1 diabetes in relation to the symptoms,
highlighted common pathophysiological processes with neurodegenerative disorders and sug-
gested calcium channel blockers as potential adjuvants for diabetes control. Additionally, the
model predicted an insulin-dependent rewiring of inter-organ crosstalk. Moreover, it allowed
to assess the impact of inter- and intra-individual variability to insulin treatment and their
implications on clinical outcome. In particular, GLUT-4 is suggested as a potential phar-
macogenomics regulator of intra-individual insulin efficacy. The organ-resolved, dynamic
model opens the way to better understand human pathology and the model-based design of
precise allopathic strategies.
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Figure 5.1: Study summary of whole-body dynamic metabolism in type 1 diabetes. A whole-
body dynamic model of type 1 diabetes integrates a whole-body, organ-resolved metabolic
model (Harvey), with a whole-body dynamic model of the glucose-insulin-glucagon system
(GIM), type 1 diabetes gene expression in the pancreas, and insulin-induced metabolite
concentration time-course. The model captured the state-of-the-art knowledge about type 1
diabetes and gave insights into within and between-patient variability to insulin response.
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5.1 Introduction
Type 1 diabetes (T1D) mellitus is a systemic disease triggered by the destruction of insulin-
producing pancreatic beta cells [139]. TheWorldHealthOrganization estimated the incidence
of up to 36.8 new cases in 100,000 persons per year with an increase of 2 to 5% worldwide
[139]. It remains the most prevalent type of diabetes in children and has cumbersome
lifelong effects [139]. The disease affects primarily the production of insulin causing acute
metabolic complications and coronary artery disease, resulting in high early mortality rates
[166]. Additionally, the misdiagnosis of T1D in adults is a recently acknowledged issue
[227], as the delay in implementing the insulinotherapy can further exacerbate the disease
symptoms. The systemic mechanism of action of insulin induces the whole-body semiology
of T1D. The symptoms include several glucose dependent metabolic processes such as micro-
and macroangiopathy, diabetic retinopathy, and nephropathy, as well as fatty acids related
implications like atherosclerosis and cardiovascular disease [11]. Supplementing patients
with exogenous insulin remains the gold standard treatment of type 1 diabetes. Although
being very efficient in preventing biochemical alterations, insulin has a high within and
between subject variability that can induce adverse reactions ranging from hypoglycemia to
uncontrolled diabetes; effects that can hamper the treatment compliance [92].
The wealth of data in type 1 diabetes helped the development of whole-body mathematical
models of insulin action and disease progression, notably the ODE-based glucose insulin
model (GIM) [202]. GIM includes fine-grained details of tissue-based insulin and glucagon
action in relation to glucose dynamics such as insulin-dependent receptor synthesis and the
gastrointestinal hormonal regulation of glucose levels. It could also reproduce the outcome
of differential diagnosis tolerance tests on type 1 diabetic patients. The model extensively
described the bihormonal regulatory events yet modeling of metabolism remained limited to
the first step of glycolytic pathways.
Therefore, the systematic analysis of disrupted metabolic processes beyond glycolysis in type
1 diabetes needs extended approaches. To better capture metabolism, we used the constraint-
based reconstruction of the organ-resolved whole-body human metabolic network (Harvey)
[225]. Harvey includes the tissue-specific metabolic pathways of 20 organs, six sex organs,
and six blood cells enabling thereby the modelling of carbohydrate disorders and the study
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of their impact on non-glycolytic pathways. Therefore, the whole-body model provides a
complete picture of organ-resolved human metabolism, yet addressing disease dynamics and
the patient’s response to insulin requires the modeling of both the metabolic pathways as well
as non-metabolic processes including insulin receptor binding, transduction of signal, and
internalisation of receptors. Recently, multi-scale, multi-algorithm, whole-organism dynamic
models in biology [168] have seen a surge in complexity, addressing mostly microbiology
[108, 43], plant physiology [77], and also human physiology and xenobiotic metabolism
[119]. Accordingly, we coupled the organ-resolved whole-body model (Harvey) with the
dynamic glucose insulin ODE-based model (GIM). The multiscale model (dHarvey) allowed
to represent type 1 diabetes through both glycolytic target effects and off-target effects that
were mapped onto the model using gene expression data. Particularly, the effects of insulin
were added through including an additional dynamical model representing its impact on liver
metabolism. The model including the target and off-target effects of both type 1 diabetes and
insulin, allowed to i) quantify disrupted metabolic process in type 1 diabetes in relation the
disease symptomatology, ii) assess insulin non-glycolytic effects, and iii) shed new light on
mechanisms underlying inter and intra-individual variability of insulin effects. The hybrid
model provides a kernel for the organ-specific integration of biological data and paves the
way for predictive human physiology.
5.2 Methods
5.2.1 Coupling the dynamical model and the constraint-based model
Determining the metabolic reaction flux in the constraint-based model (Harvey) requires
solving the usual liner program:
max: cTvH
subject to:
SvH = bH
vmin ≤ vH ≤ vmax
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,with c the objective coefficient vector, Sm,n the stoichiometric matrix of m metabolites and
n reactions, vH the flux vector bounded by vmin the lower bound vector and vmax the upper
bound vector. When bH = 0m, the problem is constrained by Sv = 0, also referred to as Flux
Balance Analysis (FBA) [167].
Points of intersection between the dynamical model (GIM) and the constraint-based model
(Harvey) included metabolites and reactions. There were four classes of correspondences
(Figure 5.2) that resulted in different implementations of the coupling constraints (Text C.2.1).
Let us first consider the concentrations of a given metabolite modelled in GIM (G) by the
following ODE:
dCG,n
dt
= XG,prod − XG,elim
,with Xprod and Xelim are reaction fluxes respectively producing and eliminating themetabolite
n through first order processes.
Case 1: If one reaction in the dynamical model corresponded to one reaction in the metabolic
model, the constraints for one time step were subjected as follows:
vH,i = XG, j
,with t as the time, v the flux vector, i the index of the reaction in the Harvey model (H), and
j the index of the reaction in the GIM model such that reactions i and j perform the same
metabolic function, e.g., liver hexokinase reaction.
Case 2: When ametabolite is represented in bothmodels, the sum of its anabolic and catabolic
fluxes in Harvey is constrained by its change-of-concentration in GIM, also referred to as
metabolite pooling fluxes [43]. The constraints are formulated as the following:
bH,m =
dCG,n
dt
,with m referring to the metabolite in Harvey, n the metabolite in GIM, Cn the concentration
of n, and b the vector of metabolite change-of-concentration in Harvey.
Case 3: The third case corresponds to one reaction inGIMbeing represented bymore than one
reaction in Harvey. Typically, they correspond to reactions catalyzed by cofactor-dependent
enzymes such as hexokinase with ATP and ADP as cofactors. The reaction pooling fluxes
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are then subjected as follows:
k∑
i=1
vH,i = XG,l
,with v1 to vk are the reactions in Harvey corresponding to reaction l in GIM.
Case 4: In the case when one metabolite in GIM corresponds to more than one metabolite
in Harvey, such as blood cells glucose in GIM corresponding to glucose in red blood cells,
monocytes, natural killer cells, B cells, platelets, and CD4 T cells in the metabolic model,
the constraints are formulated as follows:
∑
i
(vH,a(i) + vH,c(i)) =
dCG, j
dt
,with va the anabolic fluxes, vc the catabolic fluxes, i the index of the different metabolites in
Harvey corresponding to metabolite j in GIM. After subjecting the constraints, the steady-
state was assumed in the chosen time step for the non-overlapping metabolites in both models,
such as amino acids. The constraints then translates to the following:
S.vH = bH
,with S the stoichiometric matrix of Harvey, v the flux vector, and b the metabolite concen-
tration change, that equalled zero for steady-state metabolite and non-zero for metabolites
falling under case 2. When the applied constraints rendered the linear program infeasible,
the lower and upper bounds were relaxed minimally in both the amplitude of relaxation and
the cardinal of the reactions to be relaxed (Text C.2.3).
The simulation of tolerance tests, and the assessment of the inter and intra-individual vari-
ability to insulin response were performed using dHarvey with specific model parameters.
The tolerance tests parameters were as reported in the GIM model [202] (Table C.3), which
includes trials in healthy and T1D patients for intravenous insulin tolerance test (IVITT),
intravenous glucose tolerance test (IVGTT), baseline glucose concentration (Noinf), subcu-
taneous insulin bolus (SCIB), subcutaneous insulin infusion (SCII), solid meal (WB-Solid),
oral liquid glucose solution (WB-Liquid). The parameters of the GIM model were report-
edly [202] identified using tolerance tests trial data [213, 182] and bihormonal closed-loop
experiments [61]. Harvey was simulated using exchange reactions corresponding to standard
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European diet [195].
5.2.2 Comparison of the predictive capabilities of the different models
In order to compare the predictive capabilities of Harvey, GIM, and dHarvey, we simulated
the intravenous glucose tolerance test (IVGTT). GIM includes a parameter set for simulating
IVGTT (Table C.3) and glucose concentrations were obtained through integrating the ODEs.
Glucose concentrations in Harvey alone were obtained through dFBA. Briefly, the initial
amount of glucose is set as availability constraints and decreases in every time step after
subtracting the consumed glucose fluxes obtained through solving the linear program [141].
The maximum rate-of-change of glucose was set to the intravenously injected amount in the
b vector, the problem translates then to the following:
max: cTv
subject to:
Sv ≤ b
vmin ≤ v ≤ vmax
dHarvey not only reproduced the glucose time series of GIM but also could predict the time
course of ATP, which is not present in GIM. The simulation was done through setting ATP
demand reaction in each time step as the objective function as the following:
max: cTv
subject to:
Sv = 0
vmin ≤ v ≤ vmax
, with c the vector of objective function coefficients and vmin,vmax respectively, the minimum
and maximum flux going through the reaction. The c vector entry corresponding to the
indices of reactions corresponding to ATP demand in every organ were set to one. Then, the
baseline value of ATP demand reaction flux, calculated at the initial simulation time, was
subtracted from the obtained value. A cumulative sum of the resulting fluxes allowed to get
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the theoretical time course of ATP in a given tissue.
5.2.3 Modeling T1D off-target effects in the pancreas
We considered T1D as the combination of target and off-target effects. The target effects
are directly related to the decrease of insulin secretion and the increase of glucose levels
and the off-target effects are represented in the underlying chronic inflammation that triggers
the disease. To model target effects, we constructed dHarvey healthy and T1D models
that were obtained through coupling Harvey with healthy and T1D GIM models. Moreover,
consensus gene expression data [174] of pancreas biopsies of type 1 diabetic patients obtained
through whole genome sequencing of four patients after five days, nine months, five years,
and ten years post-diagnosis were used to further constrain the dHarvey diabetic model and
to capture the chronic inflammation in the pancreas leading to the development of T1D.
Differentially expressed genes were mapped on the metabolic model in order to represent the
off-target effects of the disease. Among the list of 475 differentially expressed genes, only
the metabolic genes present in Harvey were kept for further analysis, corresponding to 24
genes (Table C.1). Consequently the bounds in the linear program of dHarvey T1D model,
were modified in the reactions corresponding to every gene such that:
vtmin(i) = v
h
min(i) ∗ f c
vtmax(i) = v
h
max(i) ∗ f c
vtmin(i) < v
t
i < v
t
max(i)
, with f c the gene expression fold change between control and disease of the gene encoding
reaction i, vhmin(i) the minimum reaction flux corresponding to reaction i in the healthy model,
and vhmax(i) the maximum reaction flux of the healthy model as identified by flux variability
analysis. vtmin(i) and v
t
max(i) are the new lower and upper flux bound computed in dHarvey
type 1 diabetic models. Gene expression allowed to constrain a total of 80 reactions in the
pancreas (Table C.2).
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5.2.4 Modeling insulin off-target effects in the liver
Similarly to T1D, we considered insulin to induce target and off-target effects. The target
effects of insulin is the reduction of glucose levels, and the off-target effects are the various
physiological processes involving insulin such as the regulation of glycolysis. The off-target
effects of insulin in the liver were modelled through coupling an additional ODEmodel to the
dHarvey model. The model [256] represented the metabolic effects of insulin on glycolytic
fluxes during one hour. The amounts of eight metabolites in vitro (fructose-6-phosphate,
fructose-1,6-diphosphate, phosphoenolpyruvate, isocitrate, 2-oxoglutarate, malate, frucotse-
2,6-biphosphate, and citrate) were scaled to amounts (mmol) in vivo as following:
Ainvivo = Cinvitro ∗ Vhep ∗ HPGL ∗ Vl
,where Vhep is the hepatocyte volume, HPGL is the hepatocellularity, Cinvitro is the concen-
tration of the metabolites in vitro and Vl the liver volume. The values of the parameters were
set as following [91]:
Vhep = 3, 4.10−9 cm3
HPGL = 86.
106cells
gram o f liver
Vl = 322.6 gram
The constraintswere applied by setting themetabolites rate-of-change in the insulin dynamical
model equal to the corresponding b vector value in Harvey.
5.2.5 Simulation of inter-individual variability to insulin response
In order to assess the between subject variability of glucose dynamics after a bolus of insulin
(Table C.3), the identified differential parameters [202] (Table 5.1) between type 1 diabetes
and healthy GIM models were randomly varied within 2-fold interval to reproduce the
observed 25-35% of variability in a patient population [92] as computed by std(AUC)mean(AUC) , where
AUC refers to the area under the curve of peripheral glucose concentrations per patient. The
parameters were randomly increased or decreased for a synthetic group of 30 patients and the
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coupling between the newly obtained GIM models and Harvey was performed as described
previously.
5.2.6 CRONICS, the simulation algorithm
The simulations were done following two main methods: direct and indirect coupling [43,
119]. Indirect coupling was used to dynamically constrain Harvey with respect to each time
step. First, GIM is simulated for the entire time horizon and the constraints are computed
and applied retrospectively to Harvey as described previously (Section 5.2.1, Figure 5.2).
Direct coupling assumes an interdependency of both model, where the fluxes of GIM for a
specific time step are passed to Harvey, and where the result of the linear program defines
the initial rates in GIM for the consecutive time step. Here the outcome of the simulation
of GIM is dependent on Harvey and vice-versa. The integrative framework CRONICS
(Figure C.4) included the above mentioned coupling scenarii (Text C.2.4) and additionally
ensured the smoothness of the hybrid model. In fact, due to the alternate optimal solution
(AOS) space , maintaining the smoothness of dynamical simulations in large-scale metabolic
models could be challenging. We addressed this issue through i) performing pFBA in each
time step to obtain a reduced AOS space as suggested previously, [229], ii) minimizing the
euclidean distance between flux vectors in each time step similarly to MOMA [205], and iii)
optimizing for a set of reactions in each time step as suggested previously [74]. The latter
was used to simulate the intra-individual variability to insulin response. Additionally, the
solver parameters had to be tuned in order to optimize convergence and ensure feasibility
(Text C.2.5).
5.2.7 Metabolic network topology
To analyse topological features under different sets of perturbation, Harvey, which is a
hypergraph of metabolism, was transformed into a metabolite-centric graph and redundant
metabolite, i.e., ATP, ADP, H20, NH4, H+, NADH, NADPH, and Pi were taken out to
facilitate the subsequent analysis. It was previously shown that metabolic graphs are scale-
free networks, endowed with modular organization [102]. The distribution of metabolite
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connectivity across the metabolic network was accordingly fit on a power law as following:
P(k) = a ∗ k−γ
, where k represents the metabolite degree, a and γ are power law parameters, and P(k) is
the relative frequency of each metabolite.
5.2.8 Sensitivity analysis of the hybrid model, intra-individual variabil-
ity, and multivariate regression
In order to assess intra-individual variability to insulin injection, the GIM model parameters
were fixed for the mean patient anthropomorphic parameters [202] and the flux values of
a set of 2,817 randomly selected reactions representing all the subsystems in the organs
of Harvey model, were allowed to vary through assigning random objective coefficients.
Consequentially, a matrix X(p,q) of objective coefficients for every reaction was randomly
generated, with p as the number of trials representing within-patient metabolic states and q
as the number of reactions.
The output of the simulation of every trial with the corresponding objective coefficients was
measured in the concentration of glucose reached after insulin subcutaneous injection at each
of the n time step. The vector Y(p,n) is the subsequently obtained output vector containing
the concentration values at each time step. Using multivariate regression, the sensitivity
vector ρ, representing the contribution of each reaction flux in Harvey to the time-course of
metabolites in GIM was computed as following:
X ∗ ρ ≈ Y
ρ = (XTX)−1XTY
The ρ vector allows then to quantify the sensitivity of peripheral glucose concentration to
the considered metabolic reactions. Particularly, the minimal concentration (Cmin) and in the
final concentration reached at the end of the simulation (Cend) were considered for further
analysis.
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Figure 5.2: Subjected constraints from GIM to Harvey. The constraints followed four main
scenarii: A- Matching reaction flux corresponds to the case when a reaction in GIM is
represented in the same way in Harvey. In this case the fluxes match fully. B-Metabolite
pooling fluxes correspond to the case where the rate-of-change of a metabolite in GIM is
set as a constraint in the right hand side (b vector) of the linear programming problem in
Harvey. C-Organ-specific non-matching reaction fluxes is the case where one reaction in
GIM corresponds to more than one reaction in the same organ of Harvey. D-Cross-organ
non-matching reaction fluxes. In this case, one tissue in GIM is represented by at least one
compartment in Harvey. The sum of cross-organ anabolic (respectively catabolic) fluxes are
set equal to the anabolic (respectively catabolic) fluxes in GIM. This case is typically related
to blood cells.
5.3 Results
Our approach to construct a whole-body model of carbohydrate metabolism consisted of
the integration of a dynamical regulatory model of a glucose insulin model (GIM) with
a whole-body model of human metabolism (Harvey). The hybrid model (dHarvey) had a
better predictive ability than eachmodel on their own and showed notable differences between
healthy and type 1 diabetes metabolic states. The off-target effects of both type 1 diabetes and
the insulin treatment were modeled at the metabolic level using gene expression data of T1D
and the metabolomics of insulin treatment. Therefore, dHarvey included the different scales
of glucose metabolism (gene expression, regulation loops and metabolism). The modeling
of both the target and off-target effects of T1D and insulin allowed to address the between
and within-patient variability to insulin.
5.3.1 Whole body flux dynamics discriminate between healthy and type
1 diabetes and insulin and glucose challenges
In clinical routine, the diagnosis of diabetes mellitus is confirmed by antibody detection as
well as tolerance tests. In order to identify the global metabolic shift induced by T1D and by
the glucose or insulin challenges during the tolerance tests, we built dHarvey, a hybrid model
including continuous and discrete dynamics. The dynamical simulations of the different
tolerance tests in healthy (Figure 5.3-A) and type 1 diabetes (Figure 5.3-B) using GIM were
coupled individually to Harvey (Text C.2.2) to assess the effects on whole-body, organ-wide
metabolic fluxes. Using principal component analysis, we reduced the dimensionality of the
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Figure 5.3: Whole-body reaction flux dynamics classify type 1 diabetes and healthy. A-Time
course of glucose in peripheral blood in healthy andB-type 1 diabetes in the different tolerance
tests using GIM. C-Principal component analysis of whole-body metabolic fluxes in insulin
and glucose challenges and D-in healthy and T1D dHarvey models at five and 15 mn after
perturbation using three first components. The support vector machine Gaussian boundary
was plotted to assess the separation between classes. E-ROC curves of T1D classification.
Whole-body flux dynamics over 600 minutes of simulation discriminate between healthy
and T1D in each tolerance test alone (left) and in a combination of all tolerance tests in a
binary classifier (right), where adding gene expression constraints showed a higher predictive
capability of the model towards T1D. F-Time-course of the first principal component (PC1)
of the flux vector in each time step in the different tolerance tests showed a shift in global
metabolism as a result of glucose dynamics. IVITT: intravenous insulin tolerance test,
IVGTT: intravenous glucose tolerance test, Noinf: baseline glucose concentration, SCIB:
subcutaneous insulin bolus, SCII: subcutaneous insulin infusion, WBSolid: solid meal,
WBLiquid: oral liquid glucose solution.
predicted fluxes to three dimensions, which captured 95% of the variability with dHarvey
models representing the glucose-insulin-glucagon effects (target effects) only (Figure 5.3-C)
and 93%with models additionally including differentially expressed genes (off-target effects)
in type 1 diabetes (Figure 5.3-D). Using whole-body metabolic fluxes, a Support Vector
Machine (SVM) classifier segregated the insulin tests (IVITT, SCIB, SCII) and the glucose
tests (IVGTT, WBLiquid, WBSolid) (Figure 5.3-C) at five and 15 minutes after perturbation,
as well as on all five minute time steps in the 600 minutes of simulation, aggregated in the bi-
nary classifier (Figure C.2, AUROC=0.82). Subjecting additional constraints on the pancreas
using type 1 diabetes gene expression data (Table C.1) allowed to represent metabolic effects
that were not directly linked to the decrease of insulin levels and the consequent increase
in glucose levels as represented by GIM. The off-target effects were expectedly represented
in mainly inflammation and immune system disorders (Figure C.1-A-B) and the selected 24
metabolic genes (Figure C.3) still represented the main features of the T1D, e.g., disruption
of glucose transport and gluconeogenesis (Figure C.1-C-D-E).
The gene expression derived constraints represented both the glycolytic effects and the im-
mune system disruption effect on metabolism which allowed to segregate the whole-body
fluxes in healthy and disease models (Figure 5.3-D) at five and 15 minutes after pertur-
bation as well as on the whole time horizon of the simulation (Figure 5.3-E(left panel),
AUROC>0.68). Particularly, classifying glucose and insulin challenges improved (Figure
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C.2 when gene expression constraints were applied on the pancreas (AUROC=0.82, AU-
ROC=0.8). Furthermore, The classification of T1D improved as well through applying gene
expression constraints (Figure 5.3-E(right panel), AUROC=0.73) in comparison to the mod-
els that were not (AUROC=0.69). This finding highlights the importance of the underlying
chronic inflammation in T1D on the patient’s metabolism yet the common treatment stays
mostly symptomatic and targeted towards glycaemia control. The global metabolic change
was further supported by the time course of the first component (PC1) in the different toler-
ance tests (Figure 5.3-F). Finally, the addition of off-target effects of type 1 diabetes using
gene expression data on the pancreas enabled to accurately classify T1D and healthy models
in the whole-body flux space. The simulations of dHarvey on a whole-body scale was pre-
dictive towards both the condition, i.e., T1D, and the challenge, i.e., insulin and glucose, and
allows the study of disrupted metabolic pathways in T1D.
5.3.2 Differential reaction fluxes between healthy individuals and type
1 diabetes patients
In order to capture the non-glycolytic, off-target effects of T1D, we constrained the reaction
fluxes in dHarvey by the gene expression of T1D human pancreas and pancreatic islets [174].
The differentially expressed set of metabolic genes (Table C.1) were mapped to Harvey (Fig-
ure C.3) alongside the target effects that were modeled with the constraints arising from
GIM. The enriched terms of the selected metabolic genes (Figure C.1) showed that a large
part of the common features of the disrupted processes in diabetes was correctly captured
( in HumanCyc [189] and the dbGap [143] databases) but also represented shared feature
with glucose-involving conditions (Figure C.1) such as malaria [165] and type 2 diabetes (in
OMIM database) [143].
Using flux variability analysis [142], we compared the flux span of pancreatic reactions in
unconstrained Harvey and dHarvey model. Harvey had a reduced solution space (Figure
5.4-A), as depicted by the flux span, when coupled to GIM. Therefore, the set of obtained so-
lutions is constrained to biologically relevant phenotypes with respect to glucose metabolism.
The T1D dHarvey model showed a smaller flux span in comparison to the dHarvey healthy
model (Figure 5.4-A), thus a decreased metabolic flexibility and adaptive behaviour towards
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Figure 5.4: The multi-scale whole-body model identified disrupted metabolic processes in
type 1 diabetes mellitus. A- Flux variability analysis of the pancreas in Harvey in comparison
to dHarvey in healthy and type 1 diabetes models. B-Time course of glucose in peripheral
blood in intravenous glucose tolerance test modeled byHarvey alone andGIM alone, andATP
theoretical amount in the adipocyte during the IVGTT as predicted by dHarvey. C-volcano
plot of differential reaction fluxes (ratio of fold change) in healthy and type 1 diabetes model.
D-Differential flux distribution by organ and E- by subsystem (p<0.05).
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increased glucose levels and the reduced insulin secretion that shape the disease pathophys-
iology. We compared the predictive capabilities of each of Harvey, GIM, and dHarvey with
respect to metabolite dynamics in intravenous glucose tolerance test (IVGTT). While GIM
natively predicted glucose kinetics with top-down estimated parameters from in vivo mea-
sured concentrations [202], Harvey alone fails to predict the glucose dynamics because of
lack of insulin and glucagon regulation (Figure 5.4-B). dHarvey performs equally well as
GIM and is able to predict the dynamics of metabolites involved in imbalanced reactions such
as the ATP demand in the adipocyte during IVGTT.
The baseline glucose levels in healthy and T1D GIM models were as well coupled to Harvey
and informed about steady state glucose fluxes. Using dHarvey, we compared the fold change
of reaction fluxes in healthy and T1D (Figure 5.4-C). FVA was done on the healthy and T1D
irreversible models (where all reactions are irreversible) to guarantee positive flux values for
the consequent fold change analysis. The FVA solutions were subsequently stored, resulting
in 160,032 (number of reaction times two) flux values per reaction. Using the obtained data,
we were able to compare flux distributions as opposed to single flux values (Text C.2.6). A
fold change analysis was then performed on the flux distributions. The obtained volcano
plot showed the significantly different reaction fluxes in both conditions. A total of 33,526
reactions over a total of 80,016 reactions exhibited a change in value between the conditions,
of which 6,602 were increased and 15,205 were decreased significantly above 50% (fold
change greater than 1.5) of their healthy values (p<0.001). Reaction enrichment in metabolic
subsystems (Figure 5.4-D) and organs (Figure 5.4-E) showed an expected systematic and
ubiquitous deregulation of glucose metabolism, particularly in target organs (pancreas, liver,
and kidney). The subsystem for transport reactions is the most affected since it covers glucose
exchange from producing organs, e.g., glycogenolysis in the liver to energy-requiring pro-
cesses. Overall, the differential fluxes of reactions were related to known semiology of T1D
in the different organs (Table C.4), e.g., cardiovascular disease, retinopathy, ketoacidosis, and
liver glycogen deposition. Of notable difference, the disruption of the transport system in
T1D (Figure 5.4-E) suggested a prominent role of insulin in maintaining a global inter-organ
communication. We will investigate this aspect in the next section.
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5.3.3 Prediction of exogenous insulin off-target effects
The physiological effects of insulin mainly affect the uptake of glucose by organs. A recent
study [256] suggested a regulation of the liver isoform of phosphofructokinase (PFK) by
insulin such that upstream fluxes of PFK are downregulated and downstream fluxes upreg-
ulated. Dynamics of liver glycolysis fluxes in subcutaneous insulin bolus setting (Figure
C.6) confirmed three out of eight regulatory flux patterns, while one flux remained invariant
and four were mispredicted. As this new insight was not captured in dHarvey, we used an
additional dynamical model [256] to represent the off-target effects of insulin in the liver. The
ODE model was coupled to dHarvey which now captures both T1D and insulin target and
off-target effects. In addition to glycolysis, insulin influences amino acids uptake, particularly
large and neutral ones (LNAA), resulting in a decrease in blood concentrations of LNAA.
The model predicted a decrease in all LNAAs in the blood (Figure C.6) after 60 minutes of
insulin administration, preceded by a transient increase at 30 minutes. In order to infer the
metabolic effects of insulin, interpreting single solutions of dHarvey proves ineffective given
the high dimensionality of the model and the alternate optimal solution (AOS) space. To
characterize the AOS space, FVA provided an empirical flux probability density per reaction.
We compared the probability density estimates of the fluxe values in T1D with and without
insulin administration. Glucose uptake expectedly increased in the muscle, adipocytes, and
lungs while remaining unchanged in the liver and brain (Figure 5.5), as expected given their
vital role. Insulin stimulated the activity of phosphofructokinase, glycogen phosphatase,
and hexokinase while inhibiting glucose-6-phostphatase, contributing to its overall anabolic
effect. The uptake of phosphate by the adipocytes also increased, which links to the known
depletion of metals after continuous insulin injection, while the uptake of potassium did not
change significantly. In relation to the fatty acids biosynthesis, insulin enhanced the synthe-
sis of lipoproteins in the liver, inhibited the oxidation of fatty acids and the diacyl glycerol
lipase in the adipocytes. The prediction of triglycerides levels using CRONICS (Figure C.7),
showed an increase in the adipocytes following the administration of insulin. Finally, the
uptake of glutamine in the red blood cells and serine in the spleen, taken as example (Figure
5.5), supported our findings regarding the higher insulin-induced uptake of amino acids.
Moreover, we investigated the anabolic effect of insulin on inter-organ crosstalk. Due to large
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Figure 5.5: Insulin metabolic off-target effects assessed by the probability density estimates
of reaction flux values. The fluxes include A-glucose uptake, B-liver glycolytic reactions,
C-metal homeostasis, D-fatty acids reactions and E-amino acids uptake, in various organs
after a subcutaneous insulin administration.
running times, the simulation of the dHarvey model using CRONICS framework restricted
the distance minimization of the flux vectors between the different time steps (Figure C.4-step
VI) to a subvector including pancreas, kidney, adipocytes, muscle, liver, brain, and fluids,
e.g., peripheral blood, portal vein, blood brain barrier, intestinal compartments. The com-
parison of the inter-organ crosstalk in dHarvey after insulin administration to the T1D steady
state showed an increase in the metabolites exchange set, particularly in the muscle, kidney,
brain, and liver (Figure C.8). The total number of exchanged metabolites in T1D model
equalled 229 exchanged metabolites while insulin induced an exchange of 297 metabolites
overall. Finally, having constructed dHarvey, a dynamical hybrid model of type 1 diabetes
and insulin response, we investigated the effects of within and between patient response to
insulin administration.
5.3.4 Between-subject variability is reflected in citric acid cycle and
oxidative phosphorylation
Using the dHarvey model representing both T1D and insulin target and off-target effects, we
investigated the mechanisms underlying inter-individual variability. A set of kinetic param-
eters of the GIM model with differential values in T1D and healthy individuals (Table 5.1)
[202] was varied (Figure 5.6-A) to reproduce the clinically observed 25-35% [92] of inter-
individual variability in 31 synthetic type 1 diabetes patients (30 simulated patients and 1
reference average patient) (Figure 5.6-B). The obtained between-subject variability equalled
30.11%, in agreement with the empirical values. For every synthetic patient, the personalized
dHarvey was simulated for 600 minutes after the subcutaneous injection of insulin bolus.
The distribution of active reactions across patients and across time was very similar (Figure
5.6-C, Figure C.9), which indicated a similar metabolic network topology. Reducing the
dimensionality of flux distribution through PCA (Figure 5.6-D) showed that the observed
change is driven by the modulation of reaction flux values across time following the action
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Table 5.1: Selected whole-body parameters in inter-individual variability simulations.
Parameter GIM path Description
P_1711 Liver|Interstitial|Glucagon_0 Baseline glucagon level in the liver
P_2049 Pancreas|Interstitial|Insulin_0 Baseline insulin level in the pancreas
P_322 Fat|Endosome|End_IR_0 Adipocyte baseline insulin receptor
in the endosome
P_1757/P_1755Liver|Intracellular|End_IR_0_liv Liver baseline insulin receptor in the cell
P_1978 Muscle|Endosome|End_IR_0 Muscle baseline insulin receptor in
the endosome
P_323 Fat|Endosome|End_IRp_0 Adipocyte baseline insulin phosphorylated
receptor in the endosome
P_1760 Liver|Intracellular|End_IRp_0_liv Liver baseline insulin phosphorylated
receptor in the cell
P_1979 Muscle|Endosome|End_IRp_0 Muscle baseline insulin phosphorylated
receptor in the endosome
P_293 Fat|Intracellular|IR_cell_0 Total concentration of adipocyte
intracellular insulin receptor
P_1753 Liver|Intracellular|IR_cell_0 Total concentration of liver intracellular
insulin receptor
P_1950 Muscle|Intracellular|IR_cell_0 Total concentration of muscle intracellular
insulin receptor
P_294 Fat|Intracellular|IR_p_0 Adipocyte baseline insulin phosphorylated
receptor in the cell
P_1758/P_1727Liver|Intracellular|IR_p_0 Liver baseline insulin phosphorylated
receptor in the cell
P_1949 Muscle|Intracellular|IR_p_0 Muscle baseline insulin phosphorylated
receptor in the cell
P_1814 Liver|ReceptorRecyclingFactor-End Liver receptor recycling factor
in the endosome
P_1994 Muscle|ReceptorRecyclingFactor Muscle receptor recycling factor
P_338 Fat|ReceptorRecyclingFactor Adipocyte receptor recycling factor
P_1811 Liver|ReceptorRecyclingFactor Liver receptor recycling factor
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of insulin. Particularly, the end metabolic state was different than the initial state, confirming
a metabolic change as an action of insulin. Moreover, each individual had a differential
metabolic shift reflective of a quantitative variation in flux values across pathways (Figure
5.6-E). Interestingly, we observed that insulin exerted a hysteresis between peripheral glucose
concentrations and whole-body metabolism (Figure 5.6-F), that was achieved differently be-
tween the different individuals.
Additionally, we investigated the impact of inter-individual variability on the different
metabolic pathways. Particularly, pentose phosphate pathway and glycolysis were remarkably
robust towards insulin-induced perturbation, while citric acid cycle and oxidative phospho-
rylation total whole-body flux over time showed a patient-specific variation (Figure 5.6-G).
Furthermore, we investigated the effect of intra-individual variability to insulin response on
whole-body metabolism.
5.3.5 Within-subject variability to insulin
Within-subject variability to insulin results from internal, endogenous factors that are specific
to a particular metabolic state of the individual, e.g., postprandial state, physical activity. In
order to determine the influence of the metabolic state on peripheral glucose dynamics, we
set the kinetic parameters of the simulated patient to the reported population mean in GIM
and varied the metabolic reactions. In each metabolic state, we generated random objective
coefficient weights to every reaction (Figure 5.7-A). The weights could be lower, higher, or
equal to the mean profile. In the latter case, the simulated profile approached the predictions
of the GIMmodel. To each set of internal perturbations (input) to metabolism, i.e., increase or
decrease in reactions weights, we measured the minimal glucose concentration and the final
concentration after 10 hours of subcutaneous insulin injection (output) [200]. In all cases,
the time step was decreased from five minutes to 2.5 minutes as both integration failures and
conflicting constraints arose from higher time steps. In the described setting, the reactions
of dHarvey fell under two classes, the reactions proper to Harvey and those shared by both
GIM and Harvey, referred to as interface reactions [242]. Changing the coefficients of the
interface reactions only and simulating dHarvey with FBA for 10 metabolic states resulted
in a smooth set of glucose dynamics (Figure 5.7-B). In order to get a complete view of the
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Figure 5.6: Inter-individual variability to insulin response is reflected on key pathways of
metabolism. A- Varying a set of individual parameters within the reported inter-individual
variability range in the dynamical model yields B- different peripheral glucose concentrations
as a response to insulin injection. C- Distribution of the active reactions over simulation time
per patient. D- Evolution of the metabolic fluxes as represented by PCA over simulation
time of the average patient (patient 1) and E- the population of synthetic patients. F- Insulin-
induced hysteresis between glucose peripheral blood levels and whole-body metabolism. G-
Citric acid cycle and oxidative phosphorylation total flux reflect between-patient variability
while glycolysis and pentose phosphate pathways are stable to perturbation. The flow chart
was done using Rawgraphs [151].
within-patient variability, the reactions proper to the Harvey were included as well. Using
FBA to simulate 10 metabolic states of the hybrid model, the glucose profiles showed non
smooth profiles, with non-biological concentrations or terminated in the course of simulation
(Figure 5.7-C). Finally, performing the simulation using CRONICS ensured both smoothness
of the system and minimal debugging to resolve conflicting constraints (Figure 5.7-D), of
which only 2 simulations permanently failed as they have reached a null concentration of
glucose and were removed from subsequent analysis. The 29 metabolic states simulated with
the final setting resulted from the perturbation of a total of 2817 reaction. Each metabolic
state consisted of a set of perturbed reaction activity as depicted by the random coefficient
matrix (Figure 5.7-E). The computed intra-individual variability equalled 30% in silico and
was in agreement with the empirical value of 12-45% [92]. To determine the influence of
every reaction to the metabolic profile of glucose, a multivariate regression was performed
using the coefficients matrix as input and a matrix of glucose concentrations per state as
output. The minimal and final glucose concentrations were considered for the sensitivity
analysis as they inform about adverse reactions and treatment efficacy, i.e., hypoglycemia and
hyperglycemia. The reaction sensitivities to both of the readouts (Figure 5.7-F) showed that
GLUT4 transport had a great share of the influence on glucose profile. Interestingly, reactions
from the bile acid synthesis pathway modulated the peripheral glucose profile as well. Taken
together, these findings showed that internal reactions in Harvey, that were not in necessarily
in the interface reactions set, had the potential to modulate the glucose concentrations in
GIM, through glycolytic and non-glycolytic pathways, thereby suggesting novel approaches
to achieve diabetes control.
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5.4 Discussion
We developed a multi-scale, dynamic, and organ-resolved model through multi-algorithm in-
tegration of metabolic and regulatory processes in T1D. The short time scale insulin-glucose-
glucagon regulatory dynamics (GIM) served as constraints to the whole body metabolic net-
work (Harvey). In addition to the expected target effects, the mechanism-unrelated metabolic
effects of both insulin and type 1 diabetes pathophysiology were included in the model
through organ-specific gene expression data and metabolomics time-course. The integrative
model provided a complete picture on the network dynamics, regulation, and response to
perturbation and links it to known symptoms and clinically relevant variability of insulin
response both within and between-subject.
5.4.1 Chronic inflammation in type 1 diabetes improves disease identi-
fication using whole-body fluxes
In order to assess the impact of the tolerance tests on the whole-body level, the metabolic
model (Harvey)was constrained by the glucose-insulin-glucagon regulationmodelled byGIM
in insulin and glucose challenges involving healthy and T1D states. The metabolic fluxes
were consequently used as features in an SVM binary classifier [206]. Identifying insulin
versus glucose challenges at five minutes and 15 minutes after perturbation was possible due
to the opposite effects that these substances induced on the human body (Figure 5.3-C). The
identification of healthy and T1D flux distribution improved the separation between healthy
and T1D individuals after the addition of gene expression constraints in T1D, representing the
chronic inflammation that triggers the pathogenesis of the disease. While glycaemia control
is achieved through allopathy, the inflammatory aspect of the disease is often overlooked
[152] and has to be equally addressed. In addition, it was possible to define a healthy
and diabetic boundary using whole-body metabolic fluxes despite the subjected constraints
affected mainly the glucose-related pathways (Figure 5.3-D). These findings further reinforce
the idea that type 1 diabetes is a multifactorial, pan-organ and systemic disease because of
the key role that glucose plays in regulation of metabolism and energy.
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5.4.2 Differentially regulated fluxes suggest mechanisms underlying the
systemic symptomatology of type 1 diabetes
We used gene expression data from type 1 diabetic pancreatic islets as constraints to represent
the pathophysiology of the disease that associated both the chronic inflammation and the
disruption of glycolytic processes. The total number of metabolic reactions in T1D was the
same in the healthy model as no evidence suggested complete metabolic gene knockout in
affected patients. dHarvey predicted a decrease in ATP in adipocyte (Figure 5.4-B) following
the IVGTT test as glycogen storage pathways are activated over ATP producing pathways.
Significantly decreased pathways in T1D encompass mostly transport pathways in relation
with the pan-organ distribution of insulin and the systemic properties of the disease. The
well-known switch to fatty acid synthesis in type 1 diabetes is demonstrated in enrichment
of the corresponding pathways (Figure 5.4-E). The up-regulation of sphingolipids, has been
linked in particular to a decrease in tissue insulin sensitivity [190] in metabolic disorders and
obesity.
Interestingly, tyrosine metabolism is significantly ranked in the up-regulated processes in
T1D (Figure 5.4-E), and recent studies have found direct links between diabetes and tyrosine
pathway disruption [65]. Additionally, the alteration of the phosphoinositide metabolism
was reported in a streptozotocyin-induced diabetes in platelet cells [103]. Moreover, the
glycosaminoglycan family (chondroitin, keratin sulfate andN-glycan) which include naturally
occurringmoleculesmaintaining the tissue and cartilage, are decreased in T1D and could be at
the origin of long-lastingmanifestations such as the well-known disruption of tissue structure,
e.g., diabetic foot. A study in rats showed a decrease of chondroitin sulfate in the kidney
suggesting a possible implication in diabetes induced nephropathy [104]. Collectively, the
down-regulation of tissue remodeling pathways adds further evidence to the observed eschar-
related symptomatology in diabetes. Since these manifestations happen at later stages, the
tissue remodeling pathway [76] could be considered for interventional (either allopathic or
nutritional) targets in the diagnosis phase.
The enrichment of genes associated to the increased fluxes in T1D (Table C.2) showed
a representation of classical pathways such as the oxidative phosphorylation and carbon
metabolism and, interestingly, Alzheimer’s disease (AD), and Parkinson’s disease were found
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Figure 5.7: (Continued on the following page)
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Figure 5.7: Intra-individual variability is assessed through sensitivity analysis of the inte-
gratedmodel. A- Themethod consists of assigning randomobjective coefficients tometabolic
reactions and measuring the minimal and final concentration of glucose for every state with
the kinetic parameters set for the population mean. B-Peripheral glucose profile when only
the interface reactions are varied, the simulation is carried with FBA (n=11). C-Glucose
profile when both the interface reactions and the metabolic model reactions are varied, using
FBA (n=11). D-Glucose profile when both the interface reactions and metabolic model reac-
tions are varied, using CRONICS (n=31). E- A 31-column excerpt of the matrix of variation
of reaction weights in the objective for every state. The total number of reactions considered
was 2817. F- Computed sensitivities of every reaction in the internal state to the external
output (minimal and final concentration of peripheral glucose). The reactions are described
in table C.7.
to have potential common links to T1D (Table C.5, Figure C.5). This finding further supports
the growing evidence [127, 156] for the common pathogenesis between neurodegenerative
disorders and late-stage diabetes. Added to the comorbidities, up to 70% of diabetic patients
experience a cognitive decline [45]. Furthermore, a clinical trial repurposed Exenatide, a
glucagon-like peptide-1 (GLP-1), indicated for the treatment of type 2 diabetes, in Parkinson’s
disease [13, 14]. Following the success of the early phases, a randomised double-blind
trial [12] showed that better motor functions were achieved at 48 weeks in comparison
to a placebo, possibly in relation to insulin signalling pathways. In AD, a study showed
that higher plasma and brain glucose levels were implicated in the disease progression [8]
and the severity of the pathology. The increase in brain glucose levels was linked to a
decrease in GLUT3 neuronal transporter expression and a reduced brain glycolytic flux,
possibly explaining the comorbidities between AD and diabetes [211, 101]. Similarly, anti-
diabetic drugs were suggested in AD [82, 253], particularly GLP-1 agonists and glucagon
that conferred neuroprotective effects and reversed memory loss in AD rodent models [220].
Among the small molecules that we found to revert the expression of genes associated to both
the increased and decreased fluxes, Mibefradil and Amlodipine had a very good coverage
(Table C.6). Encouragingly, studies in experimental rodent models of diabetes have shown
that calcium blockers improved blood glucose levels and diabetes-associated nephropathy
[138, 136].
Taken together, these findings suggest the existence of a continuum between diabetes and
neurodegenerative disorders, possibly involving a strong metabolic component.
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5.4.3 Insulin rewires inter-organ exchange
Conceptually, dHarvey added the dynamic features of GIM to the genome-scale metabolic
model Harvey, enabling a hybrid approach to metabolism. While GIM accurately predicted
the glycolytic and regulatory effects of insulin, it could not capture the decrease of amino acids
in the blood and other well-known anabolic effects [52]. The addition of a dynamical model
of insulin off-target effects [256] accurately predicted several known non-glycolytic effects
of insulin (Figure 5.5). In particular, the prediction of the triglycerides time-course (Figure
C.7) using CRONICS, showed an increase in the adipocytes as a result of the inhibition
of lipases. Furthermore, we predicted the effects of insulin on metal homeostasis as they
play a prominent role in developing injection shocks due to the fast depletion of phosphate
and potassium. Phosphate and potassium showed a trend towards an increase in the uptake,
although these results are not conclusive (Figure 5.5). Given the great implication of those
ions in signaling pathways, and the demonstrated insulin-induced signalling modulation
[256], signaling pathways might play a greater role than metabolism in the ions homeostasis.
Given the small occurring concentrations of the ions in comparison to larger molecules,
metabolism alone does not capture the full spectrum of micronutrient homeostasis.
Finally, to study the effect of insulin on inter-organ crosstalk, a subset of the reactions
was selected to encompass the kidneys, liver, brain, pancreas, muscle, adipocyte, and inter-
organ compartments, e.g., plasma, as the role of these organs have been demonstrated in
the disease pathology [134, 188]. The total inter-organ crosstalk increased as an effect of
insulin administration (Figure C.8), further structuring the organs as a metabolic continuum.
Multiple organ complications related to late-stage diabetes corroborates this finding as the
loss of insulin mediates a decrease in organ crosstalk at a metabolic level. Although the
implications of endocrine secretions have been more studied in systemic organ failure in
pathology [134], the overall decrease in organ crosstalk in T1D might be a combined effect
of the signalling and metabolic properties of insulin.
5.4.4 Insulin-mediated hysteresis reflects between-subject variability
The generation of a synthetic population of T1D patients involved the variation of patient-
specific kinetic parameters [202]. The obtained peripheral glucose profile reproduced the
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reported 25%-35% of inter-individual variability to insulin and the differences were partic-
ularly noticed on the AUC, Cmin and Tmin (Figure 5.6-A,B). Interestingly, the patients had
a similar number of active reactions, reflecting a similar network topology (Figure 5.6-C)
which was also an effect of the simulation framework CRONICS that ensured a sparse set of
fluxes and a minimal change between the time steps. This observation implies also the similar
constitutive metabolic background between the patients and a conservation of the high-flux
backbone [5], in the absence of specific enzyme deficiency as in the case of IEMs [193].
Although, when projecting the principal components of the flux distribution of individual
patients during the simulation time, a metabolic shift could be observed. Two main results
were subsequently deducted, first, the differences in response to insulin lie mainly in the
modulation of flux values in the metabolic model (Figure 5.6-D) rather than the network
structure. Second, the final metabolic state is different from the initial state, although the
simulation time was large enough (10h) to ensure a return to steady state in the GIM model
uncoupled to Harvey, which was consistent with profound insulin-induced regulatory mech-
anisms on metabolism. Each patient achieved a differential control of the metabolic shift
which can be related to the varying metabolic outcomes (Figure 5.6-E). In particular, insulin
as indirectly represented by the glucose peripheral levels, induced a hysteresis in metabolism
(Figure 5.6-F) which denotes the dramatic metabolic changes of insulin administration. In
fact, the binding of insulin to its receptor and the release of GLUT transporters that has a
15h half-life under insulin treatment [199] could be key drivers of the shift of the metabolic
steady state, given the ubiquitous distribution of insulin receptors. Moreover, the hysteresis
reflected the correspondence of several internal metabolic states to a unique glucose concen-
tration (Figure 5.6-F). This finding corroborates the unreliability of plasma glucose levels as
a universal marker for the diagnosis of diabetes [24].
Additionally, the observed hysteresis revealed a differential action of insulin in the population,
where in most patients it described a quasicycle between glucose concentrations predicted
by GIM and the internal system properties modelled by the whole-body metabolic fluxes. It
is noteworthy that a few patients did not achieve a metabolic shift and remained at the initial
state, denoting ineffective insulin action, while a great distance of the final state could be a
marker of hypo- or hyper-glycaemia and uncontrolled diabetes.
Finally, as hypothesized, the values of metabolic fluxes rather than network structure were
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the driver of the observed differences between the patients (Figure 5.6-G). In particular, the
citric acid cycle and oxidative phosphorylation were supporting the observed between-subject
variability while glycolysis and pentose phosphate pathways were robust to perturbation, de-
noting their essential role in human metabolism. In the architecture of metabolism, glycolysis
and pentose phosphate pathways are at central position, while citric acid cycle and oxidative
phosphorylation are the entry points to several secondary redundant pathways. In fact, exter-
nal network nodes tend to act as buffers to absorb the perturbations and maintain the central
functionalities of the network [71].
Taken together, the reduction of inter-individual variability in the response to insulin is key to
achieving diabetes control. Particularly, a study including a cohort of 20,303 individual [4],
showed that a higher coefficient of variance of glucose dynamics in diabetic patients was cor-
related to higher mortality rates, therefore, reducing within-patient variability is additionally
a major determinant the management of T1D.
5.4.5 GLUT4 as a pharmacogenomics target for diabetes control
Within-patient variability to insulin poses a great challenge for the identification of the
internal factors that could modulate the dynamics of glucose. Assuming the same kinetic
parameters to represent the average patient, we randomly generated several internal metabolic
states and consequently measured the glucose time series after insulin administration. Each
state assumed different objective weights of a selected set of reactions. Moreover, CRONICS
ensured the smoothness of the simulated system, wherein the outcome of the constraint-
based model determined the dynamics of glucose, in contrast to the simulation setting
of the inter-individual variability. The outcome of the simulation was in agreement with
empirical intra-individual variability to insulin [92] and subsequently, the reactions were
classified by their sensitivity to the final and the minimal glucose concentration, which acted
as surrogate endpoints for insulin activity (Figure 5.7-F). Given the high computational cost
of the operation, we randomly selected representative reactions from each subsystem in all
organs. The bile acid synthesis pathway was found to highly modulate glucose concentrations
in the model. Particularly, studies have shown that dysregulation of the pathway could
contribute to the pathogenesis of diabetes through the modulation of GLP-1 and insulin
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sensitizing activities [179, 228]
Additionally, the transporter GLUT4 had a high sensitivity towards the minimal and final
glucose concentration. The insulin-dependent carrier is released to balance high glucose
concentrations and its expression could be a major factor of the pharmacodynamics of insulin
[42]. Generally, the transport subsystem, mediated by carrier proteins, provides a rationale
for the design of novel antidiabetic drugs targeting transport proteins such as SGLT-1 [197]
and SGLT-2 [238]. Finally, since the flux through the GLUT4 reactions highly modulated
glucose concentrations in the dHarvey model, we hypothesize that the carrier could be a
major pharmacogenomics effector of insulin action. The design of adjuvant therapy to
insulin, targeting the expression and release of GLUT4 is a potential avenue to decrease intra-
individual variability to insulin, overcome insulin resistance, and ultimately achieve diabetes
control. Overall, the model presented in this study expands our understanding of type 1
diabetes and has the potential to empower evidence-based approaches to human pathology.
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Chapter 6
Concluding remarks
Genome-scale metabolic models have been widely used to reconstruct bacterial organisms
in silico and to simulate their phenotype in different media. The end goal is to accumulate
as much information as possible to obtain models that resemble the actual organisms and
are entirely predictive of their capacity. Genome-scale metabolic models are knowledge-
bases of metabolism and as such they are built in a hypothesis-free manner and used to
interrogate the model for a set of questions. ODE-based dynamical models are smaller
in coverage of biological process although they harbour crucial dynamical properties that
can further characterize the organism in time and space. The dynamical models are poorly
scalable and are usually hypothesis-driven, which means that they are built in order to answer
a specific question at a specific time. As I detailed in the introduction, building hybrid
models of metabolism using both ODE-based models and steady-state genome-scale models,
can leverage the advantages of both types of models to increase the accuracy and scope of
predictions. Although, a question that hasn’t been brought up enough in the community
surrounds the compatibility of these modeling techniques. Is the hybrid model hypothesis-
free or hypothesis-driven? Is the model valid for all time, in all conditions or does it live for a
short period of time to answer a specific question? What is the compromise in time interval
for a biological system to achieve steady-state and meet the integration tolerance of ODEs?
Is the model the smallest set of equations that better describe the data? Do the steady-state
constraints apply in short-time dynamics?.
Answering these questions is crucial to properly assess the range of action of hybrid models.
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6.1 Constraining dynamical models, how much is enough?
Coupling dynamical ODE-basedmodels and genome-scale metabolic models, requires points
of intersection in metabolites or reactions. Oftentimes, the intersection set is a small set in
comparison to the size of the metabolic model. Then we can legitimately ask if the changes
induced by the intersecting set are enough to induce a whole-system shift in metabolism
and to drive a dynamic change in phenotype, dictated by the dynamical model. In the first
coupled model of Ecoli [43], the authors coupled all available reactions and metabolites in
the dynamical model to the genome-scale model. In return the genome-scale model informed
the ODE model with new rates specific to the biomass. The coupled model provided closer
results to the experimental data than each of the model on their own. Later in the first
model combining PBPK and genome-scale models [119], the intersection points were only
two reactions, namely the organ perfusion and the organ secretion for allopurinol, which
matched the uptake and secretion reactions in the genome-scale model. We used a similar
approach to predict the pharmaockinetics of levodopa with a set of diets (Chapter 3). Two
matching reactions here are enough to predict the concentrations of allopurinol, because in
PBPK models, the concentrations are entirely determined by in and out rates. In another
work [231], a dynamical model has been embedded into a genome-scale model, to backtrack
the contribution of metabolites to the biomass, which allowed to correct the predictions of
the dynamical model using species that were not initially included in the ODEs.
So to the question ’How many dynamical constraints should I apply to the genome-scale
model?’ my answer would vary with the question sought. It stays obvious that a large
number of constraints involving key processes like the biomass and imbalanced reactions
are drivers of metabolic shifts in large-scale metabolic models. If the question surrounds
the prediction of the concentration of a specific set of metabolites then coupling reactions
directly involved in their anabolic and catabolic processes is sufficient, independently of the
original size of the model.
Equally, achieving steady state is a central assumption in genome-scale metabolic models
and forms the basis for Flux Balance Analysis (FBA). In this case, the rate-of-change of
metabolites is zero, while dynamical models allow to obtain the time-course of metabolites
through integrating ODEs. Then what should be the stand of a hybrid model towards the
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steady-state assumption? The allopurinol combined PBPK and genome-scale liver model
[119] addressed this issue through maintaining the steady-state assumption and performing
the coupling on the imbalanced reactions. The imbalanced reactions in a genome-scale model
are exchange or biomass reactions whose rate-of-change is not equal to zero. As a matter of
fact, the steady-state assumption in genome-scale models is only partial and includes only
internal metabolites. In the hybrid model of E.coli [43], the authors lifted the steady-state
assumption on internal metabolites whose rate-of-change is known by the dynamical model
and kept the remaining metabolites as steady-state. Finally, the co-existence of steady-state
and non-steady metabolites is mainly driven by the availability of data and has to be clearly
communicated in the modeling phase as it could lead to confusion and misinterpretation.
How much should be the length of the time step between discrete and continuous dynamics?
Most attempts so far have taken into account the integration tolerance as a main objective
[43, 74, 85]. Then a recurrent question in field comes with regards to biological relevance:
does the biological system optimize for short time steps or does it have an endpoint objective
function? The former seems more concordant with experimental data although the latter is
more intuitive [141].
6.2 Tractability and model reduction
Building a hybrid body-wide model of carbohydrate metabolism and regulation (Ben Guebila
and Thiele, in preparation) posed a totally new set of questions that were triggered by
the exceptional size of the model (> 80,000 reactions, > 10,000 ODEs). Maintaining a
chronologically coherent set of predictions required the design of new tools (Chapter 5).
Particularly, the size of the model made it largely under-determined, which required the
selection of the solutions that are closer to the previous time step in a flip book analogy. This
type of issues was not affecting small size model as the solution space is much reduced and
usually the constraints from the dynamical model ensure the smoothness of the system. The
downside of this addition was that it turned the simulations into time-critical operations. The
simulation is in the order of days, which affects the development and re-use of this type of
models as specific hardware is required.
Although this question came up newly in the field of metabolic modelling, I find that getting
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inspiration from aerospace modelling could be salutary. In the beginning of the race to space,
the large simulation time of the shuttle trajectory reportedly delayed several missions [172].
Model reduction is based on a simple concept: first the building of the detailed mechanistic
model and the simulation for a set of output variables. Although, the original model is rich
in information and the length of simulation time makes it impracticable for real world needs
e.g., space shuttle launch, clinical trials, as no one would wait for months to make a go/no-go
decision. The problem is often referred to as the curse of parametrisation and is often dealt
with through selecting an output variable of interest to the question. Second, model order
reduction is performed through projecting it into a lower dimension after determining the
main readout variable of the model [257, 7]. In its compact form the model can hold on a
USB thumb-drive and can be exchanged and manipulated very fast to answer what-if type
of questions. The original rich system is usually sensitive to the initial conditions, it is
then perturbed and sub-regions of solutions are identified, sampled, compressed and finally
clustered to represent a set of output solutions [15, 63]. This means that for a small number
of large-scale simulations, the behaviour of the system can be reduced to the informative
regions.
6.3 A regulatory perspective
The increasing use of hybrid models in biomedical applications and particularly in pharma-
cometrics naturally brings a reflection on the regulatory aspect of modeling. The FDA has
been accepting PKPD and PBPK models [164] to support labelling of products, the optimal
design of clinical trials, drug-drug interactions, prediction of exposure in paediatric popula-
tion, estimation of absorption, and as a support for regulatory review in general [191, 169].
Recently, a closed-loop controlled insulin pump in T1D has been accepted without preclinical
trials, using solely the model simulations [117]. What would be the stand of the regulator
towards hybrid models of continuous and discrete dynamics?
While PKPDmodels are the smallest models that best fit the data, this type of hybrid model is
certainly not minimal. Constraint-based modeling is rather a semi-quantitative approach and
is not as accurate as full dynamical models in predicting reaction rates. As such, the hybrid
model is semi-quantitative, particularly for the metabolites and reactions that are covered by
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the genome-scale metabolic model alone. Hybrid models are certainly useful in preclinical
trials, target discovery, and biomarker identification. In clinical trials, a large set of con-
straints are needed to constrain the hybrid model to the biologically relevant observations,
such as the constraints provided by the GIM model that covers all the organs and a large
number of processes. Nevertheless, the detail and scope of the GIM model make it certainly
anecdotal, there are a handful of models that are equal in granularity and size. Particularly,
to estimate the large number of kinetic parameters in PBPKmodels, concentration data in the
target organs need to be measured to accurately estimate organ-specific rates of metabolism.
Nevertheless, the use of organ diffusion models can provide an accurate estimation of the
metabolised fraction [185, 186]. In order to perform classical pharamacometric analyses
on large-scale models including bootstrapping of parameters, finding correlation between
parameters, and mixed-effect non-linear population modeling, new mathematical tools have
to be developed in order to meet the needs of the regulatory bodies, particularly through
addressing parametric uncertainty and model-form uncertainty.
The increasingly accessible biological data combined with adequate open-source software
such as PKSIM [249], will make it easier to build whole-body models, which can bring
modeling in the forefront of clinical trials design.
6.4 What is next? writing the ODE of life.
Many view hybrid models of continuous and discrete dynamics as a a pitstop towards full
dynamicalmodels of biological systems. Recently, a few large-scaleODE systems of bacterial
metabolismwere developed [112, 48], equalling in size the first generation of constraint-based
metabolic models. Dynamical models are certainly more adequate than constraint-based
models in quantitatively answering specific questions with respect to the system dynamics,
particularly when the uncertainty is quantified and assessed. Although seeing them as the
ultimate goal of explaining life is certainly delusional. This is because of the large number
of parameters to estimate, the different rate processes, the modeling of the different types of
affinities and inhibitory processes, and the in vivo enzyme kinetics. While I think this goal
is within reach in the upcoming years, I believe that smaller tractable models can provide
an equally insightful result to a specific question at a given time and for a fraction of the
130 CHAPTER 6. CONCLUDING REMARKS
development cost; to quote Von Neumann: ’If people do not believe that mathematics is
simple, it is only because they do not realize how complicated life is’.
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A.1 Supplementary tables
Table A.1: Support vector machine parameter summary
Parameter Optimal value/algorithm
Feature selection algorithm ReliefF
k-ReliefF 80
Number of features 20
Cross-validation 3-fold cross-validation
Class balance Inverse of class frequencies
Observation weights Drug side effect frequency per drug
SVM kernel Gaussian
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Table A.2: Automatically optimized SVM hyperparameters.
Hyperparameter Value/Range
Standardize data True,false
Kernel Linear, Gaussian, polynomial
Polynomial order [2,5]
Box constraints [1e-6,1e+4]
Kernel scale True,false
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Table A.3: Area under the ROC curve of the predicted side effect using a multi-label support
vector machine classifier with combined gene expression and sampled metabolic flux as
features.
Side effect AUROC
Gastrointestinal pain 0.52
Gastrointestinal disorder 0.53
Functional gastrointestinal disorder 0.63
Gastrointestinal haemorrhage 0.64
Intestinal obstruction 0.67
Intestinal perforation 0.69
Gastrointestinal tract irritation 0.72
Gastrointestinal perforation 0.74
Gastrointestinal obstruction 0.75
Gastrointestinal fistula 0.79
Intestinal ulcer 0.8
Gastrointestinal hypomotility 0.8
Gastrointestinal sounds abnormal 0.9
Gastrointestinal ulcer haemorrhage 0.9
Gastrointestinal infection 0.91
Gastrointestinal necrosis 0.92
Gastrointestinal toxicity 0.92
Upper gastrointestinal haemorrhage 0.93
Lower gastrointestinal haemorrhage 0.95
Gastrointestinal carcinoma 0.96
Gastrointestinal ulcer perforation 0.96
Gastrointestinal motility disorder 0.97
Intestinal infarction 0.97
Gastrointestinal ulcer 0.97
Gastrointestinal stromal tumour 0.97
Pneumatosis intestinalis 0.97
Intestinal ischaemia 0.98
Large intestine polyp 0.98
Gastrointestinal malformation 0.98
Gastrointestinal candidiasis 0.99
Benign gastrointestinal neoplasm 0.99
Gastrointestinal inflammation 0.99
Diverticulum intestinal 0.99
Large intestine perforation 0.99
Small intestinal obstruction 0.99
Intestinal haemorrhage 0.99
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A.2 Supplementary figures
Figure A.1: Comparison of multi-label classifiers. Four classifiers namely, logisitic re-
gression, naive Bayes, random forest, and support vector machine were compared in their
predictive capabilities measured by the F1-score, accuracy,class weighted accuracy, class
weighted recall, area under the ROC curve (AUROC), area under the precision-recall curve
(PR).
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Figure A.2: Comparison of 11 feature selection algorithm with respect to the area under the
ROC curve of individual intestinal side effects with the 95% confidence interval for the mean
in red and one standard deviation in blue.
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Figure A.3: Comparison of k values for the feature selection algorithm ReliefF through the
area under the ROC curve of classifiers of individual side effects with the 95% confidence
interval for the mean in red and one standard deviation in blue. The highest mean (0.83) was
achieved for k=80.
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Figure A.4: Comparison of the effect of the number of the most predictive features on the
classification performance as assessed by the area under the ROC curve.
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Figure A.5: Comparison of cross-validation method on the loss computed as the number of
misclassified side effects per drugs over the total number of side effects, and the predictability
of the individual side effects as reflected by area under the ROC curve (AUROC). Outliers
in the loss are rare side effects that have a small number of data points. The 3-fold cross-
validation ensured a lower loss and the highest area under the ROC curve on out-of-sample
drugs. Left: distribution of AUROC of individual side effects with the 95% confidence
interval for the mean in red and one standard deviation in blue. Right: boxplot of the loss
computed for each cross-validation method.
A.2. SUPPLEMENTARY FIGURES 159
Figure A.6: Comparison of the effect of class balance set as the misclassification cost, on
the outcome of the classification as determined by the area under the ROC curve. The
misclassification cost, set to the inverse of class frequencies, allowed to obtain a mean of
0.875 of the AUROC of the individual intestinal side effects as opposed to 0.86 without class
balance.
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Figure A.7: Comparison of the effect of adding observation weights to the classifier as
compared the area under the ROC curve. The weights of drugs per class were set to their
frequencies reported in SIDER. Weighing observations has a mean area under the curve of
0.830 while unweighted observation has a mean of 0.836.
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Figure A.8: Comparison of SVM kernel functions as a function of area the under the ROC
curve of individual side effects. Over all, the Gaussian kernel had the highest predictive
capabilities.
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Figure A.9: Effect of automatic and manual hyperparameter optimisation with respect to
20% holdout accuracy as an objective function. The manually obtained parameters allowed
for a higher predictive capability of the classifier as measured by the individual side effect
area under the ROC curve.
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Figure A.10: (Continued on the following page)
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Figure A.10: Drug cluster validation and characteristics. A- Graph linking drug clusters,
intestinal side effects andFDANDCD’s established pharmacological class (EPC).B-Bipartite
graph of drug clusters and the corresponding FDA NDCD’s reported marketing date. C-
Bipartite graph of drug clusters and enriched metabolic and transport subsystems. The flow
chart was done using Rawgraphs [151]. E-Cluster stability and purity provided a means for
cluster validation.
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B.1 Supplementary tables
The following table are too large to be displayed in text and are available via the publisher’s
website.
Table B.1: Table of Ordinary differential equation-based levodopa pharmacokinetic model.
Direct download: https://images.nature.com/original/nature-assets/npjsba/2016/npjsba2016
13/extref/npjsba201613-s2.doc
Columns Description
Equation name The name of the current equation in the model.
Equation description A detailed description of the biological process associated
to the equation.
Equation The formal ODE.
Parameter description A description of the biological relevance of the equation’s
parameters.
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TableB.2: Table of whole body generic PBPK model parameter estimation from curve fitting.
Parameter Model constraints Estimated value Literature value
Molecular weight 197.18 g/mol Fixed 197.18 g/mol [115]
Blood plasma
partition coefficient > 0 0.57 -
Clearance 0.5-5 l/kg/h 0.95 l/kg/h 0.55-1.38 l/kg/h [149]
Log of permeability < 0 -4.9 -2.39
Unbound fraction 0.6-0.95 0.95 0.6-0.95
Effective luminal
intestinal permeability 0-5 cm/hour 1.8 cm/hour 1.22 cm/hour [131]
Distribution factor > 0 1.24 -
Effective basolateral
intestinal permeability 0-5 cm/hour 3.6 cm/hour
≥ Effective luminal
intestinal permeability [3]
The estimated parameters are within the reported biological interval. The clearance regroups
the overall elimination from the body in the eliminating organs (brain, kidneys, liver). The
parameters units are mentioned and dimensionless otherwise.
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Table B.3: Reactions added to the sIEC model ordered by affinity of amino acids to the
corresponding transporter.
Luminal antiport reactions GPR(Entrez ID)
34dhphe[u] + ala_L[c]→ 34dhphe[c] + ala_L[u]
34dhphe[u] + leu_L[c]→ 34dhphe[c] + leu_L[u] 11136 and 6519 [239]
34dhphe[u] + leu_L[c]→ 34dhphe[c] + leu_L[u]
Basolateral antiport reactions GPR(Entrez ID)
34dhphe[c] + tyr_L[e]→ 34dhphe[e] + tyr_L[c]
34dhphe[c] + trp_L[e]→ 34dhphe[e] + trp_L[c]
34dhphe[c] + phe_L[e]→ 34dhphe[e] + phe_L[c]
34dhphe[c] + thr_L[e]→ 34dhphe[e] + thr_L[c]
34dhphe[c] + ile_L[e]→ 34dhphe[e] + ile_L[c]
34dhphe[c] + cys_L[e]→ 34dhphe[e] + cys_L[c] 23428 and 6520 [239]
34dhphe[c] + ser_L[e]→ 34dhphe[e] + ser_L[c]
34dhphe[c] + val_L[e]→ 34dhphe[e] + val_L[c]
34dhphe[c] + leu_L[e]→ 34dhphe[e] + leu_L[c]
34dhphe[c] + glu_L[e]→ 34dhphe[e] + glu_L[c]
34dhphe[c] + ala_L[e]→ 34dhphe[e] + ala_L[c]
34dhphe[c] + his_L[e]→ 34dhphe[e] + his_L[c]
34dhphe[c] + asp_L[e]→ 34dhphe[e] + asp_L[c]
34dhphe[c] + met_L[e]→ 34dhphe[e] + met_L[c]
Complementary luminal amino acids GPR(Entrez ID)
antiport reactions
leu_L[u] + ala_L[c]→ leu_L[c] + ala_L[u]
leu_L[u] + arg_L[c]→ leu_L[c] + arg_L[u]
lys_L[u] + arg_L[c]→ lys_L[c] + arg_L[u]
lcystin[u] + arg_L[c]→ lcystin[c] + arg_L[u] 11136 and 6519 [239]
orn[u] + arg_L[c]→ orn[c] + arg_L[u]
tyr_L[u] + ala_L[c]→ tyr_L[c] + ala_L[u]
tyr_L[u] + arg_L[c]→ tyr_L[c] + arg_L[u]
ala_L[u] + arg_L[c]→ ala_L[c] + arg_L[u]
ala_L[u] + leu_L[c]→ ala_L[c] + leu_L[u]
Intracellular accumulation References
(Demand reaction) 34dhphe[c]→ [32]
Luminal competition References
0.42 34dhphe[u] + 0.1 lcystin[u]→ artefact[u]
0.38 34dhphe[u] + 0.1 arg_L[u]→ artefact[u]
0.34 34dhphe[u] + 0.1 lys_L[u]→ artefact[u]
0.3 34dhphe[u] + 0.1 leu_L[u→ artefact[u]
0.26 34dhphe[u] + 0.1 tyr_L[u]→ artefact[u] [32, 239]
0.22 34dhphe[u] + 0.1 ala_L[u]→ artefact[u]
0.18 34dhphe[u] + 0.1 orn[u]→ artefact[u]
(Demand reaction) artefact[u]→
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Table B.3: Continued
Trans-stimulation with basolateral amino acids References
(Demand reaction) 34dhphe[c] * 0.77→ [32]
The basolateral uniport reaction exits already in the original sIEC, its lower bound was
set to zero to avoid free diffusion back in the cell from the basolateral side. 34dhphe
represents levodopa and artefact represents a dummy molecule that accounts for the luminal
loss of levodopa in the presence of amino acids. The stoichiometric coefficients of luminal
competition were inferred from reported in vitro experiments and represent the percentage of
loss of levodopa. u, c and e stand for lumen, cytoplasm and blood, respectively. GPR stands
for gene protein reaction.
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Table B.4: Top 5 ranking parameter sensitivities.
Rank Parameter Description
1 intestlo Intestinal loss of levodopa.
2 stomlo Stomach loss of levodopa.
3 kabl Secretion of levodopa in the portal vein through the basolateral
membrane of enterocyte.
4 GER Gastric emptying rate
5 Kt Small intestine transit rate constant
The parameters are represented with their model designation and a description of their
biological properties.
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Table B.5: Levodopa exchange substrate in the kidney and in the blood brain barrier.
Compartment
Substrates in
(ordered by affinity
for the transporter)
Substrates out GPR (Entrez ID) References
Brain leu,his,ile,phe,tyr,trp,val,met,gln,levodopa leu 855653 [239]
Kidney
tyr,trp,phe,thr,ile,cys,
ser,val,leu,gln,ala,his,
asn,met, gly,levodopa
phe,ile,leu 7462 [239]
The substrates are ordered by affinity to the transporter. GPR stands for gene protein reaction.
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Table B.6: Constraints subjected to a three organ model accounting for levodopa absorption,
elimination, metabolism and competition with amino acids.
Added reactions and affinity coefficients Constraints(ub, lb)
Small intestine lumen : 34dhphe[u]→ -15
{amino acid}_L[u]→ -3
34dhphe[u]→ 34dhphe[elim] +5
(non-absorbed fraction in the gut)
Blood brain barrier reactions Constraints(ub, lb)
Blood brain barrier : 34dhphe[e] 34dhphe[bbb] unc
(Demand reaction) 34dhphe[bbb]→ unc
0.23 34dhphe[e] + 1 leu_L[e]→ 0.23 34dhphe[bbb] + 1 leu_L[bbb] unc
0.26 34dhphe[e] + 1 his_L[e]→ 0.26 34dhphe[bbb] + 1 his_L[bbb] unc
0.29 34dhphe[e] + 1 ile_L[e]→ 0.29 34dhphe[bbb] + 1 ile_L[bbb] unc
0.33 34dhphe[e] + 1 phe_L[e]→ 0.33 34dhphe[bbb] + 1 phe_L[bbb] unc
0.36 34dhphe[e] + 1 tyr_L[e]→ 0.36 34dhphe[bbb] + 1 tyr_L[bbb] unc
0.39 34dhphe[e] + 1 trp_L[e]→ 0.39 34dhphe[bbb] + 1 trp_L[bbb] unc
0.43 34dhphe[e] + 1 val_L[e]→ 0.43 34dhphe[bbb] + 1 val_L[bbb] unc
1 34dhphe[e] + 1 thr_L[e]→ 1 34dhphe[bbb] + 1 thr_L[bbb] unc
1 34dhphe[e] + 1 cys_L[e]→ 1 34dhphe[bbb] + 1 cys_L[bbb] unc
1 34dhphe[e] + 1 ser_L[e]→ 1 34dhphe[bbb] + 1 ser_L[bbb] unc
0.58 34dhphe[e] + 1 glu_L[e]→ 0.58 34dhphe[bbb] + 1 glu_L[bbb] unc
1 34dhphe[e] + 1 ala_L[e]→ 1 34dhphe[bbb] + 1 ala_L[bbb] unc
1 34dhphe[e] + 1 asn_L[e]→ 1 34dhphe[bbb] + 1 asn_L[bbb] unc
1 34dhphe[e] + 1 gln_L[e]→ 1 34dhphe[bbb] + 1 gln_L[bbb] unc
1 34dhphe[e] + 1 gly_L[e]→ 1 34dhphe[bbb] + 1 gly_L[bbb] unc
1 34dhphe[e] + 1 pro_L[e]→ 1 34dhphe[bbb] + 1 pro_L[bbb] unc
1 34dhphe[e] + 1 lys_L[e]→ 1 34dhphe[bbb] + 1 lys_L[bbb] unc
1 34dhphe[e] + 1 arg_L[e]→ 1 34dhphe[bbb] + 1 arg_L[bbb] unc
1 34dhphe[e] + 1 asp_L[e]→ 1 34dhphe[bbb] + 1 asp_L[bbb] unc
0.5 34dhphe[e] + 1 met_L[e]→ 0.5 34dhphe[bbb] + 1 met_L[bbb] unc
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Table B.6: Continued
Kidney reactions Constraints(ub, lb)
Kidney : 34dhphe[e]→ 34dhphe[ku] unc
0.5 34dhphe[ku] + 1 tyr_L[ku]→ 0.5 34dhphe[k] + 1 tyr_L[k] unc
0.5 34dhphe[ku] + 1 trp_L[ku]→ 0.5 34dhphe[k] + 1 trp_L[k] unc
0.5 34dhphe[ku] + 1 phe_L[ku]→ 0.5 34dhphe[k] + 1 phe_L[k] unc
0.6 34dhphe[ku] + 1 thr_L[ku]→ 0.6 34dhphe[k] + 1 thr_L[k] unc
0.63 34dhphe[ku] + 1 ile_L[ku]→ 0.63 34dhphe[k] + 1 ile_L[k] unc
0.66 34dhphe[ku] + 1 cys_L[ku]→ 0.66 34dhphe[k] + 1 cys_L[k] unc
0.69 34dhphe[ku] + 1 ser_L[ku]→ 0.69 34dhphe[k] + 1 ser_L[k] unc
0.73 34dhphe[ku] + 1 val_L[ku]→ 0.73 34dhphe[k] + 1 val_L[k] unc
0.76 34dhphe[ku] + 1 leu_L[ku]→ 0.76 34dhphe[k] + 1 leu_L[k] unc
0.79 34dhphe[ku] + 1 glu_L[ku]→ 0.79 34dhphe[k] + 1 glu_L[k] unc
0.83 34dhphe[ku] + 1 ala_L[ku]→ 0.83 34dhphe[k] + 1 ala_L[k] unc
0.86 34dhphe[ku] + 1 his_L[ku]→ 0.86 34dhphe[k] + 1 his_L[k] unc
0.89 34dhphe[ku] + 1 asn_L[ku]→ 0.89 34dhphe[k] + 1 asn_L[k] unc
0.93 34dhphe[ku] + 1 gln_L[ku]→ 0.93 34dhphe[k] + 1 gln_L[k] unc
1 34dhphe[ku] + 1 gly_L[ku]→ 1 34dhphe[k] + 1 gly_L[k] unc
1 34dhphe[ku] + 1 pro_L[ku]→ 1 34dhphe[k] + 1 pro_L[k] unc
1 34dhphe[ku] + 1 lys_L[ku]→ 1 34dhphe[k] + 1 lys_L[k] unc
1 34dhphe[ku] + 1 arg_L[ku]→ 1 34dhphe[k] + 1 arg_L[k] unc
1 34dhphe[ku] + 1 asp_L[ku]→ 1 34dhphe[k] + 1 asp_L[k] unc
1 34dhphe[ku] + 1 met_L[ku]→ 1 34dhphe[k] + 1 met_L[k] unc
While the small intestine has been represented by the genome scale model, only levodopa
transport reactions were modeled for the kidneys and blood brain barrier. Amino acids that do
not compete with levodopa have a stoichiometric coefficient of 1, amino acids that compete
have a coefficient < 1, the higher the affinity for the transporter the lower the coefficient.
20 models were generated, one for every combination of one amino acid and levodopa. ku
stands for kidney lumen, bbb for blood brain barrier ,and unc for unconstrained.
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B.2 Supplementary figures
Dynamical modeling of levodopa gastrointestinal transit and metabolism within the
whole body generic PBPK model
The generic physiologically based pharmacokinetic whole body model [170] assumes the
enterocyte as a ‘thin wall’. In other words, drugs absorbed in the lumen are directly present
in the portal vein. This assumption does not allow us to model luminal competition and
basolateral trans-stimulation. For these reasons, enterocyte compartments were added as
described in [3] that aided in the coupling of sIEC genome-scale metabolic models. The
enterocyte performs three main biological functions with regards to levodopa. The luminal
absorption, the basolateral secretion and the accumulation of levodopa which is the difference
between the absorption and secretion.
The absorption and secretion by the enterocyte was modeled with the following ODEs
([3]:
Luminal absorption in compartment i:
Absorption(i) = ka ∗ V(i) ∗ C(i)L
Basolateral secretion in compartment i:
Secretion(i) = kabl ∗ V(i) ∗ C(i)ENT
Concentration inside the enterocyte in compartment i:
dC(i)ENT
dt =
(Absorption(i)−Secretion(i))
VENT
with ka, kabl,V,C, L and ENT luminal absorption constant, basolateral absorption constant,
volume, concentration, lumen, enterocyte, respectively. i ranges from 1 to 7. The set of
equations and parameters describing gastrointestinal processes were added to the generic
PBPK whole body model as described in [170], as in tableB.1.
Parameter estimation
The data fitting and simulations was performed using Matlab (2014b release, MathWorks,
Natick, MA) and Tomlab (TomOpt Inc.). The model parameters (Table B.1) were identified
with fmincon algorithm, which finds the minimum of a nonlinear optimization problem
subjected to a set of constraints, and global search option, that ensures the converges to the
global minimum of the objective function through testing different sets of initial points. The
parameters were constrained to stay in the reported human biological values (Table B.1). The
minimized objective function is chosen as the root mean square deviation (RMSD).
Adding levodopa reactions to sIEC
The sIEC model is represented in the stoichiometric matrix S, which is obtained by the
conversion of the reconstruction into a mathematical format as following:
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Figure B.1: (Continued on the following page.)
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Figure B.1: A – levodopa PBPK whole body model structure. The small intestine compart-
mentalization is detailed in Figure 3.3. The elimination is considered only in the kidneys,
while peripheral metabolism of levodopa (e.g., liver) as well as conversion to dopamine (in
the brain) represent routes of elimination. The goodness of fit of the latter models on the
same data did not show improvement over the kidney elimination model (data not shown).
B - Curve fitting of a standard dose of 200 mg of carbidopa (levodopa and benserazide) in
healthy volunteers on PBPK generic whole body model. The solid lines represent the model
performance with the estimated parameters with the observed data values. The root mean
square deviation value was 71.13 ng/ml. C - Two occasions sequential fit of levodopa plasma
concentrations in fasted state followed by a meal [39]. The parameters identified in the fasted
state were fixed in fed state except the gastric emptying rate, which was left unconstrained and
was estimated in the second administration of levodopa with a meal. The solid line represent
the model simulation with the parameters obtained from the fitting process.
Reaction: A+B→ 2 C
,where the rows represent metabolites and the columns represent reactions. The levodopa
transport reactions were added to the sIEC model (Table B.2) and the luminal uptake of
levodopa was set as the objective function. The choice of the objective function agreed with
both empirical results and numerical simulations. The main function of the small intestine in
the gut wall is the transport and metabolism of substrates from the luminal side to the portal
vein. Since levodopa does not contribute to the homeostasis of the sIEC, considering biomass
maintenance as the objective function did not result in transport of levodopa. The luminal
and basolateral transport reactions were added according to the recently identified levodopa
transporters [32]. The competition was modeled as the loss of a luminal fraction of levodopa
in the presence of amino acids. Stoichiometric coefficients were calibrated to account for
affinities of different amino acids for the antiporter (Table B.2 – luminal competition). In fact,
amino acids with high affinity to the transporter (cystine) result in higher loss of levodopa,
thus they were assigned a higher coefficient than less affine amino acids (ornithine) for the
transporter. The coefficients for leucine and arginine were measured in vivo in mice [32].
While the unmeasured values were extrapolated following the reported order of affinity [239].
The trans-stimulation was modeled as the decrease in the flux through cellular accumulation
reaction (Table B.2 – Intracellular accumulation), by unconstraining the basolateral antiporter
with respect to the fasted value, and by setting the flux of the basolateral uniporter to the fasted
value. The resulting basolateral transport was then updated and set in the ODE model as the
gastrointestinal basolateral eﬄux term in the next time step. The percentage decrease in the
intracellular accumulation of levodopa was set to 0.7 as measured in vivo in mice [32] (Table
B.2 – Trans-stimulation). It can be adapted to account for different basolateral affinities of
amino acids. In fact, basolateral amino acids that trigger a high trans-stimulation through
the antiporter reduce the intracellular accumulation of levodopa by a higher coefficient than
less trans-stimulating amino acids. Consequently, the new flux through the antiporter was
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computed with the following linear programming problem:
maximize: cTv(objective f unction) (1)
subject to:
S.v = 0
vi,min ≤ vi ≤ vi,max
,where c is the coefficients vector for the objective function, v represents the flux distribution,
vi,min and vi,max are respectively the minimal and maximal capacity for reaction i. The system
assumes steady state for the chosen time step as well as mass balance (S.v = 0). This approach
is also called flux balance analysis (FBA) (5).
FigureB.2: Goodness of fit plot of the simulated andmeasured levodopa plasma concentration
in the fasted state, corresponding to figure S1-B. The model was simulated with the parameter
values obtained from curve fitting the model on the observed data.
Sequential fit on two occasions: fasted and fed states
First, the fitting of whole body generic PBPK model on fasted healthy volunteers plasma
concentrations of levodopa, after 200 mg of standard formulation of levodopa, allowed to get
the distribution and elimination parameters including the GER at the fasted state (3.96 h-1).
Then, all model parameters were fixed and only GER was estimated (0.33 h-1) in the second
occasion, i.e., the administration of levodopa with aproteic meal.
Amino acids ranking simulations
The small intestine model was extended by adding a kidney compartment and brain com-
partment with the corresponding levodopa transport reactions (Figure S5). The objective
function was set as the demand reaction for levodopa in the brain (Table B.4). The kidney
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Figure B.3: (Continued on the following page)
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Figure B.3: Predicted flux values of the levodopa luminal antiporter (blue), cellular accumula-
tion (turquoise), basolateral antiporter (green), and basolateral uniporter (yellow) in the seven
small intestinal compartments, after Per os administration of 200 mg of standard formulation
of levodopa at the fasted state. For the intracellular accumulation (represented in the model
with a reversible drain for levodopa (sink_levodopa)), positive fluxes refer to accumulation,
while negative fluxes represent secretion. The conversion to mmol/gDWenterocyte/hour was
done as described in section adding levodopa reactions to sIEC.
Figure B.4: Whole body PBPKmodel parameter sensitivity analysis. Over 243 parameter, the
10 most influential absolute sensitivities are plotted. The first five parameters are described
in Table B.3.
and brain exchange reaction modeling took into account the affinity of substrates for the
transporter, through assigning different arbitrary weights (Table B.2) for the fluxes repre-
senting each individual amino acid (Table B.5). The weighing coefficient is proportional to
the amount of levodopa lost due to the competition with amino acids. The higher the com-
petitive potential of the amino acid, the higher the assigned weight following the reported
order of affinity of each transporter for amino acids [239]. The coefficients were calibrated
to take into account the tissue-specific competition potential of levodopa transporters in the
following order: blood brain barrier, enterocyte, kidneys as supported by clinical investi-
gation [184, 161]. Trans-stimulation was not modeled in the kidneys and the brain as it is
not supported by experimental evidence. The liver elimination was not formulated in the
optimization problem as no records of competition were reported. An arbitrary intake of
levodopa was set to 15 mg/l/h. Two thirds of this amount are absorbed by the small intestine.
Since levodopa is antiported to the blood compartment, an excess of alanine, the contralateral
substance to levodopa, was added. In order for levodopa to reach the blood brain barrier
and the kidney, two demand reactions were added in these compartments. 30% of levodopa
was set to be eliminated by the kidneys and the rest transported through the blood brain
barrier. Then a 3 mg/l/h of each amino acid was added simultaneously with levodopa and the
fraction reaching the brain was calculated. Each amino acid either competed with levodopa
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in the small intestine, blood brain barrier or kidneys or all of the three organs. Basolateral
trans-stimulation of levodopa intestinal secretion increases the absorption of levodopa. Since
trans-stimulation was not proven in kidney and brain transporters, these were not modelled.
Figure B.5: Schematic view of small intestine, kidney and blood brain barrier transport
reactions integration. The small intestine is represents through the genome-scale sIEC
model, while only the transport reactions from blood to the organ were modelled in the other
sites of competition (e.g., kidneys and brain compartments).
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Appendix C
Supplementary material for Chapter 5
C.1 Supplementary tables
Table C.1: Differentially expressed metabolic genes in type 1 diabetes.
Number Gene symbol Gene expression variation
1 SV2A 0.33
2 ADCY1 0.32
3 AGT 0.65
4 ELA2B 0.1
5 PRPH2 2.04
6 ALOX5 0.34
7 G6PC2 0.03
8 AMY1A 0.21
9 ANPEP 2.67
10 ITGAM 2.63
11 PLA2G2A 4.85
12 PFEB1 2.87
13 ENO2 0.16
14 ONECUT2 0.47
15 PCIF1 3.86
16 ACP5 2.69
17 PECAM1 3.21
18 TCIRG1 2.71
19 FYN 3.16
20 TLR1 2.6
21 ABCC8 0.04
22 TIMP3 2.9
23 PCDHA12 0.2
24 CD36 4.06
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Table C.2: Pancreatic reactions corresponding to the differentially expressed genes in type 1
diabetes where P refers to pancreas, lu to lumen, and bp to portal blood.
Reaction name Reaction name Reaction name
Pancreas_ALACYSNaEx Pancreas_SERALANaEx Pancreas_SIAASEly
Pancreas_ALADGLNexR Pancreas_SERCYSNaEx Pancreas_r0636
Pancreas_ALADGLYexR Pancreas_SERDGLNexR Pancreas_BGAL1l
Pancreas_ALAGLNexR Pancreas_SERDGLYexR Pancreas_NEU11l
Pancreas_ALAGLYexR Pancreas_SERGLNexR Pancreas_CRNATBtc[bpP]
Pancreas_ALASERNaEx Pancreas_SERGLYexR Pancreas_ALACYSNaEx
Pancreas_ALAt4 Pancreas_SERt4 Pancreas_ALADGLNexR
Pancreas_ALATHRNaEx Pancreas_SERTHRNaEx Pancreas_ALADGLYexR
Pancreas_ASNt4 Pancreas_THRALANaEx Pancreas_ALAGLNexR
Pancreas_ATPS4m Pancreas_THRCYSNaEx Pancreas_ALAGLYexR
Pancreas_CATm Pancreas_THRGLNexR
Pancreas_CATp Pancreas_THRGLYexR
Pancreas_CSNAT2x Pancreas_THRSERNaEx
Pancreas_CYSALANaEx Pancreas_THRt4
Pancreas_CYSGLUexR Pancreas_TRPt4
Pancreas_CYSGLYexR Pancreas_TYRt4
Pancreas_CYSSERNaEx Pancreas_VALt4
Pancreas_CYSt4 Pancreas_r0637
Pancreas_CYSTHRNaEx Pancreas_r0997
Pancreas_DGNSKm Pancreas_SUCCCROT
Pancreas_FMNAT Pancreas_34DHPHELAT1tc
Pancreas_FRUt1r Pancreas_4OHPROIMINOtc
Pancreas_FTHFDH Pancreas_HISyLATthc
Pancreas_FTHFL Pancreas_LEUPHELAT2tc
Pancreas_GALASE19ly Pancreas_3HCO3_NAt
Pancreas_GLCt1r Pancreas_4HPROLTASCT1
Pancreas_GLNS Pancreas_ASPPROASCT1
Pancreas_GLNt4 Pancreas_GLUPROASCT1
Pancreas_GLYt4 Pancreas_IPDDI
Pancreas_HOXG Pancreas_25HVITD3tin
Pancreas_ILEt4 Pancreas_LCAT25e
Pancreas_IPDDIx Pancreas_GLCRt1
Pancreas_LACZe Pancreas_SELMETHte
Pancreas_LEUt4 Pancreas_BGAL2l
Pancreas_METt4 Pancreas_3HCO3_NAt[luP]
Pancreas_MTHFDm Pancreas_FRUt1r[luP]
Pancreas_PHEt4 Pancreas_GLCRt1[luP]
Pancreas_PPAer Pancreas_GLCt1r[luP]
Pancreas_PROt4 Pancreas_GLUPROASCT1[luP]
Pancreas_S6TASE8ly Pancreas_ARGLYSex
Pancreas_S6TASE9ly Pancreas_GALASE1ly
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Table C.3: Parameters of the dynamical model simulations.
Setting Dose administered (kg) Administration time (mn)
Intravenous Glucose Tolerance Test 0.04 15
(IVGTT)
Intravenous Insulin Tolerance Test 1.02 ∗ 10−7 15
(IVITT)
Baseline Glucose 0 0
Subcutaneous Insulin Bolus 1.02 ∗ 10−7 15
(SCIB)
Subcutaneous Insulin Infusion 3.66 ∗ 10−7 600
(SCII)
Oral liquid glucose solution 0.1 0
(WB-Liquid)
Solid Meal 0.04 0
(WB-Solid)
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Table C.4: Selected functions linked to type 1 diabetes symptomatology.
Enriched reaction Metabolites involved Type 1 diabetes related Related
process symptoms
Muscle_ADCim Acetoacetate Ketone bodies disrupted Ketoacidosis
Brain_FUMAC metabolism
Liver_r2079
Colon_r2082
Liver_biomass_reactionGlycogen, ATP, Glycogen liver Hepatomegaly in
Liver_SPHS1Pt2e ADP deposition uncontrolled
Liver_FPGS4 diabetes
Liver_CERK
Liver_DPCOAK
Liver_FTHFL
Liver_GLYK
Liver_KHK
Retina_O2Stm Superoxide Free radicals production Retinopathy
Retina_SPODM
Heart_RE3273C Phosphoinositides Regulation of Cardiovascular
Heart_PIACGT cardiomyocyte disease
Heart_CDIPTr metabolism
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Table C.5: Enriched KEGG terms in the genes coding for the upregulated metabolic fluxes
in type 1 diabetes.
Enriched pathway p-value Adjusted p-value Z-score
Metabolic pathways 4.463e-216 8.123e-214 -2.01
Oxidative phosphorylation 9.328e-59 8.489e-57 -1.80
Parkinson’s disease 1.931e-38 1.171e-36 -1.72
Carbon metabolism 5.054e-37 2.300e-35 -1.63
Glycolysis / Gluconeogenesis 4.251e-31 1.548e-29 -1.88
Alzheimer’s disease 7.035e-31 2.134e-29 -1.72
Huntington’s disease 1.856e-27 4.827e-26 -1.75
Non-alcoholic fatty liver disease (NAFLD) 1.514e-23 3.061e-22 -1.76
Biosynthesis of amino acids 9.612e-24 2.187e-22 -1.55
Fatty acid degradation 1.740e-19 3.167e-18 -1.44
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Table C.6: Small molecules that reverse the metabolic flux distribution associated to type 1
diabetes.
Rank Small molecule Class / Nomenclature
1 Terfenadine Antihistaminic (withdrawn)
2 SB 216641 hydrochloride 5 HT1-B antagonist (anxiolytic effects)
3 Mibefradil dihydrochloride Calcium channel blocker
4 Maprotiline hydrochloride Tetracycline antidepressant
5 L-733,060 hydrochloride Antidepressant/anxiolytic
6 AY 9944 Specific inhibitor of cholesterol biosynthesis
7 Amlodipine besylate Calcium channel blocker
8 Wiskostatin (Neuronal-WASP inhibitor)
9 Thioridazine Antipsychotic
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C.2 Supplementary figures
C.2.1 Construction of the hybrid model
We combined the glucose-insulin ODE-based dynamical model (GIM) [202] with the organ-
resolved constraint-based model (Harvey) [225] into a multi-scale model (dHarvey).
GIM was originally coded in the PKSIM-MOBI [60] format and was subsequently converted
using PKSIM into a set of ODEs in MATLAB (2014b, Natick, MA, USA) and solved using
ode15s. The model described the complex glucose regulatory mechanism by insulin and
glucagon in all organs using a whole-body PBPK model. In the intestinal tract, it models
the intestinal regulation of glucose by incretin hormones (glucagon-like peptide 1 (GLP1)
and gastric inhibitory polypeptide (GIP)) and the absorption by glucose carriers such as
SGLT1 and SGLT2. In each organ and particularly the target organs i.e., liver, pancreas,
brain, fat, and muscle, GIM represented a number of processes related to insulin action such
as its diffusion from the blood to the extracellular space, the metabolism of glucose by red
blood cells, the internalization of insulin by endothelial cells, the clearance by the lymphatic
circulation, the binding and internalisation of insulin receptors followed by the release of
glucose receptors, and the storage of glycogen. Since insulin acts with a relatively low dose,
its binding to the receptor can modulate its pharmacokinetics. Consequently, GIM modelled
the target-mediated drug disposition (TMDD) of insulin in relation to its pharmacodynamics.
The organs modelled were the bones, brain, fat, gallbladder, gonads, heart, kidney, large and
small intestine, liver, lung, muscle, pancreas, skin, spleen, and stomach connected by extra-
cellular compartments and biofluids such as arterial and venous blood, portal vein, intestinal
lumen, and saliva. Each organ is further compartmentalized into anatomical and histological
units such as the intracellular space, the interstitial space, and the endothelial compartment.
The model parameters were validated using several datasets of glucose tolerance tests and
closed-loop insulin administration in patients [182, 213, 61]. The model was applied in a
number of applications mainly pertaining to closed-loop inuslin administration in T1D pa-
tients [242, 203, 201], and the estimation of cell proliferation rate in human using labelled
glucose [126].
Harvey is the organ-resolved constraint-based metabolic model of the human body [225]. It
represents the metabolic network of 20 organs, six sex organs, and six blood cells totalling
more than 80,000 reaction, 50,000 metabolite, and 100 subsystem. The model was based
on the global reconstruction of human metabolism (Recon) through the context-specific
modeling of organs using human proteomic data and the manual curation of organ-specific
pathways. The organs were connected through biofluids and exchange compartments taking
into account inter-organ cycles and crosstalk. The model takes into account physiological
constraints such as the heart rate, basal metabolic rate, renal filtration, and oxygen uptake.
Coupling GIM with Harvey fell under one of the following situations (Figure 5.2):
1. When the fluxes in GIM and Harvey corresponds exactly, the flux in the metabolic
model was set to the one in the dynamical model,
2. When metabolites are identical in both models, the corresponding b vector entry in the
metabolic model is set equal to the rate-of-change of metabolite concentration,
3. When to a specific reaction in the dynamical model, correspond several reactions in the
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metabolic model, the reactions are pooled in Harvey such as their total fluxes equals
the reaction flux in the dynamical model,
4. Finally, when to specific metabolite in the dynamical model, correspond several
metabolites, they are pooled into one super metabolite through merging the corre-
sponding rows in the stoichiometric matrix. In the dynamical model, the blood cells
are pooled in one compartment, wherein in the metabolic model, each blood cell is
represented apart.
C.2.2 Simulation setting
Tolerance tests
We used dHarvey to simulate the outcome of the different tolerance tests. The kinetic
parameters provided with the GIMmodel were used to represent the doses and time of intake.
We applied the constraints dynamically on Harvey in each time step following the indirect
coupling method. In IVGTT, where a dose of glucose is injected intravenously, we added an
exchange reaction to represent the intake of glucose in the blood glc_D[bc] during the 15 mn
of infusion (67.7 mmol/5mn). Consequently, we solved Harvey using pFBA [132] assuming
a whole-body maintenance objective function and aggregated the results in a matrix for each
time step comprised of the tolerance tests in columns and the metabolic fluxes in rows. We
reduced the matrix through PCA, and plotted the time-course of the first component (Figure
5.3-E) to illustrate the whole-body metabolic shift induced by a insulin and glucose tolerance
tests. The points were fit on a 6th order polynomial curve (Figure 5.3-E).
Furthermore, in order to assess if the dHarveymodelwas sensitive to the dynamical constraints
applied from the GIM model, we aggregated the pFBA simulation results over 600 mn of
simulation per 5mn time step. In each tolerance test simulation, we built a feature matrix
comprised of the whole-body metabolic fluxes in columns and the tolerance test in each time
step in rows. With a time step of 5mn, 120 simulation result in T1D and healthy formed
the 240 rows. We then reduced each matrix of the tolerance test using PCA. We took the
10 first component of the PCA, as they were significant at p < 0.001. The component
significance was assessed through 100 random permutation of the columns followed by PCA
on the perturbed matrix. The 10 first component were then used as features in a binary
SVM to classify healthy and T1D based on whole-body fluxes in each tolerance test. We
used an SVM with a Gaussian kernel and performed 3-fold cross-validation on the training
set (80%) and predicted the labels of the test set (20%). The data was standardized and the
process was repeated 100 times taking every time a different partition of the training and
test set. We choose to use significant components as features instead of performing feature
selection on the whole-body fluxes as the focus was the assessment of dHarvey sensitivity
towards glucose and insulin challenges and the subsequent whole-body metabolic shift. The
fluxes used in each time step are one among many possible solutions in the AOS space,
and cannot be used as conclusive evidence on the disrupted metabolic pathways in T1D
and healthy, even though pFBA reduces considerably the AOS space [229]. We addressed
the question of disrupted metabolic pathways in T1D through performing FVA in T1D and
healthy models and using all the solution vectors of the AOS as a kernel for comparison.
dHarvey was predictive towards T1D and healthy states in the tolerance tests (Figure (Figure
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Figure C.1: (Continued on the following page)
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Figure C.1: Enrichment analysis of the type 1 diabetes differentially expressed genes in
A- Reactome and B-Panther database and the enrichment of the metabolic genes in C- the
HumanCyc database, D- the dbGap database, and the E- OMIM database.
5.3-E), moreover when we used insulin and glucose challenges as classes in the SVM instead
of T1D and healthy, whole-body fluxes were predictive towards them as well (Figure C.2).
Taken together, dHarvey is predictive towards both the condition (T1D and healthy) and the
perturbation (insulin and glucose challenges).
Figure C.2: Whole-body fluxes discriminate between insulin and glucose challenges. A
binary class support vectors machine accurately classifies insulin and glucose challenges
usingwhole-body-fluxes. Constraining themodel with T1D gene expression further improves
the classification result. Insulin challenges were used as the true class.
C.2.3 Relaxing infeasible problems
Subjecting dynamical model-derived constraints to themetabolic model could result in unfea-
sible problems. The situation could arise from conceptually different modeling approaches.
In fact, the GIM model depicted short time events, while the constraint-based model was
designed to simulate steady states. For instance, while it is commonly known that organs
such as the lungs are glucose metabolizers rather than consumers, the GIM model could
C.2. SUPPLEMENTARY FIGURES 191
show a small secretion of glucose for a short time step as a consequence of free diffusion
through the organ membrane. We relaxed the corresponding reactions in Harvey in order
to obtain a feasible model through minimally relaxing the upper and lower bounds of the
internal reactions. If the standard linear program is infeasible:
max: cTv
subject to:
Sv = 0
vmin ≤ v ≤ vmax
, where cT .v is the objective function, v is the flux vector of metabolic reactions, c is the
vector of objective coefficients, S(m,n) is the stoichiometric matrix linking m metabolites and
n reactions, lb is the vector of reaction lower bound, and ub the vector of reaction upper
bound. The following problem minimally relaxes the infeasible model:
min: | |p| |1, | |q | |1
subject to:
Sv = 0
vmin − p ≤ v ≤ vmax + q
,where p is the relaxation vector of the lower bound and q is the relaxation vector of the
upper bound. Minimizing the 1-norm of p and q ensures both sparsity (minimal cardinal of
reactions to be relaxed), with minimal total sum of relaxation amplitude.
C.2.4 CRONICS framework
The simulation of the hybrid model faced challenges related to
• The the size of the solution space in every time step and the effect of alternate optimal
solutions, the problem being largely under-determined.
• Also, the large size of the metabolic model required the reduction of the set of active
reactions for subsequent analysis and biological interpretation.
• Simulation time as a model would typically run in 2-3 days for 10 hours of simulation.
The above-mentioned challenges were addressed through combining a mosaic of existing
techniques in the CRONICS framework which consists of the following steps:
1. (optional) Depending on the simulation, the solution basis of the unconstrained problem
is generated before coupling both the dynamical and metabolic model. The solution
basis is then provided in all subsequent optimisation problems while activating the
advanced start option in CPLEX as follows:
ADVIND=1
192 APPENDIX C. SUPPLEMENTARY MATERIAL FOR CHAPTER 5
Figure C.3: (Continued on the following page)
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Figure C.3: Gene expression constraints pipeline. The pancreas and pancreatic islets gene
expression profile of type 1 diabetes patients [174] were translated into constraints. The
reactions catalysed by a protein coded by a given gene are constrained by the lower and upper
bound of gene expression fold change with respect to the control.
2. The setting starts with the simulation of dynamical model for 1 time step. Based
on dFBA, The computed constraints are subjected to the metabolic model and a 1-
norm minimal (pFBA) solution is selected given its sparse properties that allow for the
selection of a smaller set of active reactions for further analysis.
3. (Vertical coupling) The next time step in the dynamical model is simulated and the
constraints are computed and subjected to the metabolic model. The selected solution
is the one that is minimally distant to the previous solution (MOMA). This part allows
to guarantee smoothness of the hybrid system, and the chronology of the simulation.
Although the large size of the solution vector made the simulation computationally
expensive, we chose a subset of the vector to minimize for. The minimal subset would
be the coupled reactions themselves, in this case, the obtained vector is indeed nearly
identical to the initial subset vector, which results in all simulations being converging
to the dynamical model behaviour in terms of smoothness, while uncoupled reactions
can be changing values abruptly in time steps as small as five minutes. While a subset
containing reactions of the brain, liver, kidney, adipocytes, muscle, pancreas allowed to
globally constrain the fluxeswith respect to chronology of simulationwhilemaintaining
the smoothness of the system.
4. (Horizontal coupling) In this previous setting the hybrid model consisted of a dynami-
cally constrained metabolic network. In the horizontal setting, the dynamical model is
in return constrained by the metabolic model. The obtained fluxes from the metabolic
model serve as input for the next time step of the dynamical model. If the solution
fluxes correspond to the input constraints then the hybrid model reaches the behaviour
of the dynamical model alone. In both settings, the solution of the type 1 diabetes
model in the first time step is minimally distant to the healthy model in the first time
step.
We used the CRONICS framework to predict metabolite concentrations in dHarvey model.
The metabolites fell under two categories: the metabolites time-course predicted by GIM
and the metabolites in Harvey that obey the steady-state assumption. Only the concentrations
of imbalanced metabolites in Harvey can be predicted as they do not obey the steady-state
assumption. We created demand reactions, which are imbalanced reactions, for metabolites
of interest to predict the dynamic organ demand in these metabolites. We applied this method
to predict the time-course of ATP demand in the liver (Figure 5.4-B), the triglyceride demand
in the adipocytes (Figure C.7), and the valine and phenylalanine demand in plasma (Figure
C.6).
C.2.5 Software and solver parameters
The simulations were carried on MATLAB (2014b, Natick, MA, USA) with the ODE15s
built-in function andwith the COBRA toolbox v3.0 [93] and theCPLEX andMADTOMLAB
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v7.9 implementation on Windows 7 professional and ubuntu 16.04 –based high performance
computing units. The following parameters allowed a faster convergence as well as resolving
‘infeasbile after unscaling’ type of issues:
PARALLEL=1
THREADS=2
SCAIND= -1
EPMRK=0.9
NUMERICALEMPHASIS=1
EPOPT=1e-6
EPRHS=1e-6
C.2.6 Differentially expressed fluxes between healthy and type 1 diabetic
models
In order to compare the fluxes in both healthy and type 1 diabetic model, individual fluxes’
comparison would yield inaccurate results given the large alternative optimal solution space.
We compared flux distributions per reaction rather than the value provided by one solution.
In order to obtain flux probability distributions, we performed flux variability analysis on
both healthy and type 1 diabetic model. The COBRA toolbox function fastFVA [80] was
called with the solutions as an output as following:
[minFluxH,maxFluxH,optsolH,retH,fbasolH,fvaminH,fvamaxH]=fastFVA(harveyIrrev,
90,’max’,’cplex’,harvey.rxns,’A’,cpxControl)
Prior to the flux variability analysis, the metabolic model was translated to its irreversible
version, such as every reversible reaction is decomposed in the forward and the backward
reaction, in a way that fluxes obtained are positive. The conversion was done using the
following COBRA toolbox function:
[harveyIrrev,matchRev,rev2irrev,irrev2rev] =convertToIrreversibleCoupled(harvey)
The obtained flux distribution per reactions equalled 160320 sample per reaction (80160
reaction* 2 (minimization and maximization)). The two matrices containing the fluxes
values per reaction in healthy and type 1 diabetic model were used as an input to volcano plot
function mavolcanoplot in MATLAB (2014b, Natick, MA, USA). A p-value less than 0.001
was considered as a significance threshold for a minimal fold change of 1.3. Higher values of
fold change are usually used in gene expression experiments, with the objective of containing
small value change that is related to the experimental set up among several factors. As these
considerations do not apply to linear programs solutions, provided the same solver settings,
we considered a smaller fold change value.
C.2.7 Enrichment of gene vectors
After obtaining the up-regulated and down-regulated fluxes in T1D, we connected the reac-
tions to their encoding genes and performed gene set enrichment analysis. The set of obtained
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Figure C.4: CRONICS framework for dynamical simulation of genome scale models. The
algorithm starts with solving the I) general unconstrained problem with FBA and using its
solution basis as a warmstart for the next time steps. II) The first time step is then solved
using pFBA after subjecting constraints from the dynamical model to ensure the sparsity of
all subsequent solutions. Depending on the type of coupling, the algorithm would either use
the constrained-based III) solution as initial estimate for the next time step of the dynamical
model to obtain IV) new derivatives that will be subjected on the V) constrained-based
model. Alternatively, the dynamical model is independent from the constraint-based model
and feedback is only unidirectional (V but not III). The LP problem in the new time step
will get constraints from the corresponding time step of the dynamical model, and VI) it
will also be constrained by the previous time step so that solutions are minimally distant
(MOMA). In type 1 diabetes, the first time step is further constrained by the first time step
of the healthy model (I’), in order to ensure a minimal metabolic adjustment between the
conditions. Initializing the simulations with pFBA solutions that are minimal to the healthy
condition allows to propagate both the sparsity and the minimal metabolic adjustment to
the healthy model to all the time steps. The CRONICS framework guarantees a smooth,
continuous evolution of the system and reduces the effects of alternate optimal solutions on
the predictions.
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genes would correspond experimentally to the differentially expressed genes and we queried
i) the LINCS database to look for small molecules that reverse the signature of T1D, meaning
the compound that induce a reverse genetic signature to the T1D signature that we obtained,
which can potentially reverse the metabolic profile and ii) we queried the KEGG database to
assess which disease were similar in signature to T1D.
In order to determine potential small molecules that can reverse T1D, we collected the list of
up-regulated and down-regulated genes in T1D and queried the LINCS Canvas Browser [56],
setting the up-regulated genes and down-regulated genes in the up and down field respectively
and using the reverse option to look for small molecule that reverse the queried signature.
The results are reported in table C.6.
To determine the diseases that have a similar genetic signature to T1D, we merged the up-
regulated and down-regulated reactions into a unique set of differentially expressed reactions.
Since one metabolic reaction can be encoded by one or more genes using boolean opera-
tions (AND, OR), there can be several genetic profiles corresponding to a single metabolic
profile. We randomly selected 10,000 genetic profile corresponding to the metabolic profile
of T1D and queried each one of them programmatically in Enrichr [35] through the API.
Subsequently, we selected the top five most enriched terms in the KEGG database at p<0.05
for each of the 10,000 gene profiles. Then we ranked the terms by their occurrence in each
profile (Figure C.5). An example of the output of the enrichment of one profile is listed in
table C.5.
The enrichment of metabolic reactions in organs and subsystems as groups was done through
a one-sided hypergeometric test with FDR correction.
C.2.8 Comparison of flux density estimates
In order to determine the metabolic effects of insulin in T1D (Figure 5.5), we first computed
the alternate optimal solutions in T1D model prior to insulin injection, using FVA. We
obtained 160032 solutions of the AOS of T1D model, which gives us as many number of
flux values per reaction. Using the empirical flux values per reactions, we estimated the
smoothed probability density function for each reaction. In a similar fashion, we collected
solutions from the T1D model after the SCIB trial and equally, we estimated the probability
density of flux values for each reaction. Finally, both density estimates were overlaid in order
to compare the effect of insulin on the selection of flux values per enzyme/reaction.
C.2.9 Intra-individual variability to insulin response
We modelled the inter-individual variability to insulin response as the variation of kinetic
parameters in GIM model. Consequently, We created 31 GIM model and coupled them to
Harvey. The glucose concentrations are completely determined by the GIM model, also
referred to as indirect coupling [119].
Modeling the intra-individual variability to insulin consisted of using the average patient
kinetic parameters in GIM and the variation of the internal state of the system as represented
by Harvey. In this case, we randomly selected 1% of reactions in every subsystem in every
organ which resulted in a set of 2817 reactions that equally represented all the metabolic
subsystems in all the organs. We assigned each reaction a random objective weight which
corresponded to ametabolic state. Consequently, we created 31metabolic state and simulated
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Figure C.5: Enrichment of gene expression profiles in KEGG. A- The process of deriving
gene profile form metabolic profiles and B- its application to T1D. The identification of
differential reaction fluxes in T1D allows to link back to the encoding genes. Since several
genes can encode for the same reaction through AND, OR rules in the metabolic model,
there can be several differential gene (G) profiles corresponding to one metabolic profile. We
sampled 10000 profiles corresponding to the T1D profile and queried KEGG through Enrichr
[35] for each of the profiles (P). The enriched terms (T) for each profile were classified by
their occurrence in the 10000 profiles.
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the models after the subcutaneous injection of insulin. Glucose concentrations are depend
on both Harvey and GIM, also referred to as direct coupling [119]. The input matrix Xp,q
represents the objective coefficients of each of the q reactions in the p metabolic states.
Here, p = 31 and q = 2817. The output matrix Yp,n represents the glucose concentrations
at each of the n time steps in the p metabolic states, with n = 234 with a 2.5 minutes time
step length and the infusion starting at 16 minutes, totalling 10 hours of simulation. Using
multivariate regression, we estimated the matrix ρq,n that represents the sensitivities of each
of the q reactions towards each of the n time steps of the simulation. In particular, the time
steps corresponding to the minimal concentrationCmin and the final concentrationC f inal were
considered for further analysis, as they would link to hyperglycaemia and hypoglycaemia and
diabetes control in general. The estimation of the sensitivity matrix consisted of solving the
following equation:
X ∗ ρ ≈ Y
We used the mvregress routine in MATLAB and the Covariance Weighted Least Square
(CWLS) algorithm to estimate ρ. The algorithm gives p coefficients corresponding to p out
of q reactions, wherein the rest in set to zero.
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Figure C.6: Predicted off-target effects on liver glycolytic enzymes and plasma large and
neutral amino acids concentration (LNAA) after insulin subcutaneous administration.
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Figure C.7: Time-course of triglycerides in the adipocyte.
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Figure C.8: Pancreas, kidney, adipocytes, muscle, liver, and brain metabolic crosstalk with
and without insulin action.
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Figure C.9: Variation of the power law gamma across patients after a subcutaneous insulin
injection. For every patient, the changes of the metabolic network topology were assessed
through fitting the metabolite-centric model connectivity on a power law. The variation of
the gamma parameter during the simulation time was represented in the boxplot. Overall, the
network structure is quite stable across patients and the gamma parameter mean value stays
between 3.1 and 3.2 as reported for biological networks [180].
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Table C.7: Selected metabolic reactions with the highest sensitivities towards peripheral
glucose concentrations. Type refers to interface reactions (I) shared by Harvey and GIM, and
(H) for the reactions belonging to Harvey alone. The letters in brackets refer to the cellular
compartments, where e is exrtacellular, c for cytoplasm, m for mitochondria, n for nucleus,
and r for endoplasmic reticulum
Name/Type Reaction Subsystem
Glut4(I) na1[e]+glc_D[e]↔ na1[c]+glc_D[c] Transport
NMNATr(H) atp[c]+h[c]+nmn[c]↔ nad[c]+ppi[c] NAD metabolism
GF6PTA(H) f6p[c]+ gln_L[c]→ gam6p[c]+glu_L[c] Aminosugar metabolism
TRPO2(H) o2[c]+trp_L[c]→ Lfmkynr[c] Tryptophan metabolism
HMR_1280(H) CE4988[c]+nadp[c]↔ Leukotriene metabolism
CE5944[c]+h[c]+nadph[c]
SPODMm(H) 2 h[m]+ 2 o2s[m]→ h2o2[m]+o2[m] ROS detoxification
GUAPRT(H) gua[c]+prpp[c]→ gmp[c]+ppi[c] Nucleotide salvage pathway
DTMPKm(H) atp[m]+dtmp[m]→ adp[m]+dtdp[m] Pyrimidine synthesis
PPNCL3(H) 4ppan[c]+atp[c]+cys_L[c]→ CoA synthesis
4ppcys[c]+amp[c]+h[c]+ppi[c]
GGT_L(H) 17.6 ipdp[c]+ttc_ggdp[c]→ N-glycan synthesis
0.1 dedoldp_L[c] + 17.6 ppi[c]
EX_ha(e)(H) ha[e]↔ Exchange/demand reaction
r0301(H) atp[c]+nh4[c]+xmp[c]→ Bile acid synthesis
amp[c]+gmp[c]+2 h[c]+ppi[c]
PAN4PP(H) h2o[c]+pan4p[c]→ pi[c]+ptth[c] CoA catabolism
RE2235R(H) estrone[r]+h[r]+nadph[r]+o2[r]→ Androgen and estrogen
C05300[r]+h2o[r]+nadp[r] synthesis and metabolism
IPDDI(H) ipdp[c]↔ dmpp[c] Squalene and cholesterol
synthesis
DASCBR(H) dhdascb[c]+nadph[c]→ ascb_L[c]+nadp[c] Vitamin C metabolism
r0009(H) h2o[x]+ppi[x]→ h[x]+2 pi[x] Purine metabolism
SBTR(H) glc_D[c]+h[c]+nadph[c]→ nadp[c]+sbt_D[c] Fructose and mannose
metabolism
RE1303C(H) h[c]+nadph[c]+o2[c]+vitd3[c]→ Vitamin D metabolism
25hvitd3[c] + h2o[c] + nadp[c]
r2073(H) h[e]+zn2[e]→ h[c]+zn2[c] Transport, extracellular
EX_icdchol(H) icdchol[e]↔ Exchange/demand reaction
EX_CE2934(e)(H)CE2934[e]↔ Exchange/demand reaction
P4507A1r(H) chsterol[r]+h[r]+nadph[r]+o2[r]→ Bile acid synthesis
h2o[r]+nadp[r]+xol7a[r]
RAtn3(H) 13_cis_retn[c]↔ 13_cis_retn[n] Transport, nuclear
